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Abstract 
Fracture non-union is estimated to occur in approximately 5-10% of bone 
fractures. Tissue engineering strategies that aim to replicate mature tissue 
may be unresponsive to the cues observed during the initiation of fracture 
repair, and as such have limited ability to integrate with the host tissues. As 
such, this thesis aims to develop an implant that mimics the cartilaginous 
callus, the initial reparative stage of the body’s response to fracture; through 
the development of decellularised xenogeneic hyaline cartilage in combination 
with skeletal (stem) cells. 
This thesis presents data on the optimisation of an osmotic shock based 
decellularisation methodology (Vac-OS) for costal cartilage. The resultant 
scaffolds (dcECM) were investigated for the removal of cellular content and 
maintenance of cartilage-specific proteins such as sulfated 
glycosaminoglycans. The Vac-OS methodology efficiently lowered DNA 
content to levels below in vivo immunological response thresholds, while 
eliminating the highly immunogenic and abundant alpha-gal epitope. 
Interestingly, immunogenic neutralisation was achieved while retaining over 
80% of the sGAG content, surpassing published hyaline cartilage 
decellularisation methodologies. Extracellular matrix (ECM) integrity was using 
a novel methodology based on fluorescence lifetime imaging (FLIM) and 
further assessed using differential scanning calorimetry (DSC). Both FLIM and 
DSC indicated a lack of significant change in cartilage ECM integrity, post Vac-
OS decellularisation. The bioactivity of the dcECM was subsequently 
assessed using various skeletal cell populations, indicating an inherent 
capacity to enhance chondrogenesis. Furthermore, post-implantation in 
immunocompetent mice, the dcECM promoted a regenerative response, in 
contrast with native costal cartilage. The dcECM was also fabricated into 
porous scaffolds capable of being upscale to meet clinical demands and gel 
coatings that enhance in vitro chondrogenesis. This thesis demonstrates the 
dcECM’s potential as a fracture callus mimetic. The study, therefore, 
concludes that these constructs could potentially enhance bone repair in cases 
of atrophic non-union fracture, where the failure of callus formation is a defining 
event. 
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Impact Statement 
Fracture non-union results in around 10% of all fractures. Currently, the gold-
standard treatment for non-unions remains autologous bone grafts (ABG). The 
use if ABG, however, requires multiple operations and is often accompanied 
by reports of complication such as post-operative pain, and is ultimately limited 
by the amount of available donor tissue. Moreover, synthetic and natural bone 
grafts substitutes attempt to mimic the characteristics of autologous bone 
grafts are often unresponsive to the cues present at early stages of 
endochondral fracture healing, resulting in poor graft remodelling and 
integration into host tissue. 
The novel research carried out during the duration of this project focused on 
developing a grafting material that mimicked the early phase of fracture repair; 
The fracture callus. This approach harnessed the recent evidence generated 
by the scientific community that has driven a gradual shift towards engineering 
a developmental or repair process to produce more biomimetic strategies for 
bone repair. In 2017, an article was published in Tissue Engineering: Part A, 
highlighting the creation of a chondroinductive, decellularised cartilage-derived 
scaffold (dcECM). The optimised vacuum assisted methodology (Vac-OS) 
effectively balanced the removal of immunogenic components with minimal 
disruption to the extracellular matrix (ECM). Therefore, the Vac-OS 
methodology shows excellent promise for deriving decellularised scaffolds 
from other dense avascular tissues, creating impact beyond skeletal 
regeneration 
Further work was carried out to optimise a methodology for the formation of 
3D porous scaffolds using freeze-dried and milled dcECM granules embedded 
in a collagen type I scaffold. It was determined that the porous scaffolds 
support both cell infiltration and enhanced chondrogenesis. 
Moreover, the dcECM could further be digested to form a chondrogenic tissue 
culture coating. Both these key findings are novel, and it is proposed that upon 
publication these papers will form seminal contributions to the field. 
Additionally, the findings highlighted in this thesis provides the fundamental 
knowledge to develop cartilage mimetic constructs that can be used to further 
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investigate mechanisms of diseases in pathologies such as osteoporosis, 
opening opportunities for further funding, such as the foundation fellowship 
funding stream from Arthritis Research UK. 
There is currently no cartilage-derived bone graft substitute on the market, and 
with the bone graft and substitutes market being valued at 2.4 billion USD in 
2016 and a CAGR of 5.5% by 2025, there is excellent potential for a 
revolutionary approach such as described in this thesis to fill this gap the 
market. Moreover, key players such as Medtronic PLC, Nuvasive, Inc and 
Stryker Corp adopt strategies that include collaboration with academia for the 
innovation of novel bone regeneration strategies, opening further opportunities 
for funding and commercialisation.  
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1. Introduction 
 
Bone is one of the few tissues that have the remarkable ability to regenerate 
without the formation of fibrous scar tissue, attributed to the underlying repair 
mechanisms that recapitulate bone development. There have been several 
advances in the understanding of fracture healing and the cues involved in the 
highly complex process. However, despite this incredible capacity for 
regeneration, both external and pathophysiological factors can affect this 
regenerative process, leading to slow healing times and in some cases non-
unions1,2. There has, therefore, been an intense drive towards researching 
strategies to optimise the fracture healing process and reduce the incidence of 
its failure3. The following review is adapted from Val et al4. 
 
1.1 The fracture healing process 
To better understand developments within the field of skeletal regeneration 
and fracture management, we need an understanding of the complex and 
carefully orchestrated process that underpins fracture healing. Fractures heal 
through two key pathways; Direct or intramembranous (IM) fracture healing 
occurs in less than 2% of fractures, requiring rigid fixation and a gap size of 
less than 0.01mm. Formation of cutting cones near the fracture ends creating 
longitudinal cavities initiates the process of IM. Subsequently, bone laid down 
by osteoblasts then bridge the gap and re-establish bone’s lamellar structure 
without the formation of a cartilaginous callus1.  
Long bones, however, heal through the process of indirect fracture healing 
(Figure 1.1), driven primarily by the process of endochondral ossification (EO). 
EO has thus become a critical area of focus for the development of tissue 
engineering-based regenerative strategies 5–8. Unlike direct fracture healing, 
the process of EO is enhanced by limited micromotion at the fracture site1,2. 
There are several key stages in the process of endochondral bone formation, 
as illustrated in Figure 1. EO recapitulates many aspects of skeletogenesis as 
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observed pre-natal bone development. The process of EO begins with the 
initial inflammatory response that leads to the formation of a haematoma; this 
lays down a template for callus formation. The repair process is initiated by the 
secretion of proinflammatory cytokines,  triggered by the release of platelet-
derived interleukin 1β 9,10, IL-6 11,12, tumour necrosis factor-α (TNF-α) 13,14 and  
IL-17 10,15,16.  These proinflammatory cytokines modulate immune and 
surrounding skeletal stem cell populations 14,15,17–20.  
Additionally, hypoxic conditions within the haematoma lead to an increase in 
the expression of pro-angiogenic factors promoting vascularisation around the 
fracture site 19,21. Several growth factors including transforming growth factor 
beta-1 (TGFβ1), fibroblastic growth factors (FGFs), bone morphogenic 
proteins (BMPs), platelet-derived growth factor (PDGF) and  stromal-derived 
factor 1 alpha (SDF1α) play a key role in the activation and recruitment of 
skeletal progenitor cells from the surrounding periosteum and bone marrow 
space 20,22–25. Several studies indicate that the hypoxic conditions present 
within the fracture site is a driver of skeletal stem cell differentiation towards a 
chondrogenic phenotype, subsequently producing an avascular cartilage 
callus 1,21,26. The fracture callus provides some degree of stability while 
chondrocytes within the fracture callus eventually stop proliferating and 
become hypertrophic.  
Chondrocyte apoptosis and matrix mineralisation result in the subsequent 
degradation/resorption of the cartilage matrix 1, through the actions of 
osteoclasts and osteoblasts, gradually replacing the mineralised callus with 
woven bone. The cortical shell surrounding the callus provides stability by 
bridging the bone ends; this allows for limited weight bearing. Eventually, 
woven bone is replaced with lamellar bone. Although the process of 
remodelling is initiated at 3-4 weeks, depending on the age of the patient the 
process can take years to complete1. 
The biological processes that drive fracture repair can be affected by several 
factors leading to the disruption of bone healing. These include the severity of 
the fracture and resulting damage to the surrounding soft tissue and 
vasculature, associated with high impact fractures 27. However, the most 
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common factors are inherent to the host. These include metabolic diseases 
such as diabetes 28, lifestyle choices such as smoking 29. Moreover, other 
underlying pathologies such as the age of the patient or osteoporosis can also 
affect bone quality 30. One or several of these factors can result in the failure 
of the finely balanced bone repair process, resulting in a delayed or non-union 
31. 
A non-union as defined by the Food and Drug Administration (FDA) is 
incomplete fracture healing after nine months, alongside a lack of radiological 
characteristics associated with fracture healing observed during the first three 
months32. Around 10% of all the fractures seen in the UK result in non-unions 
annually. The estimated cost to the NHS can range from £7000 to £79000, 
with the higher costs being associated with failed surgical interventions and 
repeat surgeries. Overall, results in an annual burden of over £670 million 
which is predicted to rise33. 
Non-unions are classified as hypertrophic or atrophic, determined via the 
radiological examination of the fracture callus34. Hypertrophic non-unions are 
classified by the presence of a fracture callus that has taken a distinct 
horseshoe like morphology. Additionally, they have a good vascular supply 
and are, therefore, associated with poor fixation. In contrast, atrophic non-
unions are identified by a lack of cartilage callus formation, instead replaced 
by the formation of fibrous tissue at the fracture ends. Atrophic non-unions are 
also commonly associated with poor vascularisation around the fracture site, 
often linked to underlying host factors such as smoking or diabetes or a 
significant loss of surrounding tissues, as seen in complex fractures29,28. 
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Figure 1.1: Stages of endochondral ossification during fracture repair. Stage I - 
Haematoma: Initial injury leads to the disruption of surrounding vasculature resulting in the 
formation of a platelet-rich fibrin clot. Secreted chemokines promote stem cell expansion and 
localisation to the fracture site; Stage II - Soft Callus: Hypoxic conditions and instability at the 
fracture fracture site favour chondrogenic differentiation of stem cells from the periosteum 
resulting in a cartilage callus; Stage III - Hard Callus: Chondrocytes within the stabilised callus 
undergo hypertrophy and eventually apoptosis permitting the invasion of blood vessels and 
woven bone formation; Stage IV - Remodelling: Woven bone is remodelled into lamellar bone 
through the synergistic action of osteoblasts and osteoclasts thus re-establishing native bone 
physiology. Figure generated using the Servier medical art database 
(http://www.servier.com/Powerpoint-image-bank) and adapted from Roberts et al.; 201435 and 
Vas et al., 20174. 
 
1.2. Clinical approaches to non-union fracture 
management 
In most cases fractures, especially non-union fractures, efficient bone 
regeneration and union cannot be achieved without external intervention. In a 
majority of hypertrophic non-union fractures, efficient stabilisation of the 
fracture site results in union. However, atrophic non-unions, especially open 
fractures or those accompanied by significant bone or soft tissue loss require 
further intervention to prevent infection and promote fracture healing36–40. The 
overall aim of treatment is to improve the mechanical and biological 
environment at the fracture site, thus making it conducive to bone 
regeneration. In brief, the treatment of atrophic non-unions involves a 
combination of rigid fixation and the use of grafting material. To date, 
autologous bone grafting (ABG) is considered to be the gold standard41. 
Below, we further discuss some of the clinical approaches used in combination 
with fixation to enhance bone regeneration. 
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1.2.1. Bone Grafts 
Globally, around 2.2 million orthopaedic grafting procedures are carried out 
annualy42. The biological activity of bone grafts is often described in terms of 
their osteoconductivity, osteoinductivity and osteogenicity. 
Osteoconductivity is the ability of a graft to direct resident skeletal cell 
migration into the scaffold, in turn producing new bone and directing the in-
growth of new blood vessels. Osteoinductivity is a characteristic that is 
attributed primarily to the 3D structure of the graft and is, therefore, a passive 
process. Osteoinductivity is the ability of a graft to stimulate the deposition of 
new bone through the recruitment and differentiation of skeletal stem cells 
towards a chondrogenic or osteogenic lineage. This process is driven primarily 
by the presence of factors such as PDGF, (BMP) -2, -4 and -7 and interleukins 
43,44. In contrast, the osteogenicity of a graft is associated with the presence of 
bone-forming cells within the graft45. 
The ideal bone graft substitute would be osteoinductive, osteoconductive and 
osteogenic while carrying no inherent risk of infection or host rejection. 
Furthermore, a bone graft should undergo complete remodelling and 
integration. The characteristics above are present in autologous bone tissue 
(Figure 1.2).  Therefore, autologous bone grafting has mostly remained the 
gold standard for the treatment of non-unions and other bone defects46. 
Therefore, the development of grafting materials has primarily focused on 
mimicking the properties of mature bone or the use of growth factors that drives 
bone formation (Table 1.2). Some of these approaches are further discussed 
below. 
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Figure 1.2: (A) Gross structural illustration of cortical bone: Haversian canals contain 
blood vessels that provide nutrient supply and waste removal to the osteocytes contained 
within each osteon. Osteoclasts are involved in bone resorption, whiles osteoblasts form new 
bone, both participating in the process of bone remodelling47. Bone lining cells envelop the 
bone surface and may be a source of mature osteoblasts during bone remodelling48. (B) 
Potential cell-matrix interactions within the bone extracellular matrix: Osteocytes within 
the bone extracellular matrix may be tethered to collagen type I through integrins49. 
Hydroxyapatite can also bind to collagen type I fibrils.  Glycosaminoglycans that are bound to 
the collagen structure and sequester local growth factors within the ECM. Sequestered growth 
factors interact with resident osteocytes, modulating their interaction with progenitors in the 
bone marrow50. Figure created using the Servier medical art database 
(http://www.servier.com/Powerpoint-image-bank). The figure was adapted from Vas et al., 
20174 
 
1.2.2. Autografts 
Autografts make for an ideal choice due to properties that are osteoinductive, 
osteoconductive and osteogenic (Table 1.1). Furthermore, as they are 
obtained from the patient, they demonstrate good histocompatibility and 
healing rates51,46,52. Cancellous bone is often the preferred choice for 
autografts due to its higher osteogenic potential, associated with an abundant 
population of osteoblasts and osteocytes that direct bone formation and 
remodelling, required for the successful incorporation of the graft with the host 
bone. This process occurs primarily through the process of intramembranous 
ossification53. Despite these ideal characteristics, complication rates have 
been reported to range from 20% to 50%, with a significant drawback being 
donor site morbidity. Further complications have been associated with 
variations of bone graft quality, vitality, handling and processing 54,55,56, while 
the need for additional surgery increases the risk of infection57,58. Additionally, 
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the cost of harvesting itself can exceed the cost of commercially available bone 
graft substitutes, however, by far the most significant limiting factor is the 
inadequate supply of tissue for grafting58,59 
 
1.2.3. Allografts 
Allografts are a common alternative to ABG, as they can circumvent significant 
problems associated with ABG such as graft availability, donor site morbidity 
and long-term pain. Another derivative of allografts is demineralised bone 
matrix (DBM). DBM is produced through the removal of the mineral content of 
bone using acid extraction60. Allografts, however, demonstrate primarily 
osteoinductive properties, largely dependent on their maintenance of the bone 
3D microenvironment that contains collagen type 1. Any osteoconductive 
properties are dependent on the variable amounts of present growth factors61. 
Their use, however, also carries significant risks that include bacterial or viral 
disease transmission, especially during procedures involving fresh implants62. 
In an attempt to mitigate the infection risk, some processing methodologies 
involve subjecting allografts to harsh gamma irradiation. Coupled with 
inadequate storage and handling, the resultant damage to the extracellular 
matrix and its components can cause variations in its biological properties 
varying clinical outcomes63.  
 
1.2.4. Synthetic bone graft substitutes  
Synthetic bone graft substitutes are also a common alternative, due to their 
relatively cheap pricing and the absence of limiting factors faced by allografts; 
these include potential donor site morbidity and the risk of disease 
transmission. Additionally, synthetic bone graft substitutes can be 
manufactured in several forms, from powders to pellets, to a  high compressive 
strength cement; this provides versatility during clinical application. Typical 
examples are calcium phosphates based bone graft substitutes that aims to 
mimic the mineral hydroxyapatite that comprises 70% of the dry weight of 
bone64. Furthermore, some substitutes can be mixed with antibiotics making 
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them effective for the treatment of infected orthopaedic defects. Research is 
also underway to combine synthetic bone graft substitutes with growth factors, 
some of which have received clinical approval such as, rhBMP-7 (INFUSE 
Bone Graft, Medtronic Spinal and Biologics)65; and stem cell populations to 
obtain a more osteogenic material. These attempts aim to mimic the desirable 
properties of autografts66,62,67,68. A significant drawback of using synthetic 
variants, however, is a slower resorption rate when compared to naturally 
occurring bone grafts; they have therefore been shown to remain at the 
fracture site several years post implantation69.   
 
1.2.5. Factors affecting graft incorporation 
Several factors can impact the ability of a bone graft material to incorporate 
with host bone tissue. Vascularisation plays an essential role in the 
remodelling process. Therefore, the ability of the graft to allow for and promote 
angiogenesis has a significant impact on graft incorporation70,71. The initial 
immune response also has an impact on the graft remodelling and eventual 
incorporation. A dysregulated secretion of pro-inflammatory cytokines such as 
tumour necrosis factor-β (TNF-β), interferon- γ (IFN-γ) and interleukin-2 (IL-2), 
produced by Th1 lymphocytes can indicate host rejection that adversely 
impacts bone remodelling72,73. However, cytokines such as IL-10, IL-6, IL-5 
and IL-4, secreted by Th2 cells are also involved in tissue remodelling and can 
be considered a positive indicator for tissue remodelling and repair72,73. 
 
1.2.6. Growth factors 
The fracture healing process is reliant on the temporospatial secretion of 
growth factors. The growth factors (GF’s) acting on the cellular component of 
a fracture site are either embedded within the bone extracellular matrix (ECM) 
or is secreted by various cellular populations at the fracture site74.  GF’s have 
therefore become the focus of research aimed at enhancing the fracture 
healing process75. A vital group of osteoinductive factors associated with 
autologous bone grafts are BMPs as first described by Urist and colleagues76. 
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BMP-2 and 7 have been strongly implicated in bone regeneration and have 
therefore been implemented into long bone fracture non-union management 
approaches77–81. Despite the benefits, however, it has been suggested that 
supraphysiological levels of BMP’s may lead to the formation of ectopic bone 
or stimulate cancer cell growth. There is, however, little evidence to 
established a definitive link between BMP’s used orthopaedic applications and 
an increased risk of developing malignancies82. 
Manufacturer Product Name Composition/Use Approved by 
AlloSource AlloFuse™ Heat sensitive 
copolymer with DBM 
in injectable gel and 
putty form/ Bone void 
filler 
US FDA 
Integra 
LifeSciences 
Holdings 
Corporation 
Acell TBM® DBM/ Bone void filler US FDA 
MTF DBX DBM in sodium 
hyaluronate carrier/ 
Bone void filler 
US FDA 
Tutogen Medicals Tutoplast® Allograft Bone/ Bone 
void filler 
US FDA 
IsoTis 
OrthoBiologics Inc. 
OrthoBlast® II DBM/ Bone void filler US FDA and EU 
Weyth Pharma InductOS® BMP-2 in bovine 
collagen sponge 
carrier/ Anterior 
lumbar spine fusion 
US FDA and EU 
Medtronic Infuse® Bone 
Graft 
BMP2 Absorbable 
collagen sponge/ 
Anterior lumbar spine 
fusion 
US FDA 
Stryker OP-1™ BMP-7 in a collagen 
carrier/ Autograft 
alternative 
US FDA and EU 
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Table 1.1: Commercially available osteoinductive bone substitutes. DBM = 
Demineralised Bone Matrix. BMP = Bone Morphogenic Protein. US FDA = United States Food 
and Drug Administration. EU = European Union. Adapted from Miron et al83 and Lui et al84. 
 
1.3. Harnessing the fracture repair process as a 
strategy for non-union repair 
The majority of long bone fractures heal primarily EO, which closely replicates 
the mechanisms of bone developmental. Lenas and colleagues defined the 
concept of "developmental engineering" as a modality for the creation of 
reparative implants that mimic tissue repair or development intermediates. The 
concept of developmental engineering states that tissue development 
progresses through several intermediates, which can be incorporated into an 
engineered regenerative strategy 85,86. EO that occurs during fracture repair 
progresses through several stages (Figure 1). A critical intermediate stage of 
endochondral fracture healing includes the formation of a cartilage callus (soft 
callus) 87. Therefore, understanding the fundamental components that make 
up its ECM of this tissue could be vital for the development of biomaterials 
capable of participating in the process of EO. Besides, factors that regulate 
cartilage callus formation should be carefully considered to mimic its ECM or 
in priming its progenitor cells. 
The ECM is an elaborate 3D scaffolding structure particular to each tissue type 
88,89.  The versatility of the ECM allows it to regulate the production, 
degradation and remodelling of its macromolecules, thus facilitating in the 
development, function and repair of tissues 88–90. The cartilage ECM is largely 
composed of collagen type II, non-collagenous glycoproteins, hyaluronan and 
proteoglycans 90 (Figure 1.3). Collagen type II is formed by a self-assembly 
process that results in a crystalline D-periodic structure, in vivo, proteoglycans 
such as fibromodulin and decorin bind to the collagen type II fibrils to stabilise 
fibril bundles that are larger91. However, stability is maintained mainly via the 
crosslinking between collagen molecules, driven by the covalent bonding of 
lysine and hydroxylysine; this crosslinking is crucial to maintain collagen type 
II stability in vivo92. The ECM also acts as a reservoir for growth factors and 
cytokines that initiate and are involved in regulating cell activation and turnover 
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90,93,94. Mimicking the complex structure of the ECM may allow us to harness 
the natural processes that govern tissue, thus improving tissue regeneration 
strategies, by providing niches to drive the generation of tissue-specific cell 
populations.   
The concepts involving the creation of these mimetic niches will be further 
discussed in the context of improvement made in synthetic polymer 
engineering, natural scaffolds and tissue intermediates composed of stem 
cells and cell-derived matrix. 
 
Figure 1.3: Potential cell-matrix interactions with the soft/hypertrophic callus. 
Chondrocytes and chondroprogenitor cells within the fracture cartilage callus extracellular 
matrix (ECM) may be tethered to collagen type II and X through integrins 90. Cell to cell 
interactions occurs through cadherins. Glycosaminoglycans are bound to the collagen 
structure and sequester local growth factors within the ECM. Sequestered growth factors 
interact with chondroprogenitors, activating cell signalling pathways that promote 
chondrogenesis, which in turn promotes the expression of matrix remodelling factors 94. Figure 
generated using the Servier medical art database (http://www.servier.com/Powerpoint-image-
bank). Adapted from Vas et al4.  
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1.3.1 Synthetic polymer engineering to mimic cell -matrix 
interactions  
Scaffold design and fabrication have been significant areas of research in the 
field of tissue engineering and regenerative medicine 94–97. Materials to create 
tissue-engineered constructs can be either synthetic or natural, and non-
degradable or degradable depending on their application 97. Some of the first 
biodegradable biomaterials used clinically were natural polymers 95; their 
bioactivity was attributed to their ability to interact with cell populations. Natural 
polymers include proteins such as silk, gelatin, fibrinogen and collagen, and 
polysaccharides such as amylose, cellulose, chitin, dextran and 
glycosaminoglycans 97,98. However, a significant limitation of most naturally 
derived polymers relates to manufacturability and functionalisation. Combined 
with inconsistent results, it means that synthetic polymers are not more widely 
investigated for tissue engineering purposes97.  Much work is focussed on 
using fabricated polymer constructs to modulate the interaction of cells with 
the material in an attempt to replicate major cell niches. High throughput 
screen platforms have further driven the use of surface topography modulation 
for tissue engineering. 
There are several synthetic polymers that have been used for bone and 
cartilage tissue engineering; these include polyglycolide (PGA), polylactic acid 
(PLA) and polysulfone (PSU) 99–102. The applications of these polymers have 
been extensively reviewed 103,104 and cover their limitations which are primarily 
associated with their lack of bioactivity105–107.  
Surface modifications such as the use of heparin functional groups, growth 
factors such as basic fibroblast growth factor (bFGF) localised to the material 
surface have resulted in enhanced cell attachment and proliferation 108. 
Moreover, modifying surface topography has also shown great promise in 
enhancing cell attachment and differentiation, with enhanced osteoblastic cell 
adhesion observed through the fabrication of specific nanoscale topographies 
109–111. Electrospun PLA/Polycaprolactone (PCL) hybrid scaffolds with 
controlled fiber alignment, demonstrate enhanced chondrogenic differentiation 
of septum-derived progenitors 112. Similar studies have also reported success 
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in directing cells towards a chondrogenic fate through surface modifications 
113–118. Further modulation using methacrylates via the addition of functional 
groups such as phosphates and glycosaminoglycans, which are found in 
native bone and cartilage, induce hMSCs towards an osteogenic or 
chondrogenic lineage, respectively 119. The approach of polymer modifications 
offers excellent promise as a tool for the development of novel biomaterials 
capable of regulating cellular function in vivo.  
Polymer array technologies have employed varying physical properties or 
chemical concentrations allowing for the simultaneous screening of several 
polymer blends, reducing the time and resources needed to develop novel 
synthetic biomaterials. Polymer array technologies 120,121 (the emergence of 
polymer array technologies has been extensively reviewed elsewhere 122). 
Recent developments in microfabrication using robotic liquid-dispensing 
technology has been used to examine various conditions and their impact on 
cell behavior, with research directed towards pluripotent stem cells 123,124, 
primary articular chondrocytes 125. Moreover, polymer array technology has 
been utilised to identify specific material properties that can enhance the 
process of isolation, expansion, and differentiation of human skeletal 
progenitors 126,127. There is a possibility that this technology could be leveraged 
to identify polymers that mimic specific cell-matrix interactions that are 
observed during the fracture repair process as a means to engineer the 
endochondral fracture healing response. 
Technologies such as “TopoChip” have driven further automation of array 
screening; that uses unbiased algorithms to fabricate varying topographies on 
PLA. This approach resulted in the identification of specific patterns that 
demonstrate enhanced osteogenic differentiation 128,129. The TopoChip was 
further optimised using a chip carrier has helped reduce variations within the 
culture system that may affect cell viability and adhesion 130. Moreover, the 
emergence of additive fabrication techniques such as 3D printing allows for 
finer control of spacial arrangement, and more dynamic and rapid prototyping. 
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1.3.2. 3D printing of bone and cartilage tissues 
The field of tissue engineering has strived to mimic the cellular and 
extracellular bone matrix as a means of restoring bone tissue and improving 
its functions in vivo. The tissue microenvironment, including bone and cartilage 
tissue, is a complex 3D structure that provides a template for cell adhesion and 
initiates bone repair in vivo 131,132. It is essential to control the 
microenvironment to achieve efficient micronutrient transport and waste 
removal to and from the most innermost regions of the scaffold, this can be 
achieved either via controlling porosity or promoting vascularisation of the 
construct132,133. Traditional fabrication techniques such as particle/salt 
leaching 134, chemical/gas foaming 135 and thermally induced phase separation 
136 only allow for gross control of the 3D structure and are thus limited in their 
ability to mimic the complex ECM micro-architecture. Therefore, the field has 
turned to additive manufacturing methods such as 3D printing. Izana and 
colleagues optimised a 3D printing process to obtain collagen and calcium 
phosphate-based scaffolds that demonstrated robust new bone formation 
when implanted into critically sized murine femoral defects in 9 weeks137.   
Developments such as biopolymer printing have resulted in the production of 
constructs aimed at cartilage and osteochondral tissue engineering 138–140. 
Moreover, 3D printing offers a distinct advantage when it comes to cartilage 
tissue engineering due to due to the limited ability to incorporate cells into 
cartilage mimetic scaffolds. Additive manufacturing could be used to print and 
incorporate a cellular component into the scaffolds alongside key 
chondrogenic factors such as the TGF-β superfamily 141. 
 
1.3.3. Biomimetics through the use of natural target-tissue ECM 
The preliminary aim of tissue engineering was focused on developing 
materials that mimicked adult tissues, with the aim of incorporation into the 
host and subsequent remodelling, as defined by Langer and Vacanti in 1993 
142. Initial attempts were made using biodegradable scaffolds in combination 
with adult cells. However, in the context of bone repair, this approach has to 
date provided no clinically approved therapies. Due to this, current research 
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towards improving the bioactive properties of regenerative implants through 
the use of naturally occurring target tissue ECM has emerged. Indeed, the 
process of xenogeneic tissue decellularisation and its use for tissue 
engineering strategies within the field of regenerative medicine has been 
intensively studied 143–146. Xenografts overcome one of the key issues with 
transplantation; the lack of available tissue by providing a seemingly abundant 
source of material.  
The process of decellularisation aims to remove all immunological components 
while leaving behind the ECM of the tissue and its associated growth factors, 
to maintain the ECM proteins complex spatial arrangement 147. The ECM plays 
a crucial role in maintaining cell-matrix interactions that favour native tissue 
organisation and remodelling 88. Importantly the structural and functional 
proteins in the ECM are well conserved within species. This high level of 
homology allows these matrices to be implanted in recipients of other species 
without rejection 148. The past decade has driven research towards novel 
biomaterials through the process of organ and tissue decellularisation. Some 
of the many examples of positive clinical results include the use of FDA 
approved decellularised matrices such as porcine heart valves (Synergraft®; 
Cryolife) and acellular dermis (Alloderm®; LifeCell) 149.  
The use of decellularised cartilage has drawn much attention due to its ability 
to harbour a large number of bioactive cues for tissue formation. The 
interaction of decellularised cartilage with resident cells, several chemotactic 
stimuli and activation of chondroinductive signalling pathways could result in 
continuous remodelling of the tissue. Decellularisation of cartilage, however, 
requires a vigorous protocol due to its dense nature, an approach known to 
reduce the glycosaminoglycan (GAG) content and elasticity of the matrix 147. 
Despite this, the use of decellularised and lyophilised cartilage scaffolds have 
previously demonstrated bone formation in a rabbit model by Gawlitta and 
colleagues 150. The study involved coupling pre-primed chondrogenic MSCs 
with decellularised cartilage scaffolds and demonstrated effective bone 
mineralisation when compared to the unseeded decellularised matrix. 
However, the contributing factors to the endochondral bone formation were 
unidentified but could include components within the decellularised 
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cartilaginous matrix, or factors produced by the cells as a result of the cell-
matrix interaction 150. The choice of articular cartilage-derived scaffolds used 
in the study by Gawlitta et al. do pose limitations due to both tissue physiology 
and in vivo function. Articular surfaces are formed during pre-natal skeletal 
development and are highly stable during adult life 151. Indeed, factors such as 
chondromodulin 1 (ChM-I) have been implicated in the stability of articular 
cartilage by inhibiting EO in porcine models 152, and it has been further 
suggested that ChM-I functions as an inhibitor of angiogenesis, a process 
essential to endochondral remodelling 153,154. 
Additionally, a plethora of Wnt and BMP signalling modulators have been 
implicated in articular cartilage stability. Therefore, there is a requirement for a 
source of chondrogenic ECM-derived scaffolds that is intrinsically primed for 
endochondral remodelling. Other cartilaginous regions such as costal cartilage 
provide a promising option, as it gradually undergoes EO well into adult 
development 155. Furthermore, a study by Okihana & Shimomura (1992) 
indicated that when devitalised costal cartilage was implanted subcutaneously 
into rabbit and mouse models it underwent endochondral remodelling 156. 
In summary, innovative decellularisation approaches may allow for the 
development of methodologies that minimise ECM damage and when 
combined with underexplored and more targeted tissue sources may be the 
key to developing viable grafts that can mimic a critical phase the 
endochondral repair process. 
 
1.3.4 Mechanical Properties of a cartilage callus mimetic bone 
graft. 
The mechanical properties of native tissue can be an indicator of its structural 
integrity, with several disease processes affecting the mechanical properties 
of both bone and cartilage. Several studies have therefore investigated the 
mechanical properties of bone and cartilage in both healthy and disease 
states157–159.  
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Fracture stabilisation is, therefore, carefully considered during the treatment of 
fractures, especially non-unions160,161. Moreover, bone grafting materials, the 
mechanical properties of the graft must not only facilitate fracture stability but 
allow for graft placement without damage to surrounding tissues162,163. The 
most widely used method of autografting can utilise bone tissue from either 
cancellous regions or cortical regions, with the latter providing greater 
mechanical support, while the latter is more malleable and carried a reduced 
risk of intra-operative fractures during implantation.164 Additionally, due to the 
limited mechanical stability provided by cancellous allografts, their use is 
limited to bone cavity defects165. 
There are several factors that may influence the mechanical properties of a 
bone graft substitute. For example, the porosity of a grafting material may be 
beneficial for cellular infiltration but may have a significant impact on the 
mechanical stability of the graft166. Assessment of these mechanical properties 
may therefore, provide important insight into the biological performance of a 
grafting material. Moreover, mechanical testing can be an important tool for 
the testing of decellularised tissues167. Properties such as flexural mechanical 
stiffness and Planar biaxial tensile strength can be assessed168.  
 
 
1.3.5. Stem cells for the creation of bone-forming tissue 
intermediates. 
Many of the key developments within the field of tissue engineering centre on 
the ability of cells to interact positively with its carrier and mediate tissue 
formation and integration. It is therefore essential to investigate the interactions 
of key cell types in any regenerative approach to developing effective stem 
cell-based skeletal regenerative strategies. 
Embryonic stem cells 
The embryonic stem cell (ESC) is derived from an early mammalian embryo, 
and possesses a remarkable potential for differentiation into cell types from all 
three germ layers as demonstrated by Kaufman and colleagues using mouse 
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embryos, termed ES cells 169. In vitro, culture protocols paved the way for 
isolation and culture of the first human ES cell in 1998 170, where it was 
demonstrated that human ES cells could be kept in culture for up to 5 months 
followed by subsequent differentiation into all three embryonic germ layers. 
This facilitated further research into ES cell culture and differentiation 
programmes. Since then, ES cell research has generated promising results 
towards the treatment of diabetes 171, cardiovascular disease 172–174 and 
musculoskeletal regeneration 175. In vitro differentiation of murine and human 
ES cells towards the osteogenic lineage has also been successfully achieved 
176,177.  Although multiple studies have shown that ESCs seeded onto scaffolds 
and primed in osteogenic media do not produce bone in vivo 178,179, the 
formation of bone within teratomas aligned with hypertrophic cartilage regions 
has been observed, indicating the capacity of ES cells to form bone through 
the developmental process of EO. This potential to form endochondral bone 
was confirmed with murine ESCs which were seeded onto ceramic scaffolds 
and differentiated towards a chondrogenic lineage using TGF-β 178. 
Furthermore, when implanted in vivo at an ectopic site into nude mice for 21 
days, bone formation was observed on every one of the implanted cartilage 
tissue-engineered constructs (CTECs). Their capacity to form bone was further 
demonstrated when the CTECs were implanted orthotopically in rats with 
critical-size cranial defects. Similar results have also been obtained using 
human ESCs 180,  thus highlighting the ability of ESCs to form bone via the 
endochondral pathway, hence mimicking both developmental skeletogenesis 
and fracture repair. Despite this vast potential of ESCs within tissue 
engineering and especially within the field of bone tissue engineering, their 
application is restricted by complex culture conditions, ethical constraints 
related to ESC isolation and their inherent tumour forming capacity 181,182.  
Induced pluripotent stem cells 
There was a renewed interest in pluripotent stem cells when Takahashi and 
Yamanaka broke new ground by re-establishing the principles of 
developmental biology, which state that somatic cell differentiation is an 
irreversible process. Transfecting murine and human fibroblasts with the 
embryonic factors Oct4, c-Myc, Sox2, and Klf4 caused the regression of cell 
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characteristics to a pluripotent, embryonic-like state, leading to them being 
named induced pluripotent stem cells (iPSCs) 183,184. It was also demonstrated 
that like ES cells, iPSCs were able to form tissue from all three germ layers. 
However, iPSCs also had the inherent capacity to form teratomas (tumours) in 
vivo. Importantly, establishing a route for producing stem cell populations from 
a patient’s cells overcomes many of the ethical issues faced by ES cell use. 
In the context of bone repair, deriving progenitors with bone forming potential 
from iPSCs has been an intensively studied area. Recent work has described 
a xeno-free defined culture condition for the differentiation of iPSCs into iPSC-
derived mesenchymal stem cells (iPS-MSCs), which were able to differentiate 
into chondrogenic, osteogenic and adipogenic lineages in vitro 185. 
Furthermore, when these cells were osteogenically differentiated for 4 days 
and implanted into calvarial defects in immunocompromised mice, de novo 
bone formation originating from the implanted iPS-MSCs was observed 185. A 
recent study by Shey and colleagues has also demonstrated the efficacy of 
iPSC-MSCs for the treatment of non-union defects in mice 186. Furthermore, 
their chondrogenic differentiation capacity, and therefore their potential 
application towards endochondral tissue formation, has been demonstrated 
187. The ability to create iPSC-derived cartilage constructs was also 
demonstrated with optimised culture conditions utilising scaffold-free hyaline 
cartilage tissue that displayed good integration into surrounding cartilage 
tissue when implanted, while not forming tumour masses 188. Although this 
study was targeted towards the treatment of cartilage defects, it is envisaged 
that the differential stimulation of these cartilage constructs may allow the 
generation of implants capable of bone repair. Indeed, iPSCs have been 
shown to undergo chondrocyte hypertrophy similarly to ESCs 180. Furthermore, 
the possibility of direct cellular reprogramming towards chondroprogenitors, a 
process that takes many of the concepts used to derive iPSCs, has 
demonstrated the ability of engineered cells to undergo in vitro hypertrophic 
differentiation. Implants containing these cell populations can drive 
endochondral bone formation and remodelling post-implantation in nude mice 
189.  
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Mesenchymal stem cells 
One of the most desirable properties when choosing a cell type for bone tissue 
engineering is the ability to isolate tissue-specific regenerative cell populations. 
As previously discussed, ESCs provide a highly malleable cell source, and the 
development of iPSCs has further advanced the field of personalised medicine 
through the generation of pluripotent populations from somatic cell sources. 
However, despite these developments, the most popular cell type still 
employed for the development of skeletal regeneration strategies is the 
mesenchymal stem cell (MSC). MSCs are widely recognised for their ability to 
differentiate towards osteochondral lineages 190,191 and can be derived from 
several tissue sources.  The most commonly used source of MSCs is the bone 
marrow, from which cells are isolated through the extraction of a bone marrow 
aspirate 192. Another common source of MSCs is adipose tissue from which 
MSCs (pericytes) are isolated from digested fat tissue 193.  
Caplan first coined the term MSC in 1991 194. It was, however, in the 1960s 
and 1970s that seminal studies by Friedenstein isolated mesenchymal stromal 
cells and revealed their osteogenic potential by heterotopic transplantation 
195,196.  Since then, MSCs have been defined by the minimal criteria of positive 
expression of CD105, CD73, and CD90 and negativity for CD45, CD34, CD14, 
CD79α and HLA-DR 197. MSCs have been extensively used and reviewed for 
their clinical applicability within the field of bone tissue engineering 198,199. In 
relation to the treatment of bone fracture repair, it has been shown that the 
delivery of allogeneic BM-MSCs in combination with demineralised bone 
matrix enhances fracture healing in clinical models of diabetes mellitus in rats 
200. Similar results are also demonstrated by several other studies 
incorporating MSCs with scaffolding material for the treatment of fracture 
repair, particularly in their proposed use in non-union fractures 201–203.  
Until now, the treatment of large bone defects has primarily relied on 
approaches that aim to harness the intramembranous pathway of bone 
regeneration. However, as discussed previously, recapitulating EO may be 
more efficacious. Martin and colleagues applied this approach by creating 
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cartilage constructs in vitro using human BM-MSC pellet cultures. Hypertrophy 
within these engineered constructs was induced through the withdrawal of 
TFG- β and the introduction of β-glycerophosphate with Thyroxin. The 
resulting constructs displayed increased collagen type X deposition, typical of 
hypertrophic cartilage. Upon implantation in immunocompromised mice, these 
engineered hypertrophic cartilage constructs formed bone around the 
periphery at four weeks, with extensive endochondral bone formation after 
eight weeks 5. More recent work has also illustrated that the addition of anti-
inflammatory/tissue repair macrophages may further enhance the cartilage 
forming capacity of BM-MSCs 204. This highlights the potential role of 
inflammatory cells during the fracture repair process; however further 
orthotropic investigations are required to establish their clinical significance. 
 
1.3.6 The periosteum – The master regulator of fracture repair  
Despite the immense progress directed towards the design of fracture repair 
implants, the integration of all necessary tissue properties and functions into a 
single system remains a major research challenge. With this in mind, the ability 
to mimic cell-matrix interactions with novel biomaterials, developed using 
natural matrices or engineered through systematic screening of polymers and 
surface topography, is of course of key relevance. However, if these systems 
are to be combined with cells, these should also be carefully selected to 
represent those modulating the fracture repair process. 
The periosteum is a highly vascularised connective tissue that envelops the 
bone surface of long bones 205. It serves as a biophysical barrier to modulate 
the environmental conditions on the bone surface. The periosteum is 
composed of two distinct layers: an outer fibrous layer composed of fibroblastic 
cells in a collagen and elastin matrix and an inner cambium layer, which 
provides a niche for a range of cell types, including fibroblasts and 
stem/progenitor cells 205,206. Recent prominent evidence has documented the 
regenerative potential of periosteal tissues and the functional capacity of 
periosteum-derived cells (PDCs) in the bone healing process 207,208.  The 
periosteum is predominantly responsible for 90% of cartilage and woven bone 
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formation in the early fracture callus, with its removal significantly attenuating 
bone repair 206,209. In this respect, the periosteum has drawn considerable 
attention in pre-clinical bone tissue engineering approaches 35. The 
regenerative potential of the cells contained within the periosteum has been 
further demonstrated in vivo where they play a role in direct bone formation as 
well as in chondrogenesis and EO 210.  
Consequently, great efforts have made to target and isolate PDCs as a cell 
source for bone tissue engineering purposes. Previous work has shown that 
once these cells are inoculated into nude mice in scaffold 207 and scaffold-free 
systems 211, they give rise to bone and cartilage tissue. Indeed, murine PDCs 
expanded in the presence of FGF demonstrated an enhanced capacity for in 
vivo bone production mediated by BMP-2 via the endochondral pathway, a 
characteristic unique to PDCs. Although culture-expanded PDCs have 
increased our knowledge and understanding of the periosteum, in vivo 
targeting of these cells within their niche, or replication of this tissue and 
therefore mimicking the role of the periosteum are both attractive avenues for 
further investigation.  
 
1.4. General Aim of the thesis 
This thesis aims to investigate the potential of harnessing the process of 
endochondral ossification, developmental engineering and decellularisation to 
establish and validate a methodology to produce a hypertrophic cartilage-
based fracture callus mimetic with the potential for clinical application (Figure 
1.4).  
Objective 1: Three distinct methodologies (Vac-Stx, Vac-OS and Vac-SDC) 
will be applied to porcine costal cartilage. Subsequently, the resultant scaffolds 
will be vigorously characterised for the elimination of immunogenic 
components, including key factors of graft rejection such as residual DNA and 
alpha-gal. Moreover, the matrix integrity of the resultant will initially be 
assessed using sulfated glycosaminoglycans (sGAGs) as an indicator. An 
optimal decellularisation methodology will be selected based on both efficient 
removal of immunogenthe ic components and the retention of sGAG content. 
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Objective 2: Scaffolds produced using the optimal decellularisation 
methodology (dcECM) will be subjected to further ECM analysis using highly 
sensitive, novel approaches such as fluorescence lifetime imaging microscopy 
(FLIM) and Raman spectroscopy that will aim to determine minute changes in 
the ECM post decellularisation.  
Objective 3: The ability of the dcECM to promote or enhance chondrogenesis 
in skeletal articular chondrocytes and human periosteal stem cells (hPDSCs) 
will then be tested in vitro. Subsequently, the dcECM will be tested for it is in 
vivo biocompatibility via implantation into immunocompetent mice and 
assessed for the cellular immune response to the scaffolds. 
Objective 4: The dcECM will be further processed to produce constructs that 
can be upscaled using a reproducible method.  The upscaled scaffolds should 
have sufficient porosity to allow for cellular infiltration. Moreover, upscaled 
scaffolds should demonstrate chondroinductive properties when assessed 
using hPDSCs.  
Objective 5: The dcECM will be digested and coated onto tissue culture plastic 
to give a chondroinductive tissue culture surface for the rapid differentiation of 
hPDSC’s towards a chondrogenic phenotype.  Moreover, the tissue culture 
coating will be sterilised using either an autoclaved solution or UV light.  
 
Hypothesis 
Through the development of an optimised decellularisation methodology 
porcine costal cartilage will be decellularised with minimal damage to the 
native extracellular matrix. Moreover, the decellularised cartilage matrix should 
be non-immunogenic and could be used to enhance chondrogenic 
differentiation in skeletal cell populations (Figure 1.4). Subsequently, the 
decellularised scaffolds will be used to generate upscalable constructs to meet 
clinical needs 
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Figure 1.4: Illustration of the production process for a decellularised costal cartilage 
implant. (1) Fresh porcine costal cartilage will be obtained and subjected to an optimised 
decellularisation methodology and processed to form an implant of the required dimensions. 
(2) In tandem, autologous periosteum-derived cells will be obtained from the intended recipient 
and expanded. (3) Expanded patient cells will be seeded onto the scaffold and primed towards 
a chondrogenic phenotype. (4) Primed scaffolds will be implanted into the intended patient. 
Figure generated using the Servier medical art database (http://www.servier.com/Powerpoint-
image-bank 
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2. Development of an optimised costal 
cartilage decellularisation methodology 
 
2.1 Introduction 
2.1.1 Overview of decellularisation 
The concept of developing a bone graft substitute capable of mimicking the 
callus phase of endochondral fracture repair is based on the principle of 
developmental engineering, that suggests mimicking bone repair intermidiates 
of a repair process may be able to better participate in the early endochondroal 
fracture healing8,19,212. This approach may have an advantage over traditional 
bone grafts such as DBM, that mimic the bone microenvironment. Moreover, 
although massive strides have been made in the manufacture of synthetic 
scaffolds, through the use of innovative fabrication technique, they are unable 
to mimic the complex structure of the native ECM213. The use of natural tissue 
sources has, therefore, remained an area of interest since the establishment 
of the modern field of allografting, first pioneered during world war II214. The 
use of allogeneic tissues for transplantation eventually led to the exploration of 
the transplantation potential of xenogeneic tissues. Despite this, both 
allografting and xenotransplantation,  are hapmpered by the host immune 
response they elicit in the recepient215. In the late 1970’s more importance was 
given to the immunogenicity of orthopaedic allografts. Preliminary work 
demonstrated a reduction in immunogenicity when allografts were frozen and 
a further decrease when they were freeze-dried, whilst having minimal effect 
on functionality216. Since, it has been recognised that components of the ECM 
are conserved amongst species217 and therefore well tolerated in xenogeneic 
transplants, while cellular components are largely responsible for the adverse 
immune response218–220. The processing of xenogeneic tissue for clinical 
application must, therefore, involve the removal of immunogenic cellular 
components221, a process termed decellularisation. 
 The ideal outcome of decellularisation would be the complete removal of 
cellular components from a tissue or organ while retaining native ECM 
41 
 
structure and composition. To date, however, no decellularisation 
methodology has achieved complete removal of cellular components without 
some disruption to the extracellular matrix. A more realistic aim is, therefore, 
the reduction of immunogenic material to levels falling below the threshold 
required for an immune response, while causing minimal damage to the ECM. 
When considering the use of decellularised xenogeneic tissues, it becomes 
especially important to monitor levels of remnant cellular antigens such as 
alpha-gal and DNA, both key promoter of xenogeneic transplant 
rejection222,223.  
Optimal conditions for decellularisation can vary depending on the tissue being 
considered; this results from tissue specific differences in cell and matrix 
density. Several methods have been applied for the decellularisation of tissues 
and organs; these can be combined and modified for optimal efficiency. 
Cartilage due to its dense and avascular nature often requires more disruptive 
physical and chemical decellularisation approaches, as highlighted in Table 
2.1 these include mechanical agitation and the use of ionic surfactants such 
as SDS and SDC. Generally, the methods most suitable for the 
decellularisation of dense tissues such as cartilage are also the most disruptive 
to the ECM.  
Method Mechanism of 
Action 
Impact on ECM Tissues/ 
References 
Physical 
Mechanical 
Agitation 
Can cause cell 
lysis, facilitate 
exposure to the 
decellularising 
agent and 
facilitate cellular 
removal 
- Intense 
agitation can 
disrupt the ECM 
- Insufficient for 
the removal of 
DNA fragments 
Heart 
Valves224,225, 
Cartilage226,227, 
Arteries228 and 
Dermis229–231 
Freeze-Thaw Facilitates with 
cell lysis via 
formation of 
- Has minimal 
impact on ECM 
Cartilage226,232, 
Tendon233,234, 
Larynx235 
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intracellular ice 
crystals 
structure and 
protein content 
- Ineffective for 
DNA removal 
High hydrostatic 
pressure 
Pressures greater 
than atmospheric 
pressure can be 
applied for cell 
lysis 
- Denatures 
ECM Proteins 
Blood 
Vessels236,237 
Non-Ionic Detergents 
Triton X-100 Disrupts lipid-lipid 
interactions 
aiding in cell lysis 
- Effectivity is 
highly dependent 
on the tissue. 
- Results in the 
disruption of 
GAG Content 
Trachea238, 
Tendon239, 
Bone240, 
Cartilage241 
Tween20™ Disrupts lipid-lipid 
interactions and 
aids in the 
clearance of cell 
debris 
- Ineffective 
unless it's 
combined with 
another 
decellularisation 
agent 
Lung242, 
Cartilage243 
Ionic detergents 
Sodium dodecyl 
sulfate (SDS) 
- Solubilise both 
cytoplasmic and 
nuclear 
membranes 
- Aids in clearing 
nuclear remnants 
and cytoplasmic 
proteins 
- Can damage 
the collagen 
structure 
- Removes 
GAGs 
Heart Valves244, 
Dermis245, 
Cartilage150,226,24
6 
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Sodium 
deoxycholate 
(SDC) 
-Similar 
mechanisms to 
SDS 
- More disruptive 
to ECM structure 
than SDS 
Heart Valves247, 
Trachea238 
Enzymes 
Trypsin Cleaves peptide 
bonds helping 
disassociate cell-
matrix 
interactions248 
- Can disrupt the 
ECM structure 
and facilitate 
GAG loss 
- Exposure to 
trypsin must be 
limited to prevent 
extensive 
damage 
Heart Valves225, 
Cartilage249 
Deoxyribonuclea
se 
Facilitates the 
hydrolysis of mid-
fragment and 
terminal bonds of 
deoxyribonucleoti
de chains 
May remain in 
decellularised 
ECM and elicit 
an immune 
response. 
Whole 
hearts250,Cartila
ge 246, Tendon-
bone251 
Ribonuclease Facilitates the 
hydrolysis of mid-
fragment and 
terminal bonds of 
ribonucleotide 
Similar to 
Deoxyribonuclea
se 
Annulus 
fibrosus252, 
Cartilage238 
Osmosis 
Hypotonic and 
hypertonic 
solutions 
Cell lysis due to 
osmotic shock 
May affect the 
mechanical 
properties of the 
ECM253 
Cartilage254,255, 
Dermis231 
Table 2.1: Approaches for the declularisation of tissues and organs. Adapted from Yang 
et al256 and Badylak et al148 
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2.1.2 The use of decellularised scaffolds in tissue engineering 
Further justification for the use of decellularised scaffolds can be found in the 
abundance of decellularised ECM products that have been trialled for clinical 
use. Examples include but are not limited to porcine heart valves (Synergraft®; 
Cryolife) and Acellular dermis (Alloderm®; LifeCell). Furthermore, a pre-clinical 
study involving intestinal sub-mucosa has yielded positive results for the 
surgical repair of the rotator cuff 257 and Achilles tendon injuries258. Recent 
advances in tissue engineering have, however, shown that although biological 
scaffolds can be used at non-homogenous sites, tissue-specific scaffolds may 
yield better outcomes259. These findings stem from the fact that there is a huge 
variation in the ECM composition of various orthopaedic tissues such as 
cartilage, bone, tendon and ligaments260. Furthermore, the tissue-specific 
ECM composition allows seeded tissue-specific cells to follow intrinsic 
biological cues to produce the cell phenotypes required for maintenance of 
tissue or organ specific functions89. Current treatment approaches with 
xenografts have, however, yet to yield results that are comparable to the gold 
standard of autografting261,262. As previously suggested, a better approach to 
developing a bone graft for fracture healing may require the fabrication of an 
ECM derived scaffolds that mimics the cartilage callus phase of fracture repair, 
thus capable of undergoing endochondral ossification. 
 
2.1.3 Decellularisation of dense avascular t issues 
Due to its ability to gradually undergo endochondral ossification in vivo when 
subcutaneously implanted156 and the physiological similarities between 
humans and pigs263, porcine costal cartilage was an ideal source of tissue for 
the production of an endochondral scaffold primarily due to the ease of 
extraction and abundance of tissue. When compared to sources of articular 
cartilage, costal cartilage has the tendency to undergo gradual endochondral 
ossification throughout the life of the animal, while healthy articular cartilage is 
largely stable264,265. Since the aim of this study is to produce constructs that 
will be used as endochondral substrate, it is important to select a source that 
is pre-disposed to endochondral ossification. Moreover, articular cartilage in 
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porcine models on average are 1.5mm thick compared to costal cartilage that 
can range from 30-40mm in thickness depending on the age of the animal266, 
this characteristic allowed us to investigate the effect of tissue thickness or 
volume on the decellularisation process. Costal cartilage, like other hyaline 
cartilage sources is sense and avascular in nature, hindering the delivery of 
decellularisation agents into tissues267. Overall, this characteristic can impede 
the process of decellularisation148,268. Studies such as that by Xu and 
colleagues attempt to overcome limited tissue permeability by utilising harsh 
ionic surfactants such as SDS  in combination with hydrostatic pressure of up 
to 200 mmHg, 251. Although this approach was successful in removing cellular 
content, significant loss of Glycosaminoglycans was reported. The principle 
behind the use of ionic surfactants and hydrostatic pressure for the 
decellularisation of dense avascular tissue, however, remains in its ability to 
disrupt the matrix allowing for better penetration of decellularisation agents and 
removal of cellular content. Unfortunately, the use of harsh ionic surfactants or 
physical methods results in the disruption of the structural and biological 
integrity of the native ECM. The use of ionic surfactants such as SDS and SDC 
can have a significant impact on the native sGAG content; this is evident with 
tissues such as hyaline cartilage150,226,249,269. Although, sGAGs that are 
present in various tissue types, they are especially abundant in cartilaginous 
ECM serving as both structural and functional components 267,270. Additionally, 
besides their role in cartilage ECM homoeostasis 271, sGAGs have also been 
associated with their ability to promote chondrogenesis 272–274 and regulate 
endochondral ossification275. Therefore, it is essential to consider the 
maintenance of sGAG content, especially when developing a decellularised 
cartilage derived scaffold with a capacity for endochondral ossification. 
Gawlitta and colleagues faced similar challenges in the development of an 
articular cartilage derived endochondral substrate. The use of cryomilling and 
SDS during decellularisation resulted in morselised cartilage scaffold granules, 
there were further fabricated into scaffolds that that were incapable of driving 
orthotopic endochondral ossification without the addition of stem cell 
populations and extensive periods of chondrogenic priming150. Thus, in the 
pursuit of developing a cartilage callus mimetic, we faced the challenging task 
of developing a decellularisation methodology that effectively increases the 
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permeability of the dense costal cartilage ECM, allowing for enhanced cellular 
clearance, all while retaining substantial sGAG content.  
 
Vacuum Assisted Decellularisation 
Vacuum desiccators have been used extensively in the processing and 
storage of food items276. Additionally, freeze-drying under vacuum is routinely 
utilised for the removal of water content, thus facilitating long-term storage of 
clinically used, natural ECM derived tissue substitutes such as NuOss® and 
Acell TBM®. Since many clinically available decellularised tissues are stored 
in a freeze-dried state, time-consuming rehydration is required before use. Jun 
and colleagues incorporated the use of vacuum in a process they termed 
“vacuum pressure impregnation” to aid in speeding up the rehydration process. 
The study demonstrated that the use of vacuum assistance reduced 
rehydration times from 6 hours to just 30 minutes. These findings we attributed 
to the increased permeation of water into the freeze-dried tissues as a result 
of hydrating under a low-pressure environment. Lange and colleagues were 
the first to incorporate this principle into a decellularisation methodology for 
whole human and porcine trachea238. The principle of using vacuum 
assistance for decellularisation relies on the removal of air from the tissue, 
forcing water alongside any decellularising agent into the tissue, thus 
improving permeability (Figure 2.1). The results obtained by Lange and 
colleagues238 demonstrated a distinct increase in decellularisation efficiency, 
especially when considering the hyaline cartilage tracheal rings. When vacuum 
was added to the protocol there was an 84% increase in the removal of 
residual DNA compared to an identical methodology lacking vacuum 
assistance. Overall, these results also suggested that the greater 
decellularisation efficiency would mean shorter decellularisation times when 
using vacuum assistance277,278. These findings were further confirmed in a 
study by Butler and colleagues279 that utilised the same vacuum assisted 
decellularisation methodology for the production of human tracheal scaffolds 
for clinical implantation. Although both of the studies above have demonstrated 
a reduction in decellularisation times when combined with vacuum-assistance, 
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they report minimal differences in sGAG retention compared to non-vacuum 
assisted methodologies. These results may stem from the rapid removal of air 
from the tissues and replacement with the aqueous decellularisation solution, 
primarily due to the large water content forming an integral part of the cartilage 
ECM280.  Moreover, both studies employ SDC as an ionic surfactant, known to 
cause extensive damage to the ECM247. Therefore, there is still the need for a 
decellularisation methodology that limits the used of ionic surfactants and 
enzymes that actively target the ECM. 
It was therefore hypothesised that by incorporating vacuum assistance (Vac) 
alongside three previously established methodologies for the decellularisation 
of dense or cartilaginous tissues; would aid in the development of an optimal 
decellularisation methodology for porcine costal cartilage that minimises ECM 
disruption and sGAG loss. 
 
Figure 2.1: Schematic highlighting Mechanisms of forced tissue impregnation using vacuum 
assistance. Figure generated using the Servier medical art database 
(http://www.servier.com/Powerpoint-image-bank 
 
2.2 Methods 
 
2.2.1 Costal cartilage harvest 
Fresh porcine costal cartilage was obtained from Large-White/Landrace 
crossbred pigs ranging from 40 to 70 Kgs (being terminated from unrelated 
studies at Northwick Park Institute for Medical Research; NPIMR, London, UK; 
approximately 8 ribs were harvested from each pig; n=5). Lateral thoracic 
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incisions were made and the soft tissue excised and cleared to expose the 
costal regions of the rib cage.  Costal cartilage directly adjacent to the bone 
tissue was isolated from the rib cage. Any remaining adherent soft tissue was 
removed using a sterile scalpel and the harvested costal cartilage placed in 
sterile plastic bags and stored immediately at -20°C. 
 
2.2.2 Development of decellularisation methodology 
Frozen costal cartilage samples were defrosted at room temperature (18-
21°C). The cartilage tissue was dissected into discs measuring 10 mm in 
diameter and 1 mm in height, with a volume of 78.5 mm3. These discs were 
allotted into three groups each containing five discs.  These groups were 
subjected to three independent decellularisation methodologies (Table 2.2). 
Post freeze-thaw, the subsequent steps in all the methodologies were carried 
out under negative pressure at 2000 µmHg (267 Pa) (Figure 2.2), using a 
vacuum desiccator (Sigma-Aldrich, Dorset, UK).   All decellularisation methods 
utilised 250 mL of solution per step. All methodologies also included a 
nuclease digestion step to eliminate nucleic acids. The DNAse/RNAse buffers 
contained 10 mM CaCl2 and 60 mM MgCl2, required for the activity of 
nucleases. This step was carried out at 37°C under agitation using an orbital 
shaker (ThermoFisher, Bedford, UK). All non-enzymatic steps were carried out 
at 4-8ºC. Hypertonic solution contained 1M NACL, 50mM of Tris HCL and 
10mM of EDTA. Hypotonic solution contained 10mM of Tris HCL and 5 mM of 
EDTA.  
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Vac-OS Vac-STx Vac-SDS 
Freeze/Thaw 
Duration: 24 Hours 
Freeze/Thaw 
Duration: 24 Hours 
Freeze/Thaw 
Duration: 24 Hours 
Distilled Water 
Duration: 6 Hours 
0.25% Triton X + 0.25% 
SOC 
Duration: 24 Hours 
1% SDS 
Duration: 4 Hours 
Hypertonic Solution* 
Duration: 12 Hours 
HBSS 
Duration: 24 Hours 
PBS 
Duration: 12 Hours 
Wash Buffer 
Duration: 12 Hours 
DNAse/RNAse 
Duration: 24 Hours 
Hypertonic Sol 
Duration: 10 Hours 
Hypotonic Solution* 
Duration: 12 Hours 
HBSS 
Duration: 24 Hours 
PBS 
Duration: 12 Hours 
Wash Buffer 
Duration: 12 Hours 
Sterilisation Hypotonic Sol 
Duration: 10 Hours 
DNAse/RNAse 
Duration: 24 Hours 
 DNAse/RNAse 
Duration: 12 Hours 
Wash Buffer 
Duration: 12 Hours 
 PBS 
Duration: 24 Hours 
PBS 
Duration: 12 Hours 
 Sterilisation 
Sterilisation   
Table 2.2: Decellularisation methodologies, highlighting each step along with the length of 
time. Methodologies were adapted from Greco, et al231 and Lange, et al238. *Hypertonic 
solution contained 1M NACL, 50mM of Tris HCL and 10mM of EDTA. Hypotonic solution 
contained 10mM of Tris HCL and 5 mM of EDTA. Vacuum was applied to all the described 
methodologies post freeze-thaw. 
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Figure 2.2: Vacuum assisted decellularisation setup. (A) Vacuum pump, (B) Vacuum 
desiccator, (C) Digital vacuum gauge. 
 
Vac-OS methodology adapted from Greco and colleagues 231 utilised a 
freeze/thaw cycle to initiate cell disruption, followed by the use of hyper- and 
hypotonic steps in order to facilitate cell lysis. Washing with wash buffer 
containing 0.2% wt/vol Tween-20 (Sigma-Aldrich, Dorset, UK) was 
incorporated between each step to aid the removal fragmented cellular 
components. 
Vac-STx methodology adapted from Lange and colleagues 238 utilised a 
freeze/thaw cycle to initiate cell disruption, followed by a combination of 
sodium deoxycholate (SDC) (Sigma-Aldrich, Dorset, UK) and Triton-X100 
(Sigma-Aldrich, Dorset, UK) in order to facilitate cell lysis and the removal of 
cellular components, respectively. 
Vac-SDS methodology utilised sodium dodecyl sulphate (SDS), a zwitterionic 
detergent that solubilises cell membranes and dissociates DNA from proteins 
along with hyper- and hypotonic solutions to further aid with cellular component 
fragmentation and removal. 
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2.2.3. Histological analysis 
Histological examination was used to assess cellular clearance and gross 
tissue morphology. Briefly, samples from each of the methodologies, along 
with a control sample, were fixed in 10% NBF for 24 hours at room temperature 
(18-21°C). The samples were processed for paraffin wax embedding using 
routine histological techniques. Subsequently, 5 µM thickness paraffin 
sections were cut using a rotary microtome (ThermoFisher, Bedford, UK). The 
sections were mounted onto poly-lysine coated histology slides 
(ThermoFisher, Bedford, UK) and stained with haematoxylin & eosin. The 
dcECM was further stained for picrosirius red and toluidine blue, according to 
routine procedures.  Additional sections were stained with 4′, 6-diamidino-2-
fenylindool (DAPI) and visualised using inverted Axio fluorescence imager 
(Zeiss, UK). Nuclei were quantified using ImageJ (NIH). Based on histological 
examination the Vac-SDS was eliminated at this stage from further analysis.   
 
2.2.4. DNA quantification  
To assess the quantity of DNA present, cartilage samples were cryomilled 
using a SPEXSamplePrep 6775 freezer mill (SPEX, London, UK) into a 
homogenous paste.  25 mg of the resultant paste was transferred to 
DNase/RNase free microcentrifuge tubes.  The total DNA of the samples was 
isolated using the GenElute mammalian genomic DNA miniprep kit (Sigma-
Aldrich, Dorset, UK) in accordance with the manufacturer’s instructions and 
eluted in 50 µL nuclease-free water. The eluted DNA was quantified using the 
NanoDrop ND1000 spectrophotometer by absorbance (ThermoFisher, 
Bedford, UK) and normalised to the wet mass of each sample. Based on DNA 
and GAG quantification the Vac-STX condition was eliminated from further 
analysis and the Vac-OS methodology selected as the optimal methodology. 
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2.2.5. Protein extraction and Western blotting for alpha-Gal 
content. 
Western blot analysis was utilised to determine the presence of the Alpha-Gal 
epitope. Briefly, Control cartilage, muscle and Vac-OS decellularised cartilage 
(dcECM) were cryomilled using a SPEXSamplePrep 6775 freezer mill (SPEX, 
London, UK) to form a paste. To further solubilise, 200 mg of the sample paste 
was combined with 1 mL of RIPA buffer (Sigma-Aldrich, Dorset, UK) and 
frozen at -80oC until analysed.  The total protein content of the lysate was 
quantified using a BCA protein assay kit (ThermoFisher, Bedford, UK) in 
accordance with the manufacturer's instructions. 10 µg of the protein was 
combined with 2 x Laemmli sample buffer in a 1:1 ratio containing β-
mercaptoethanol (Sigma-Aldrich, Dorset, UK) and size fractionated using 
SDS-PAGE, run on Mini-PROTEAN® TGX™ Precast Gels (Biorad, Herts, UK) 
followed by electrotransfer using the Trans-Blot® Turbo™ Mini PVDF Transfer 
Packs (Biorad, Herts, UK). The transferred proteins were stained using 1% 
Ponceau S (Sigma-Aldrich, Dorset, UK) for 1 hour. The blots were then 
blocked using 3% filtered bovine serum albumin (Sigma-Aldrich, Poole, UK), 
and incubated overnight at 4°C with an antibody against Alpha-Gal 
(EnzoLifeSciences, Exeter, UK) at 1:500 dilution. A secondary anti-mouse 
HRP conjugated antibody (VectorLabs, Cambs, UK) was then added to the 
blot at the concentration of 1:1000 and incubated for 1 hour at room 
temperature (18-21°C).  Detected proteins were visualised using Clarity™ 
Western ECL Blotting Substrate (Biorad, Herts, UK) and images were obtained 
using ChemiDocXRS+ (Biorad, Herts, UK). 
 
2.2.6. Sulphate glycosaminoglycan (sGAG) Quantification. 
The sGAG content in both control cartilage samples and decellularised 
samples were measured using the Blyscan s-GAG assay kit (Biocolor, 
Ireland). Briefly, each sample was cryomilled using a SPEXSamplePrep 6775 
freezer mill (SPEX, London, UK) and 50mg of the sample was placed in 1.0 
mL papain digestion buffer containing 400 mg sodium acetate, 200 mg EDTA 
disodium salt, 40 mg cysteine HCL and 0.1mg papain for 12 hours at 65°C 
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with occasional mixing. The digests were centrifuged at 13,000 rpm for 10 
minutes.  50 µL of each digest supernatant was mixed with 1.0 mL Blyscan 
dye reagent.  The samples were mixed for 30 minutes using an orbital shaker 
(IKA, Staufen, Germany), followed by centrifugation at 13,000 rpm for 10 
minutes to obtain a pellet containing insoluble sGAG-dye complex.  0.5 mL of 
dissociation reagent was added to each tube and centrifuged at 13,000 rpm 
for 5 minutes.  A standard curve was generated with 50 µL serial dilutions 
ranging from 0.0-5.0µg/mL of chondroitin sulphate in distilled water.  The 
standards and samples were mixed with 1.0 mL Blyscan dye reagent and 200 
µL of each transferred into clear flat bottom 96-micro well plates in triplicate. 
The absorbance was measured using a Tecan Infinite M200pro microtiter plate 
reader (Tecan, Männedorf, Switzerland) at 656 nm.  Absolute sGAG content 
in µg/mL was determined and samples normalised to the wet mass of each 
sample. 
 
2.2.7. Statistical analysis 
Data are expressed as the mean ± standard deviation (SD). Statistical 
significance was determined using one-way analysis of variance (ANOVA) with 
Bonferroni’s posthoc corrections applied. Statistical significance is indicated 
on all graphs as follows: *p<0.05, ***p<0.001 (n=3).  All statistical analysis was 
performed using GraphPad Prism version 6.0 for windows (GraphPad Prism 
Software, La Jolla California USA, www.graphpad.com). 
 
2.3 Results 
2.3.1. An optimised Vac-OS decellularised methodology results 
in the efficient removal of cellular components.  
Macroscopic examination of the dcECM shows a pearlescent white scaffold, 
distinctive of decellularised tissues when cellular content has been eliminated 
(Figure 2.3A&B). Light microscopy of H&E stained sections revealed that all 
methodologies resulted in some level of cellular clearance, with the Vac-OS 
and Vac-STx methodologies resulting in the highest clearance. Some 
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morphological changes in lacunae structure can also be observed (Figure 2.3 
;C-F). Cellular clearance was further validated through nuclear staining with 
DAPI (Figure 2.4;A) and subsequent quantification (Figure 2.4;B). The Vac-
SDS based methodology resulted in an 89.5% (p<0.001) reduction in DAPI 
positive nuclei while the Vac-STx and Vac-OS methodologies were the most 
effective at clearing cellular and nuclear content from the cartilage samples, 
as evidenced by a 100% (p<0.001) reduction in visible DAPI positive nuclei.  
These two methodologies were ,therefore, chosen for further characterisation 
and assessment. 
 
 
Figure 2.3: Macroscopic and histological examination of decellularised costal cartilage. 
Representative macroscopic image of control (A) and Vac-OS (B) decellularised costal 
cartilage. (C-F) Representative histological of H&E stained sections (n=3) for the analysis of 
cellular clearance from hyaline cartilage. There is a visible reduction in cellular content with all 
three methodologies (scale bar = 50 µm). 
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Figure 2.4: Nuclei staining and qualification of decellularised tissues (A) DAPI stained 
sections demonstrate an absence of intact nuclei in the Vac-OS and Vac-STx methodology. 
(B) Image-based quantification of intact nuclei using ImageJ presented as mean ±SD (n=3 
**p<0.01, ***p<0.001). Statistical analysis performed using a one-way ANOVA using 
Bonferroni’s posthoc correction. 
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2.3.2. Vac-OS decellularisation results in effective DNA content 
removal and superior sGAG retention  
To validate the efficient removal of cellular and nuclear content from the 
decellularised cartilage samples the DNA content of the resultant scaffolds 
was analysed.  Initially, total DNA content post Vac-OS and Vac-STx 
decellularisation was quantified in 78.5 mm3 (small) tissue volumes. Sample 
voloume was upscale by a factor ten and DNA removal was assessed in the 
tissue samples with an increased volume of 785 mm3 (large). Values were 
normalised to tissue wet weight and compared to the control native costal 
cartilage samples. There was no significant difference in DNA content between 
the small and large samples with either of the methodologies employed.   
Furthermore, DNA content in both Vac-OS and Vac-STx decellularisation 
methodologies (Figure 2.5; A&B) fell below the clinically acceptable level of 50 
ng/mg of tissue (p<0.0001) 147 for both tissue sizes. Despite the similarity in 
DNA content, distinct differences in sGAG retention (Figure 2.5; C&D) between 
the two methodologies and tissue volumes were observed. Tissue subjected 
to the Vac-OS methodology retained 85.79% (p<0.05) and 28.2% (p<0.001) 
sGAG for the large and small volumes, respectively; when compared to control 
cartilage tissue. Tissue subjected to the Vac-STx methodology, however, 
retained 57.64% (p<0.001) and 16.64% (p<0.001) for the large and small 
volumes, respectively. The results indicated that the Vac-OS decellularisation 
methodology resulted in 28.15% (p<0.001) higher sGAG content retention 
compared to the Vac-STx methodology, when considering the larger volumes. 
This difference in sGAG retention was not observed between the two 
methodologies in the smaller tissue volume.  The Vac-OS decellularisation 
with larger tissue volumes was thus selected as the optimal methodology for 
costal cartilage and subjected to further analysis, and the resultant scaffolds 
were termed dcECM. 
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Figure 2.5: DNA and sGAG content analysis of decellularised tissues. DNA content in cartilage 
subjected to (A) Vac-STx (n=3) and (B) Vac-OS (n=5) based methodologies.  Data presented as mean 
ng/mg wet mass of tissue ±SD.  Both scaffold volume DNA contents fell below the threshold of 50 ng/mg 
for the Vac-STx and Vac-OS treated samples. Percentage sGAG content per mg wet mass tissue ±SD, 
subjected to (C) Vac-STx (n=3) and (D) Vac-STx (n=5) methodologies, normalised to native cartilage 
sGAG content. Statistical analysis was performed using a one-way ANOVA, using Bonferonni’s posthoc 
correction. The figure has been reproduced from Val et al281 with permission from Mary Ann Liebert, Inc., 
New Rochelle, NY 
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2.3.3. Vac-OS decellularisation results in effective removal of the 
highly immunogenic alpha-gal epitope. 
The alpha-Gal epitope is an abundant immunogenic component found on the 
cell surface of all non-primate species, it has, therefore, been repeatedly 
implicated in an acute and adverse host immune response, facilitating tissue 
rejection222. Therefore, alpha-gal content post Vac-OS was investigated using 
immunoblotting. Protein loading was confirmed using ponceau S (Figure 2.6; 
A) as other markers that are cell or ECM-associated would be affected by the 
decellularisation process, the ponceau bands post Vac-OS are faint, 
potentially, due to the removal of a number of cell and matric-associated 
proteins during the Vac-OS decellularisation methodology. Control levels of 
alpha-gal were established using porcine costal cartilage and muscle tissue 
with distinct bands visible at 56 kDa (Figure 2.6 B; Lanes 1-4). The band 
indicative of alpha-gal is, however, absent in the Vac-Os decellularised costal 
cartilage tissue. 
 
 
Figure 2.6: Western blot analysis of Alpha-Gal epitope residues. Vac-OS decellularisation 
eliminates highly immunogenic alpha-Gal epitopes. (A) Representative images of Ponceau S 
staining of transferred proteins indicating traces of protein bands in each lane. (B) 
Representative Immunoblot image illustrating the presence of the Alpha-Gal epitope at 56 kDa 
in both the control muscle (lanes 1&2), control cartilage samples (lanes 3 &4) and absence in 
Vac-OS decellularised cartilage (lanes 5, 6 &7) (n=3). The figure has been reproduced from 
Val et al281 with permission from Mary Ann Liebert, Inc., New Rochelle, NY. 
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2.3.4. The dcECM demonstrates even collagen content 
maintenance and sGAG distribution. 
To assess the impact of the Vac-OS decellularisation methodology on sGAG 
content distribution and collagen content, sections were stained using Alcian 
blue and picrosirius red (Figure 2.7). Analysis of the stained sections revealed 
almost identical structural morphology with minimal changes to the size and 
shape of the lacunae. The collagenous structure of the dcECM remained 
largely unchanged, with only a small observable change in staining intensity, 
consistent between the outer regions (Figure 2.7; A1&B1) and the inner 
regions (Figure 2.7; A2&B2).  
Alcian blue staining (Figure 2.8) revealed a slight decrease in the amount of 
staining for indicative of a reduction in sGAG content; this corresponds in with 
the sGAG quantification values. However, a surprising observation is that 
despite the volume of the dcECM, sGAG content distribution remained 
identical between the outer margins and the inner regions of the dcECM. This 
is despite the inner regions of the native tissue having visibly higher sGAG 
content. 
 
Figure 2.7: Picrosirius red stained dcECM.  Representative brightfield images of (A) 
native costal cartilage tissue and the (B) dcECM. Picrosirius red was performed to visualise 
the collagenous content of the ECM. (1) Images were taken at the outer edge of the cartilage 
tissue (CT) with perichondrial tissue (PT) visible. (2) Images were taken at the centre of the 
sectioned tissue (Scale bar = 50 µm).  
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Figure 2.8: Alcian blue stained dcECM. Representative brightfield images of (A) native 
costal cartilage tissue and the (B) dcECM cartilaginous constructs. Alcian blue was 
performed to visualise the sGAG content of the ECM. (1) Images were taken at the outer 
edge of the cartilage tissue (CT) with perichondrial tissue (PT) visible. (2) Images were taken 
at the centre of the sectioned tissue. (A1& B1) There is visibly lower intensity of Alcian blue 
staining near the periphery of the Native tissue, this is not visible with the dcECM. Scale bars 
= 50 μm. 
 
2.4 Discussion 
There is currently an unmet need for a methodology capable of efficiently 
decellularising dense hyaline cartilage tissues with minimal disruption to the 
ECM. Herein, we describe the development of an optimised decellularisation 
methodology for porcine costal cartilage, capable of effectively removing 
cellular and immunogenic content while maintaining sGAG content levels far 
surpassing published methods. 
The Vac-OS methodology was developed to efficiently decellularise hayline 
costal cartilage tissue without interfering with the integrity of the resultant ECM 
scaffold, thus, overcoming challenges in decellularising dense avascular 
tissues148,150,268,282. Recent studies applying vacuum-assisted decellularisation 
demonstrate increased decellularisation efficiency, especially concerning 
complex organs that include dense tissues, i.e. trachea and larynx 238,279.  The 
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enhanced cellular clearance reduces the need for harsh physical or enzymatic 
treatments that may contribute to the loss of bioactive molecules from the ECM 
238,279. Similarly, osmotic shock has also been applied towards the efficient 
decellularisation of dense tissues with minimal ECM disruption231,255. Both 
these approaches were, therefore, combined with vacuum assistance to 
formulate the optimised Vac-OS methodology used in this study.  
Vac-OS was also compared to previously used vacuum-assisted 
decellularisation (Vac-STx) that incorporated the detergents triton-x and 
sodium deoxycholate (SDC) 238. Interestingly, despite the Vac-OS 
methodology lacking any ionic surfactants, the resultant scaffolds (dcECM) 
exhibited DNA content falling below levels that are known to be immunogenic 
in vivo 147. Additionally, enhanced sGAG retention was also observed with the 
Vac-OS methodology compared to both the Vac-STx and to the best of our 
knowledge, other published methodologies aimed at decellularising hyaline 
cartilage tissues. Often, to improve the efficiency of cellular content removal, 
studies have milled cartilage tissues, resulting in more effective removal of 
cellular content but also a significantly higher removal of sGAG’s during the 
decellularisation process, highlighting the impact on tissue volume on 
decellularisation efficacy and sGAG retention150,226. To optimise the Vac-OS 
methodology for better sGAG retention larger tissue volumes were used. 
Results indicated that upscaling tissue size by a factor of 10 did not have a 
significant impact on the clearance of DNA content (Figure 2.5; A&B). This can 
be attributed this to the use of vacuum assistance, which has previously been 
used to enhance cellular clearance in dense whole organs such as the trachea 
and larynx238,279. Moreover, although not investigated in this study, the 
structure of costal cartilage may be more naturally permeable when compared 
to other sources of hyaline cartilage such as the articular regions as the costal 
regions are unstable and gradually undergoing endochondral ossification155, 
potentially, resulting in the infiltration of blood vessels near the hypertrophic 
regions of costal cartilage. Although not explicitly investigated in this study, we 
hypothesised that the Vac-SDS approach that incorporated SDS a potent ionic 
surfactant would also cause a significant loss of sGAG’s due to previous 
decellularisation approaches reporting similar results147,256,283. Moreover, DAPI 
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assessment revealed that the Vac-SDS was unable to effectively eliminate 
intact nuclei even with the addition of 1% SDS. Therefore, we eliminated the 
Vac-SDS methodology early during the optimisation process.  
As previously emphasised, sGAGs are especially abundant in cartilaginous 
ECM and play a key role as facilitators of chondrogenesis and endochondral 
ossification by binding to and enhancing the functionality of chondrogenic 
growth factors such as TGF-β 267,270,272–275. Therefore, the maintenance of 
sGAG content was a key factor when developing the optimised Vac-OS 
methodology. Indeed, Vac-OS allowed for the retention of up to 85% of the 
native sGAG content, which was observed specifically when tissue volume 
was upscaled by a factor of ten (Figure 2.5; C&D). Additionally, despite the 
larger tissue’s volumes, Alcian blue staining of the dcECM reveals 
homogenously distributed sGAG content (Figure 2.8). Interestingly, alcian blue 
staining of native costal cartilage (Figure 2,8; A1&A2) reveals a lower intensity 
of sGAG content near the periphery of the costal cartilage flanking the 
perichondrium, these findings may highlight that the core of the costal cartilage 
should be isolated and used for the production of the dcECM due to their higher 
native sGAG content. 
Homogeneity of sGAG content may be a factor in complete endochondral 
remodelling and integration of the dcECM. The enhanced retention of sGAG’s 
alongside the removal of cellular material highlights the synergy between the 
use osmotic shock and vacuum assistance, evident when compared to the 
more disruptive Vac-STx methodology. These results further bolster previous 
findings that suggested the proteolytic nature of ionic surfactants such as SDC 
may be critical facilitators of sGAG loss150,226,269,284. More accurate methods 
could be used in future studies to measure sGAG content. Moreover, 
techniques such as HPLC could be used to determine how the sGAG profile 
changes post-decellularisation. 
The enhanced maintenance of sGAG content demonstrated by the Vac-OS 
methodology may also be indicative of the overall preservation of the ECM 
ultrastructure, a desirable characteristic since the ECM structure and 3D 
spatial arrangement of macromolecules also both play a vital role in cellular 
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adhesion, stem cell fate determination and in vivo tissue remodelling 88,285,286. 
The histological techniques employed so far, however, provide a limited view 
of the dcECM’s ultrastructure. Therefore, more sensitive methodologies are 
needed to assess the full extent of any changes. 
The dcECM was further characterised for remnant alpha-gal content. Its 
removal was essential  due to the highly immunogenic nature of alpha-gal, 
making it a key barrier to clinical translation222. Moreover, failure to assess 
alpha-gal content in commercially available grafts has previously resulted in 
negative long-term clinical outcomes223,287,288. The Vac-OS methodology has 
overcome this key barrier to clinical translation by successfully eliminating 
alpha-gal from the native costal cartilage matrix as highlighted by 
immunoblotting (Figure 2.6B; lanes 5-7). The western blot methodology used 
for the assessment of residual Alpha-gal content may not have a limit of 
detection comparable to more sensitive approaches such as HPLC289, this 
definitive establishment of a scaffold free of alpha-gal would be a crucial part 
of developing implant for human use. Although not investigated in this study, 
the waste decellularisation solution could be assessed for some of the key 
immunogenic and biological components that were assessed such as DNA, 
alpha-gal and sGAG content. This would aid in assessing the efficacy of each 
of the decellularisation steps in each methodology. 
 
Conclusion 
This study that has further optimised and build upon existing vacuum assisted 
methodologies, resulting in the Vac-OS methodology that is capable of 
efficiently removing cellular and immunogenic components from hyaline costal 
cartilage, maintaining 85% of its sGAG content and overcoming long-standing 
challenges associated with decellularising dense hyaline cartilage tissue, often 
requiring harsh physical or chemical approaching, resulting in a significant loss 
of structure and sGAG content. As the resultant dcECM retains the majority of 
its sGAG content there is great promise of retained matrix integrity and 
chondroinductive properties. The dcECM is, therefore, a promising construct 
for further investigations into its matrix integrity and its capability to drive 
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chondrogenesis. Moreover, due to the removal of highly immunogenic 
components such as DNA and Alpha-Gal, the dcECM is an ideal candidate for 
further investigations in vivo, both for its biocompatibility and potential to 
undergo endochondral ossification at an orthotopic site. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
65 
 
3. Characterising dcECM Matrix integrity 
 
3.1. Introduction 
The extracellular matrix (ECM) is a highly dynamic assembly of structural and 
functional proteins, present in all tissue types. The ECM is subjected to 
frequent yet highly regulated remodelling89. Moreover, every organ has a 
unique ECM composition that is established during the early stages of 
embryonic development290. Embryonic lethality commonly occur as a result of 
mutations in genes coding for ECM components290–292. Very early 
investigations into the ECM suggested that it fulfilled the role of a passive 
structural component, merely filling the space between cells. It was not, 
however, until the mid-1980’s that through the discovery of key proteins such 
as integrins, the role of the ECM in tissue homeostasis, development and 
disease was fully appreciated293 (Figure 3.1). Subsequent investigations have 
further elucidated underlying mechanisms that support the ECM’s role as a 
mediator of tissue repair and regeneration88,294–296. The modulation of the ECM 
biochemical environment to influence stem cell behaviour has, therefore, 
emerged as a concept in regenerative medicine297.  
Cellular proteins such as integrin modulate Cell-ECM interaction by binding to 
cellular receptors and activating pathways such as phosphoinositide 3-kinase 
(PI3K) and focal adhesion kinase (FAK); involved in regulating cell renewal 
and proliferation298–300. In addition, the ECM can control cell behaviour through 
the binding and presentation of growth factors, a process that also allows for 
the creation of local growth factor gradients301. These gradients within the ECM 
allows for the differential regulation of resident and migratory cell populations; 
establishing various zones within the same tissue, as present in articular 
cartilage267. Examples of ECM-growth factor binding occurs with growth 
factors such as FGF and TGF-β that bind to the collagenous and proteoglycan 
component of the ECM, this enhanced its signalling potential and facilitates 
controlled release during ECM breakdown by enzymes such as matrix 
metalloproteinases301,302.  
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Figure 3.1: Cell-ECM interactions. A schematic summarising the functions of the ECM 
during tissue formation and homeostasis. Schematic was adapted from Rozario et al290 
&Frantz at al213. Figure generated using the Servier medical art database 
(http://www.servier.com/Powerpoint-image-bank 
 
3.1.1. Key components of hyaline cartilage ECM 
The ECM’s composition and spatial arrangement are crucial to its functionality. 
In mammalian species, around 300 ECM-associated proteins have been 
identified; these are known as the core matrisome213,303. Included in the core 
matrisome are proteoglycans, collagens, and glycoproteins213,303. The 
differential expression of these proteins determines tissue type during 
development213,290,303. The aim of this thesis is the development of costal 
cartilage based endochondral bone graft. Therefore, the cartilage ECM will be 
the point of focus for discussion. 
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Human hyaline costal and articular cartilage have similar compositions304. 
However, the information we have on hyaline cartilage is obtained primarily 
from studies that focus on articular cartilage. A significant component of 
hyaline cartilage is water, representing about 65 to 80% of its total weight, 
while the dry weight of hyaline cartilage is composed mainly of collagens and 
proteoglycans267. Around 30% of the water content is associated with the 
collagenous structure, with approximately 70% of the overall water content 
residing in intracellular and pore spaces. The water component of hyaline 
cartilage plays a key role in the diffusion of nutrients and ions through the 
avascular ECM of hyaline cartilage305,306. Additionally, a majority of the 
unbound water in hyaline cartilage is present in the form of a gel with high 
frictional resistance, contributing to the compressive strength of hyaline 
cartilage, by reducing tissue permeability 307,308.  
At around 60%, collagen type II is a significant contributor to the overall dry 
weight of hyaline cartilage267 and it the major collagen type. Other collagen 
sub-types are present in small proportions; these include collagen type I, IV, 
V, VI, IX and X. Although not as abundant, the minor collagen types do play 
an essential role in stabilising the collagen type II structure308. Studies have, 
for example, found several sites within collagen type X that facilitate it's 
crosslinking it to either collagen type II or other type X molecules309–311. When 
considering articular cartilage, collagen type II expression is drastically 
reduced, post-skeletal maturation, however, the expression is upregulated 
post-injury312. 
Proteoglycans are the second largest group of macromolecules in hyaline 
cartilage267. These glycosylated protein monomers account for around 15% of 
the wet weight of hyaline cartilage. Aggrecan is the most abundant 
proteoglycan, with each monomer containing more than 100 keratin sulfate 
and chondroitin sulfate chains267. A fundamental characteristic of aggrecan is 
its ability to bind to hyaluronan, forming proteoglycan aggregates that occupy 
the interfibrillar space within hyaline, resulting in the typically observed osmotic 
properties and load-bearing capacity of cartilage313. Additionally, 
glycosaminoglycan chains that are associated with the proteoglycan core have 
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been implicated in sequestering and presenting growth factors, adding to the 
regulatory mechanism for cell-ECM signalling314. 
 
3.1.2. Assessment of extracellular matrix components  
Due to the importance of the ECM in disease and regeneration, research has 
continually focused on establishing novel techniques for the evaluation of its 
structure and composition. Many of the standard established methods for the 
assessment of the ECM are destructive. These include histological techniques 
such as H&E’s, picrosirius red and alcian blue315. Furthermore, these only yield 
qualitative data on gross morphology, collagen composition and sGAG 
distribution. Further assays are often required to obtain quantifiable outputs for 
each of the components above316. Additionally, these approaches ignore more 
subtle changes in collagen structure, while assay’s that do target collagen 
quality through the monitoring of structural components such as 
hydroxyproline317,318 are inherently limited, as they ignore other collagen 
interactions that contribute to overall ECM integrity. Despite their limitations, 
the assessment of decellularised tissues has remained largely dependent on 
these standardised techniques. All decellularisation approaches have an 
impact on native extracellular matrix integrity, there is, therefore, a need for 
the development of standardised, rapid and non-destructive methods, capable 
of robustly assessing decellularised tissue matrix integrity.  
Palmer and colleagues utilised contrast-enhanced microcomputed 
tomography (μCT) to image proteoglycans in soft tissues and cartilage319. A 
concept that was further developed by Xie and colleagues to also allow for the 
identification of healthy and degraded cartilage by using sGAG distribution 
patterns 320. This approach is, however, limited in its ability to monitor changes 
in other prominent ECM components. Additionally, the use of ionising radiation 
and a contrast agent limit its use in monitoring live cellular constructs.  
Gessner and colleagues’ utilised ultrasound to monitor ECM integrity non-
destructively, eliminating the need for disruptive sample preparation or 
damaging ionising radiation321. The methodology was optimised for imaging 
cellular liver scaffolds and was especially effective at assessing blood vessel 
69 
 
formation. However, when ultrasound has been used to investigate dense 
cartilaginous tissues322, it has demonstrated limited resolution, limiting its use 
to evaluating the gross morphological structure. 
An alternative but less utilised approach to determining the biochemical 
makeup of biological tissues is Raman spectroscopy. The technique of Raman 
spectroscopy relies on quantifying changes in a photon’s energy state after its 
collision with a target molecule; in a phenomenon known as Raman 
scattering323. The Raman spectra of a target sample are obtained via 
illumination with a monochromatic laser beam and the quantification 
subsequent loss or gain in photon energy that is recorded as a shift in wave 
numbers (cm-1). The observed change in photon energy is unique to specific 
molecular interactions323. The resultant peaks, therefore, provide a molecular 
fingerprint of the sample, that can be obtained non-destructively324. Raman 
spectroscopy primarily serves as a powerful tool in law enforcement for the 
identification of illegal substances325. There have, however, been some 
reported studies that employ Raman spectroscopy for the assessment of 
biological tissues such as Bone326, cartilage327 and the cornea328, while studies 
have also utilised Raman spectroscopy as an innovative tool for clinical 
diagnosis329,330. Recently, Raman spectroscopy has been applied to monitor 
the biochemical composition of decellularised tissue scaffolds, post 
decellularisation and subsequent recellularisation331. The need for highly 
specialised equipment and expertise has, however, limited the use of Raman 
spectroscopy in medical research. 
Fluorescent probes have been used extensively for imaging components of 
the extracellular matrix, both in live and fixed tissues332,333. Fluorescence 
microscopy can enhance the inherent contrast of biological tissues, improving 
image resolution and allowing for the examination of more minute structural or 
morphological changes334. Furthermore, fluorescence microscopy allows for 
the imaging of specific protein targets334. The development of Imaging 
technologies such as laser-scanning confocal microscopy (LSCM) further 
improves fluorescence imaging approaches by allowing for the elimination of 
out of focus light, via the use of a pinhole aperture. The relevant software can 
use multiple confocal images to piece together a 3D image sequentially335. A 
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fundamental limitation of standard fluorescent microscopy, however, is its 
inability to track subtle biochemical changes in the target protein, especially in 
live cultures. 
Fluorescence lifetime imaging microscopy (FLIM) can create a spatially 
resolved image of fluorescence decay; a characteristic that is independent of 
variables such as concentration336. Collagen forms a major component of the 
cartilage extracellular matrix of which around 90% is collagen type 2337. 
Collagen is also inherently autofluorescent when excited with single or two-
photon excitation at around 730nm. Therefore, the lifetimes of the collagen 
have been harnessed to monitor collagen biochemical environment338. 
Additionally, collagen can also generate strong second harmonic signals that 
have been leveraged by techniques such as second harmonic generation 
(SHG) to identify collagen fibril arrangement and collagen crosslinking339,340. A 
study by Ranjit and colleagues demonstrated that a combination of FLIM and 
SHG could be applied to isolate and identify specific to various collagen 
subtypes338. Therefore, FLIM could have potential applications in monitoring 
biochemical changes in the ECM post decellularisation. 
In this chapter, we address the need for more comprehensive methods for the 
assessment of the extracellular matrix, especially, post VacOS 
decellularisation. The dcECM was, therefore, subjected to in-depth matrix 
analysis using Raman spectroscopy, differential scanning calorimetry and the 
novel approach of using fluorescence lifetime imaging microscopy. These in 
combination provided an overall image of matrix integrity and would further 
confirm the results observed during initial histological and sGAG composition 
analysis. 
 
3.2. Methods 
3.2.1. Raman Spectroscopy 
The dcECM and native costal cartilage samples (dimension ∼5 mm height × 
10 mm in diameter) were analysed without further processing. The spectra 
were acquired directly from the surface of the flat surface of the samples using 
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an InVia Raman microspectrometer (Renishaw). This was equipped with an 
830-nm laser, producing 300 mW at source. Calibration was performed before 
every run using silicon which has a known Raman band (520.5 cm−1), and on 
polystyrene to measure bands in the same range as that of cartilage (wave 
numbers between 1000 cm−1 and 1030 cm−1). The spectra were acquired at a 
laser power of 2 mW for 1 second with 4 accumulations. 3 different spectra 
were acquired from each end of the flat ends of the cylindrical samples. The 
spatial resolution (at 50× objective) was 2 μm × 2 μm. No thermal heating or 
degradation of the samples was observed at the laser powers utilised. Data 
was analysed used Matlab 7 (Mathworks, UK), and peaks were identified using 
previously published literature (Table 3.1).  
 
Raman shift (cm-1) Assignment ECM Component 
822-875 C-C Hydroxyproline 
(Collagen) 
900-950 C-C, α helix Proline (Collagen) 
1001 H-O Phenylalanine 
(Collagen) 
1063 OSO3−, symmetric 
stretch 
Chondroitin sulfate 
(sGAGs) 
1230-1280 Amide III Collagen 
1620-1690 C==O, Amide I Collagen 
Table 3.1: Raman spectroscopy band assignments. Based on previous literature 
investigating collagen, glycosaminoglycans and amino acids341–344. 
 
3.2.2. Differential scanning calorimetry (DSC)  
DSC was used to measure collagen denaturation temperatures as an indicator 
of the structural integrity of the matrix345. This has previously been applied to 
cartilaginous tissues346. Control native costal cartilage samples were 
compared to dcECM samples. Briefly, samples were cut into cubes weighing 
10 mg each. Each 10mg sample was placed into 40 µL aluminium crucibles, 
that were unperforated to prevent background noise because of water 
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evaporation. Native samples did not undergo any prior processing. The 
dcECM, however, was washed overnight to remove any excess salts that have 
accumulated due to decellularisation process, as unwashed samples 
demonstrated inconsistent results. The calorimetric experiments were 
performed using Mettler Toledo DSC-1 calorimeter (Mettler Toledo, 
Greenfield, UK). All experiments were performed between 25 °C and 95 °C at 
a heating rate of 3 °C/min. Data analysis was carried out using the STARe 
Thermal Analysis Software (Mettler Toledo, Greenfield, UK). The obtained 
readings were normalised to an empty unperforated reference crucible. 
 
3.2.3. Multiphoton imaging   
SHG and FLIM were used to measure changes in the collagen biochemical 
environment as a measure of matrix integrity, this work was carried out in 
collaboration with the Duchen Lab (Department of cell and developmental 
biology, UCL). Without any prior processing Native costal cartilage and dcECM 
(dimension ∼5 mm height × 10 mm in diameter) were placed in PBS in 
preparation for imaging. Laser scanning microscopy with multiphoton 
excitation was carried out using a Zeiss LSM 510 microscope (Zeiss, 
Oberkochen, Germany) with a 10x 0.3 N.A water-dipping objective and the 80 
MHz pulsed output of a Chameleon (Coherent, Santa Clara, USA) Ti:sapphire 
laser. Second harmonic generation and autofluorescence were observed 
using 920 nm and 720 nm illumination wavelengths respectively. In both 
imaging modalities, a 650 nm dichroic filter separated the two-photon 
excitation from the shorter wavelength emission, collected with a 460(±25) nm 
band-pass filter before detection by a high-speed hybrid detector (HPM-100), 
(Becker & Hickl, Berlin, Germany). Single photon emission events were 
recorded by a commercial time-correlated single photon counting SPC-830 
electronics module (Becker & Hickl, Berlin, Germany) in a desktop computer. 
Fluorescence lifetimes were extracted from the measured time-resolved 
emission data by least-squares fitting of a monoexponential decay in 
SPCImage (Becker & Hickl, Berlin, Germany). 
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3.2.4. Statistical analysis 
Data are expressed as the mean ± standard deviation (SD). Statistical 
significance was determined as described in Chapter 2.2.  All statistical 
analysis was performed using GraphPad Prism version 6.0f for windows 
(GraphPad Prism Software, La Jolla California USA, www.graphpad.com). 
 
3.3 Results 
3.3.1. Raman spectroscopy indicated the retention of key ECM-
associated molecular bonds, post Vac-OS. 
Raman spectroscopy utilises monochromatic light to harness the phenomena 
of inelastic scattering providing a qualitative view of the biochemical 
composition of a samples can be observed347. Raman spectroscopy was 
therefore utilised to monitor changes in the dcECM’s composition. Raman 
spectra were obtained from both native costal cartilage and the dcECM. Key 
molecular interactions were identified and associated with hyaline cartilage 
ECM macromolecules using previous literature (Figure 3.2). The identified 
peaks included Hydroxyproline (850 cm-1), Proline (920 cm-1), Phenylalanine 
(1001 cm-1), sulfated glycosaminoglycans (1063 cm-1), Amide III (1230-1280 
cm-1) and Amide I (1630-1690 cm-1) (Table 3.1). 
Spectral analysis indicated that all bands present in the native costal cartilage 
tissue are retained post Vac-OS decellularisation. Qualitative analysis 
suggests there was a significant change in the intensity at band assignment 
1063 cm-1, indicative of sGAG associated chondroitin sulfate342. 
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Figure 3.2: Raman spectroscopy comparing native costal cartilage and the dcECM. 
Average intensity of the obtained Raman spectra (Raman shift 750-1800 cm-1) from native 
control costal cartilage (Black line) and VacOS treated costal cartilage samples (Red line).  
 
3.3.2. Thermal analysis of the dcECM indicated minimal ECM 
damage post Vac-OS decellularisation. 
Thermal denaturation of collagen is indicative of collagen crosslinking345 and 
has been used to determine cartilage matrix integrity346. Therefore, DSC was 
used to compare collagen denaturation temperatures in the dcECM vs native 
costal cartilage. The STARe Thermal Analysis Software (Mettler Toledo, 
Greenfield, UK) was used to evaluate and analyse the obtained changes in 
enthalpy to determine peak denaturation temperatures (Figure 3.3; A). 
Thermal analysis indicated significant changes in the denaturation 
temperatures between the dcECM and native costal cartilage (Fig 3.3; A&B). 
However, a large amount of variation observed in the denaturation 
temperatures of the dcECM, with some readings lacking the presence of 
collagen denaturation curve. Further investigation was carried out to determine 
the cause of this variation. 
These findings highlighted that the changes were observed were only in the 
Vac-OS decellularised samples. The VacOS methodology is based around the 
use of high salt concentrations, and although wash steps were incorporated in 
the methodology, it was hypothesised that salt residues present in the dcECM 
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might be interfering in the thermal analysis process348. Both native and 
decellularised cartilage samples were, therefore, washed in deionised water 
for 16 hours at 4 ºC. While there were no changes in the Native cartilage 
denaturation temperatures, there was a significant decrease in the variation of 
collagen denaturation temperatures when considering the dcECM. However, 
the observed decrease was still insignificant when compared to native costal 
cartilage (Figure 3.3B). 
 
 
Figure 3.3: Thermal denaturation of the dcECM. (A) Representative differential scanning 
calorimetry thermal analysis curves and (B) quantification of average denaturation 
temperatures comparing control cartilage vs dcECM vs dcECM (Washed), (*Peak 
denaturation temperature). Data is expressed as mean ±SD (n= 4, ns = non-significant). 
Statistical analysis performed using a one-way ANOVA using Bonferroni’s posthoc correction. 
 
 
3.3.3. Optimised multiphoton imaging and analysis indicates 
minimal disruption to the Vac-OS decellularised matrix. 
In order to non-destructively assess the matrix integrity of the dcECM 
multiphoton imaging and analysis techniques were applied (Figure 3.4 A-E). 
The highly non-centrosymmetric structure of fibrillar collagen gives rise to 
intense second harmonic generation when exposed to a high-intensity 
coherent light source 349. This allows collagen structures to be imaged using 
laser scanning microscopy by observing light emitted from a sample at half the 
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wavelength of the incident illumination. Collagen also possesses intrinsic 
fluorescence properties due to the presence of a range of spectrally-
overlapping endogenous fluorophores 350. Changes in the local nanoscale 
environment of these fluorophores are reflected by alterations in their 
fluorescence lifetime351, the average time taken for emission to occur following 
excitation. Combining second harmonic and fluorescence lifetime imaging 
would allow the assessment of morphological changes within the extracellular 
matrix. Initial assessment of the obtained FLIM images involved selecting nine 
random regions of interest (ROI) (Figure 3.4;D). Initial results indicate a 
significant shift in lifetimes when comparing control costal cartilage and the 
dcECM.  
Closer examination of the SHG images, however, reveals subtle changes in 
lacunae size, post Vac-OS decellularisation when comparing native costal 
cartilage to the dcECM (Figure 3.4; A1&2). The lacunae being empty do not 
have an ECM associated lifetime reading. Therefore, variations in size could 
affect the total fluorescent signal-producing region of an image. In addition, as 
the methodology for ROI selection was random, it did not account for non-ECM 
specific signals or out of focus regions that did not have sufficient signal. SHG 
signals are produced due to the inherent fibrillar arrangement of collagen and 
therefore, was specific to the ECM. Considering this characteristic, Image J 
was used to select SHG signals above a given threshold, thus selecting a 
collagen-specific signal specifically from the ECM (Figure 3.5; A). The SHG 
generated ROI was subsequently applied to the corresponding FLIM image, 
isolating autofluorescence lifetime signals that were specific to the ECM 
(Figure 3.5; B). The optimised methodology demonstrated that there was no 
significant change in fluorescence lifetimes when comparing control costal 
cartilage and the dcECM (Figure 3.5; C). 
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Figure 3.4: Pre-optimised FLIM and SHG imaging. (A) Second harmonic generation (SHG) 
microscopy image. The decellularised sample retains its architecture with minimal disruption 
to the collagen component of the extracellular matrix (B)Two-photon autoflouresence image 
at 720nm excitation. Cells are observed within the lacunae of the control sample while being 
absent within the osmotic shock treated sample. (C) False coloured fluorescence lifetime 
Imaging microscopy (FLIM) image indicative of the distribution of the fluorescence lifetimes 
within the samples (D) Relative FLIM intensity images with 9 regions within the sample 
quantified using imageJ (The displayed images are representative of four independent 
experiments; scale bar = 50µm). (A1-D1) Control costal cartilage samples, (A2-D2) VacOS 
decellularised costal cartilage samples (dcECM).(E) ImgeJ quantification of the ROI’s indicate 
there is an overall decrease in the average fluorescence lifetimes due to the osmotic treatment. 
Representative quantification data are represented as mean ± SD (n=4; ***p<0.001)..  
Statistical analysis performed using an unpaired t-test with Welch's posthoc correction.   
 
78 
 
 
Figure 3.5: Optimisation of FLIM and SHG imaging. (A) Representative second harmonic 
generation (SHG). The ROI is selected using an intensity threshold, thus negating non-ECM 
regions. (B) Representative FLIM intensity image with the superimposed ROI obtained from 
the SHG image, used to quantify fluorescence lifetime. (The displayed images are 
representative of four independent experiments). (C) ImageJ quantification of the ROI’s, 
measuring the average fluorescence lifetimes (n=4).  Quantification data are represented as 
mean ± SD.  Statistical analysis performed using an unpaired t-test with Welch's posthoc 
correction. 
 
3.3.4. Thermal analysis and optimised multiphoton imaging are 
capable of detecting changes in cartilage ECM structure.  
DSC and FLIM have both been applied to determine disease-associated 
changes in articular cartilage346,352. However, while DSC has been applied for 
the analysis of decellularised tissues353,354, there are no identifiable studies 
that utilise FLIM. Moreover, it was essential that the ability of both DSC and 
FLIM to assess matrix integrity was verified. Therefore, the dcECM was further 
denatured using collagenase to induce matrix damage.  
Auto fluorescence images demonstrate a clear disruption of the collagenase 
treated dcECM when compared to both the control cartilage and undigested 
dcECM (Figure 3.6; A-C). Changes in morphology are accompanied by a 
decrease in collagen denaturation temperatures when comparing the 
collagenase treated dcECM compared to both the untreated dcECM and 
control costal cartilage (p<0.05)(Figure 3.6; D). Collagenase digestion of the 
dcECM also has a significant impact on the autofluorescence lifetimes (Figure 
3.6;E). However, more interestingly, the shift in lifetimes was more significant 
than the shift in denaturation temperatures(p<0.001).  
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Figure 3.6: Quantitative FLIM analysis of the dcECM. Further disruption of the Vac-OS 
decellularised scaffold using collagenase. (A-C) False coloured fluorescence lifetime imaging 
microscopy (FLIM) images indicative of the distribution of the fluorescence lifetimes within the 
samples (scale bar= 50µm). (D) Quantification of average denaturation temperatures 
comparing control cartilage vs dcECM vs collagenase treated Vac-OS samples. (E) ImageJ 
quantification of the ROI’s, measuring the average fluorescence lifetimes (n=4 *p<0.05, 
**p<0.01, ***p<0.001, ns= non-significant).  Representative quantification data is expressed 
as mean ±SD. Statistical analysis performed using a one-way ANOVA using Bonferroni’s 
posthoc correction. 
 
3.4 Discussion 
ECM structure, composition and 3D spatial arrangement of macromolecules 
play a vital role in cellular adhesion, stem cell fate determination and in vivo 
tissue remodelling 88,285,286. Additionally, cartilage matrix components such as 
collagen type II and sGAGs play a crucial role in promoting chondrogenesis 
and endochondral ossification 272–275,355. Maintenance of ECM structure was, 
therefore, thoroughly considered when developing the Vac-OS 
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decellularisation methodology. Most studies utilise standard histological 
techniques for the assessment of decellularised cartilaginous matrices, which 
only allow for the gross examination of matrix architecture 356,357. This chapter 
considers the need for more in-depth ECM analysis that is rapid, sensitive and 
non-destructive and attempts to meet it. 
Raman spectroscopy has been utilised for the assessment of biological tissues 
due to its molecular-level resolution, allowing for the monitoring of minute 
changes in matrix integrity358 that may be otherwise missed by other gross 
assessment techniques.  Raman spectroscopy was, therefore, utilised for 
qualitative analysis of the dcECM’s molecular composition (Figure 3.2). 
Results indicate there were minimal changes in crucial collagen associated 
peaks such as hydroxyproline, proline, phenylalanine and amides. Proline and 
hydroxyproline levels have previously been used as an indicator of collagen 
systhesis318, in combination with amides these key components have been 
heavily implicated in the unique structural organisation of collagen type II and 
it's stability359. Overall, the maintenance of these molecular interactions 
suggest the conservation of vital cartilage-associated proteins and, therefore, 
minimal damage to the cartilage matrix ultrastructure341–344.  
The only distinct difference highlighted by the Raman spectra was in the sGAG 
associated chondroitin sulfate peak at 1063 cm-1, demonstrating a reduction 
relative peak intensity. The previous chapter reported a minimal 15% loss in 
sGAG content, post VacOS decellularisation. The two results, however, cannot 
be directly corroborated as the Raman spectra obtained only analysed 
chondroitin associated interactions and were not truly quantitative. 
Additionally, Raman spectroscopy gives a highly localised view of surface 
molecular composition and sGAG content, this leaves using Raman 
spectroscopy for quantitative analysis prone to inaccuracies. Destructive 
assays that quantify overall sGAG content may, therefore, supersede Raman 
in terms of overall quantification accuracy. The presence of a sGAG 
associated peak, however, is promising, due to the crucial role played by 
sGAG’s in cartilage homeostasis271, mechanical strength360 and their ability to 
promote both chondrogenesis272–274 and endochondral ossification275.  
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There are a number of Raman spectroscopy methodologies that are available 
for the assessment of biological tissues; each specialised for detecting specific 
molecular interactions347. Therefore, the accurate quantification of molecular 
interactions using Raman spectroscopy requires highly specialised equipment, 
in-depth expertise and extensive optimisation. Furthermore, the presence of 
other organic compounds or matrix damage induced by the extended exposure 
to a laser may interfere with data quality361. Raman spectroscopy is a powerful 
non-destructive analytical tool for qualitative analysis. However, when applied 
for quantitative analysis, its accuracy is highly dependent instrument response, 
and levels of interference thus reducing its reliability347. This is further amplified 
when used with biological tissues as they contain a plethora of molecular 
interactions. 
The underlying mechanisms of collagen crosslinking and its role in collagen 
structural integrity was first established in the late 1960’s362–366. Furthermore, 
collagen crosslinking pathways are also activated during the repair of hyaline 
articular cartilage367. Methodologies such HPLC367 and chromotography368 
have been applied for the in-depth analysis of collagen crosslinking in 
cartilage. While these approaches provide a comprehensive view of collagen 
crosslinking, they require extensive sample preparation making them both time 
consuming and labour intensive. 
DSC is based on the principle of thermal analysis via the monitoring of changes 
in enthalpy that are associated with changes specific to the molecular 
composition of the desired substrate369. This approach has been applied to 
measure key ECM structural components such as proteins370–372 and lipids373. 
Interestingly, it has also been reported that alterations in articular cartilage 
matrix integrity between healthy and osteoarthritic cartilage are reflected by 
variations in the collagen denaturation temperatures374, that are affected by 
the extent of collagen crosslinking375. Therefore, determining collagen 
denaturation temperatures in native costal cartilage and the dcECM using DSC 
provides a reflective measure of collagen ultrastructure damage post Vac-OS 
decellularisation. The obtained results demonstrated a lack of change in 
collagen denaturation temperatures when comparing the dcECM to native 
costal cartilage. These results highlights the effective maintenance of collagen 
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crosslinking, indicative of minimal damage to the collagen ultrastructure post 
VacOS decellularisation. 
In order to assess the efficacy of using DSC to monitor changes to the hyaline 
cartilage matrix, dcECM samples were digested using collagenase to induce 
matrix damage. The collagenase digested samples demonstrated a significant 
reduction in denaturation temperatures, verifying the capability of DSC to 
monitor matrix damage. DSC is, however, not immune to interference from 
other components such as salt content, this was demonstrated in the highly 
variable results that were obtained from the dcECM, with some runs' failing to 
demonstrate a visible collagen denaturation peak. It was only by washing the 
dcECM in deionised water that residual salt content could be removed 
providing more reliable results. Additionally, changes in enthalpy can also 
result from the evaporation of water376, and while this study used sealed 
crucibles to prevent loss of water through evaporation, the prevention of 
evaporation could not be guaranteed, especially as the samples were 
subjected to near boiling point temperatures. This susceptibility to various 
factors associated with the environment and used has been highlighted by 
Deangelis and Papariello377. Furthermore, other analytical techniques such as 
FLIM allows for the non-destructive analysis of collagen crosslinking, while 
also monitoring other subtle change in collagen biochemical environment378. 
FLIM is based on the principle of measuring the lifetime of a fluorophore to 
determine its molecular interactions and thus its biochemical environment379–
381. Recently, FLIM has been utilised as an alternative approach to monitor 
subtle changes in the ECM382. It is widely accepted that site-specific 
modifications in collagen cross-linking can be identified through imaging 
techniques that quantify the lifetimes of collagen auto-fluorescence378. 
Additionally, second harmonic generation (SHG) microscopy was developed 
as a method for the assessment collagenous structures339 and when combined 
with FLIM has been efficiently applied for the identification and separation of 
collagens sub-types338. SHG and FLIM were, therefore, combined for both the 
gross morphological assessment of the collagenous architecture and the 
biochemical environment of the collagen, respectively. 
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The SHG images reveal a subtle change in lacunae size post decellularisation. 
The difference in lacunae size could result from the low atmospheric pressures 
that the costal cartilage is subjected to during VacOS decellularisation (Figure 
3.4) causing ECM deformation. Initially, ROI’s for FLIM analysis of each image 
were chosen as nine random regions of the same area using ImageJ. The 
results demonstrated a significant change in lifetimes when comparing native 
costal cartilage and dcECM samples. Upon closer examination of the raw data, 
it was apparent that the random selection of ROI’s for each FLIM image was 
resulting in the selection of regions that were void of an autofluorescent signal, 
either as a result of a lack of focus or empty lacunae. This was also a 
disadvantage that was highlighted by Becker336. Attention was, therefore, 
drawn back to the changes in lacunae size, as they could impact the amount 
of non-ECM specific fluorescence, affecting the overall lifetime readout of each 
image. Since SHG relies on the non-centrosymmetric structure of collagen, an 
ECM-specific region can be obtained. Therefore, SHG images were used to 
choose threshold based ROI’s, eliminating non-ECM specific areas (Figure 
3.5). This approach ensured that each image had an ROI that was unaffected 
by changes in lacunae size or image focus. The optimised FLIM analysis 
approach demonstrated minimal changes in the lifetime when comparing 
native costal cartilage to the dcECM; this was also now in agreement with the 
DSC data. 
An investigation into the efficacy of using FLIM for the monitoring of changes 
in collagen biochemical environment and ultrastructure was required. The 
dcECM was again subjected to matrix damage using collagenase. The 
enzyme-treated dcECM constructs demonstrated an evident shift in lifetimes, 
indicating the inherent capacity of the optimised FLIM analysis to detect and 
quantify changes in matrix integrity. Interestingly, the results also highlighted 
a more significant difference in lifetimes, between the digested dcECM and 
native costal cartilage, when compared to parallel results obtained from the 
thermal analysis. These findings suggest that the FLIM approach surpasses 
the DSC regarding sensitivity to changes in matrix integrity. Despite the 
advantage of non-destructively monitoring matrix integrity, the use of FLIM 
cannot identify specific changes in collagen when they do occur. Therefore, 
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further optimisation is required before FLIM can be utilised as an in-depth 
methodology for the molecular analysis of biological tissues. This study 
harnesses FLIM to assess matrix integrity of decellularised ECM and with 
sufficient optimisation could be widely applied in the non-destructive 
monitoring of tissue during the optimisation of decellularisation methodologies 
or fabrication of clinically applied decellularised substrates. 
Investigations into the matrix integrity of the dcECM have yielded valuable 
information into the ultrastructure maintenance post-VacOS decellularisation. 
There are, however, approached such as biodegradation assay’s that may 
provide an indirect measure of matrix integrity. This, in combination with the 
retention of crucial cartilage matrix components such as sGAG’s highlights the 
dcECM’s potential to drive chondrogenesis and promote endochondral 
ossification in vitro. There are, however, two essential steps for the 
development of a fracture callus mimetic; the production of a matrix and the 
use of an appropriate cellular component. The promising results obtained from 
the investigation of the dcECM now provides sufficient impetus for the further 
in vitro and in vivo investigations of the dcECM to analyse its bioactivity and 
non-immunogenic nature. 
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4. Biological characterisation of the 
dcECM 
 
4.1. Introduction 
Cellular interactions during fracture repair are an indispensable part of the 
healing process. Therefore, it is crucial to assess the in vitro and in vivo 
interactions of the dcECM with the relevant cellular population. Chapter 3 has 
highlighted that the dcECM retains its native structural integrity post Vac-OS 
decellularisation. Structural and functional components of the ECM such as 
the collagen type 2 fibrillar structure and GAG content could play a crucial role 
in promoting or enhancing chondrogenesis in relevant cell populations such as 
human-derived chondrocytes and hPDSC’s. However, the bioactivity of the 
dcECM can only be determined via assessment of its interaction with relevant 
cellular populations, both in vitro and in vivo. 
 
4.1.1 Monitoring cell-matrix interactions.  
For the creation of a cartilage fracture callus mimetic, the dcECM needs to 
interact favourably with cell populations that are involved during the 
endochondral fracture healing. Therefore, the choice of cell type and culture 
conditions need to be carefully considered. 
During the initial inflammatory phase of fracture healing,  factors such as TNF-
α, act as secondary inflammatory signals attracting surrounding stem cells 
from the bone marrow and periosteal niche via chemotaxis383. The stem cell 
population resident in the periosteal niche has been identified as a key 
regulator of fracture healing384. There has, therefore, been a drive to isolate 
PDCs as a cell source for bone tissue engineering purposes. Indeed, it has 
previously been shown that human periosteum-derived stem cells  (hPDSC’s) 
seeded onto a decellularised/devitalised bone matrix can undergo 
endochondral bone formation with the resulting bone containing a 
hematopoietic compartment 207, a process that is driven by early PKC, BMP 
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and Wnt signalling 385. These promising characteristics of hPDSC’s make them 
an ideal cell type for combination with the dcECM derived cartilage callus 
mimetic. 
Underlying all biological processes is the multilayered, gene expression control 
mechanism that regulates protein expression and is, indeed, a critical factor in 
determining cell phenotype and function386.  Gene expression analysis targets 
the principal component of the protein synthesis pathway, by quantifying 
intracellular mRNA levels.  The gene expression profiles of skeletal stem cells 
undergoing chondrogenesis and maturation have been extensively studied, 
both in vitro387,388 and in vivo389,390. SRY-related high-mobility-group box 9 
(SOX9) has been recognised as the master regulator of chondrogenesis, as 
its role in enhancing the expression of cartilage matrix associated proteins 
such as aggrecan and collagen type II have been well established391,392. It is, 
therefore, widely accepted that the upregulation of SOX9 expression is an 
early indicator of chondrogenesis in MSC’s393–395. An upregulation of COL2A1 
swiftly follows upregulation of SOX9 and its continued co-upregulation during 
the early stages of chondrogenesis396,397. Aggrecan accumulation as a result 
of SOX9 promotion is also common during chondrogenesis and cartilage 
tissue formation398, however, there is some doubt in using aggrecan gene 
expression as a reliable indicator for identifying early chondrogenesis, as 
studies have highlighted that aggrecan expression may be an in vivo 
phenomenon that is not replicated in vitro399. SOX5 and SOX6 are transcription 
factors with closely related DNA binding regions to SOX9 and are upregulated 
during the later stages of chondrogenesis, forming the SOX-trimer super 
enhancer, further driving late chondrogenesis400. 
 
4.1.2 Factors that drive endochondral fracture healing  
Recruited stem cell populations must undergo a tightly regulated process of 
cellular differentiation to generate the fracture callus; a crucial phase of 
endochondral fracture healing2. The process is primarily driven by the 
chondrogenic differentiation of stem cells, that largely originate from the 
periosteum niche35.  
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Several biological and mechanical factors influence the chondrogenic 
differentiation cascade that results in the formation of the bridging cartilaginous 
callus, and its subsequent hypertrophy and ossification. The traumatic nature 
of bone fracture can also damage the surrounding soft tissues and vasculature 
resulting in localised hypoxia31. Research has suggested that the resultant 
hypoxia is a crucial environmental cue that promotes chondrogenesis of 
recruited stem cells as cells with a chondrocytic phenotype are more adapted 
to survive low nutrient and oxygen conditions401. However, prolonged hypoxia 
due to lack of angiogenesis can have a detrimental effect on endochondral 
ossification, resulting in delayed or non-union fracture healing402,403. Therefore, 
an inadequate blood supply has been identified as a principal underlying cause 
of atrophic non-unions404; a subtype commonly associated with prolonged 
treatment times and poor patient outcomes405. In response to the hypoxic 
environment, growth factors such as VEGF are secreted in a controlled 
manner, promoting neo-angiogenesis due to its ability to mobilise endothelial 
progenitor populations, influence their proliferation and promote cell 
differentation406,407. VEGF expression generally peaks during early fracture 
and later during chondrocyte hypertrophy408. 
In addition to environmental factors, several growth factors are also associated 
with the chondrogenesis and hypertrophy of mesenchymal and periosteum-
derived stem cell populations. TGF-β is a common component in chondrogenic 
differentiation media due to the well-established role in driving the 
chondrogenesis via the binding of TGF-β to type II receptors, that further 
interact with type I receptors, the signal is then transduced via the 
phosphorylation of the R-SMAD signalling pathway, eventually promoting the 
transcription of chondrogenic genes409. TGF-β, therefore, regulates the 
expression of crucial chondrogenic transcription factors such as SOX9, 
subsequently upregulating the expression of cartilage matrix-associated 
proteins, especially COL2A1410–412. Bone morphogenic proteins (BMP’s) are 
the largest group from the TGF-β superfamily, playing an important role in 
cartilage and bone formation413,414. Mutations in the DNA regions coding for 
BMP can cause severe impairment in endochondral bone formation; thus, 
dysregulating skeletal development415. The addition of BMP2 can initiate 
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chondrogenic lineage development in MSC’s, including cell populations 
derived from the periosteal niche, where BMP also plays a crucial role in 
osteogenesis during endochondral bone formation416–418.  
 
4.1.3 Monitoring immunogenicity and biocompatibility of 
biological scaffolds. 
ECM derived scaffolds, such as the dcECM, may be an ideal target for tissue 
engineering of the fracture callus due to its structural and biochemical 
homology with the target tissue. However, the host immune response to 
xenogeneic tissues remains a significant barrier to the clinical translation of 
xenogenic tissue-derived grafts419. The optimised Vas-OS decellularisation 
methodology was effective at reducing levels of immunogenic components 
such as DNA and Alpha-Gal below levels required for an adverse host 
inflammatory response. These findings do not, however, suffice as the sole 
predictor of in vivo immunogenicity thus requiring further in vivo 
biocompatibility. 
The role of macrophages in the biological response to foreign antigens, 
including those presented by implanted biomaterials is well documented420–422. 
Macrophages primarily facilitate with the removal of residual cellular and 
fibrous debris via phagocytosis423. Moreover, they also secrete a plethora of 
chemotactic and inflammatory factors that initiate cellular recruitment required 
for tissue remodelling423,424. Macrophages activated by the cytokine release 
from damaged tissues or local immune cells, migrate to the source and acquire 
several transient polarisation states to fulfil their function425. These include pro-
inflammatory M1 and pro-regenerative M2 populations, identified by their 
presentation of markers such as CD86 and CD163, respectively 426–428.  
C57BL/6 and BALB/c mice are the most commonly used strains used in 
biomedical research 429,430.  Subcutaneous implantation of scaffolds into 
BALB/c mice has previously been employed to investigate the host response 
to the constructs in the context of musculoskeletal applications including large 
bone defect healing431,432.  Overall these studies have illustrated that BALB/c 
mice are capable of eliciting a host rejection response towards xenogeneic 
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grafts while also being capable of driving tissue integration and remodelling. 
Considering this evidence, BALB/c mice would be an ideal choice to assess 
the acute immune reaction to the dcECM while also gauging its potential for 
subsequent tissue remodelling and integration432. 
This chapter addresses the need to assess the bioactivity of the dcECM and 
elucidate the underlying mechanism and conditions that drive the cellular 
differentiation of relevant skeletal and in vitro and immunogenicity in vivo. 
 
4.2. Methods 
4.2.1 Human articular chondrocyte isolation.  
Human cartilage was harvested from the articular surfaces of the knee and hip 
from patients undergoing joint replacement surgeries.  Articular chondrocytes 
were extracted from cartilage using a methodology that was adapted from 
previous studies 207,411,433,434.  Briefly, two grams of cartilage were finely 
minced and placed into a collagenase type IV (consisting of 4400 enzyme 
activity units) digestion buffer containing growth medium (GM) comprising of 
high-glucose Dulbecco’s Modified medium supplemented with 10% foetal 
bovine serum (FBS) (Invitrogen, Paisley, UK), 1 mM sodium pyruvate 
(Invitrogen, Paisley, UK) and antibiotic-antimycotic solution (100 units/mL 
penicillin, 100 μg/mL streptomycin and 0.25 μg/mL amphotericin B; Invitrogen, 
Paisley, UK) for 16 hours. The digest was passed through a 70µM cell strainer 
and centrifuged at 1300 rpm for 10 minutes. The resultant chondrocyte pellet 
was resuspended in growth medium and expanded in monolayer until passage 
2 and cryopreserved. Informed consent was obtained preoperatively from each 
patient in accordance with the approval from the Ethical Committee of the 
Royal National Orthopaedic Hospital in compliance with the United Kingdom 
Human Tissues Act 2004. 
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4.2.2 Chondrocyte seeding and micromass culture 
Chondrocytes are the primary cell population in hyaline cartilage435. It was, 
therefore, essential to assess the interaction of chondrocytes with the dcECM. 
Human primary articular chondrocytes were thawed, sub-cultured and upon 
confluence at passage 3. Cells were counted using a Neubauer 
hemocytometer containing 0.4% trypan blue and culture media at a ratio of 
1:2. Subsequently, cells were seeded in micromass cultures directly onto the 
plastic surface or onto dcECM at a density of 5x105 per 100 µL of growth media 
into the centre of a well. Micromass culture is extensively used in chondrogenic 
differentiation protocols as it effectively mimics cell aggregation and allows an 
intra-aggregate environment to be acquired that is permissive for 
differentiation436. These events mimic those that occur in vivo during limb 
development.  Briefly, dcECM was cut into 6 mm diameter and 1 mm thick 
sections using a biopsy punch (ThermoFisher, Bedford, UK). 5x105 
chondrocytes in 10 µL of growth media were seeded onto the surface of the 
dcECM, whereby the low seeding volume aided localisation of the cells on the 
surface of the dcECM until attachment. Cells were seeded in micromasses and 
onto the dcECM surface at the same density. The cells were left for 3 hours to 
attach, following which 2 mL of growth media supplemented with 5% FBS was 
added, micromasses were cultured in these conditions for 7 days (n=3 per 
group). The media in each well was replaced daily with fresh growth media. 
 
4.2.3. Human periosteal stem cell culture and expansion 
(hPDSCs).  
hPDSC’s are a key cell skeletal cell population, playing a major role in both 
bone homeostasis and fracture repair35 and were, therefore, a key cell type for 
investigating the in vitro bioactivity of the dcECM. hPDSCs were isolated as 
previously described 207 (obtained from Prof Frank Luyten, KU Leuven, 
Belgium).  Subsequently, hPDSCs from a pool of six different donors were 
expanded to passage 5.  All experiments described herein were performed in 
pooled hPDSCs at passage 6. All cell counting was carried out by combining 
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0.4% trypan blue and culture media at a ratio of 1:2, that was manually counted 
using a Neubauer hemocytometer (Sigma, UK). 
 
4.2.4 Optimisation of scaffold seeding 
It was observed during initial seeding with chondrocytes that cellular content 
does not remain localised on the surface of the dcECM, even when small 
seeding volumes were utilised, this was primarily due to the dcECM surface 
not being completely flat and due to the dcECM being used while wet. 
Therefore, alternative methodologies that facilitated better cell localisation 
were required, before further investigations. Moreover, two prominent RNA 
isolation methodologies were investigated by employing the RNeasy Mini Kit 
(Qiagen, UK) and the Direct-zol RNA MiniPrep kit (Zymo, Cambridge 
Biosciences, Cambs, UK). 
Sterile dcECM was cut into 6 mm diameter and 1 mm thick sections (n=3) 
using a biopsy punch matching the diameter of Nunc 96-well tissue culture 
plate (Thermo Fisher Scientific, UK). It was proposed that a majority of the 
seeded volume would remain on the dcECM surface (Figure 4.1; B) due to a 
large proportion of the volume being localised on the dcECM surface. An 
additional group of plates (n=3) were filled with sterile 2% agarose. The 
agarose was poured into each well and allowed to cool to 40°C at which point 
a cut out dcECM constructs was pushed down into the agarose, ensuring that 
the surface of the dcECM was not covered. It was hypothesised that that 
agarose would cover any gaps between the dcECM and the walls of the well, 
limiting localisation of the cells to the surface of the dcECM, as the cells and 
media used would not flow into the gaps between the dcECM and well plate. 
(Figure 4.1; A). All wells were seeded with hPDSCs (passage 6) at a cell 
density of 1x106 per 100 µL of growth media (10%FBS) into 96-well plates. 
Control micromasses of the same density (n=3) were seeded onto the surface 
of the 96 well plates as a comparator. After 24 hours each well was lysed in 
accordance with manufacturers instructions for each kit. Briefly, in accordance 
to the Zymo kit guidelines, all dcECM constructs and micromasses were 
washed in sterile PBS, sterile forceps were used to move the dcECM 
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constructs into 1.5 mL micro-centrifuge tubes (Star Labs, UK) containing 350 
µL of Trizol (Sigma-Aldrich, UK). For micromasses 350 µL of Trizol was added 
into each well and rigorously scraped, the lysate was transferred into 1.5 mL 
micro-centrifuge tubes (Star Labs, UK). For extraction using the Qiagen Mini-
prep kit, the previously described process was repeated and Trizol was 
replaced with 350 µL of the provided Qiagen RLT lysis buffer. For the rest of 
the extraction, the manufacturers’ instructions for each kit were followed. Total 
RNA isolated was quantified using the Nanodrop 1000 spectrophotometer 
(ThermoFisher, Bedford, UK). 
 
Figure 4.1: hPDSC seeding optimisation. Schematic illustrating the experimental layout for 
establishing an optimal seeding and RNA extraction methodology for maximum yield. 
 
4.2.5. hPDSC seeding and micromass culture. 
It was determined that the dcECM seeded in a 96-well was the optimum 
condition for total RNA extraction and this was, therefore, used as the optimal 
seeding conditions for further cell seeding experiments. 
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Micromass cultures (MM) were seeded as previously described. Briefly, 
hPDSCs (passage 6) were seeded at a cell density of 1x106 per 100 µL of 
growth media into 96-well plates. Cells were seeded at this density onto the 
dcECM as previously described and allowed to attach for 3 hours before being 
treated with various chondrogenic media.  The cells seeded in micromasses 
and on the dcECM were segregated into three media condition groups (n=3 
per group).  The control group was treated with low glucose DMEM (Invitrogen, 
Paisley, UK) supplemented with 2% FBS, (Invitrogen, Paisley, UK) and 
antibiotic-antimycotic solution (100 units/mL penicillin, 100 μg/mL streptomycin 
and 0.25 μg/mL amphotericin B; Invitrogen, Paisley, UK).  The second group 
consisted of basal chondrogenic group or C(-) group consisting of low-glucose 
DMEM (Gibco, UK) supplemented with 100µM ascorbate-2-phosphate 
(Sigma-Aldrich, Dorset, UK), 100nM dexamethasone (Sigma-Aldrich, Dorset, 
UK), 40 mg/mL proline (Sigma-Aldrich, Dorset, UK), ITS+premix universal 
culture supplement (BD Biosciences, Bedford, MA) and  10 µM of Y27632 
(Axon Medchem, Groningen, Netherlands ). The final group consisted of 
chondrogenic or C(+) group containing basal chondrogenic media 
supplemented with 10 ng/mL of TGF-β. 
 
4.2.6. Total RNA extraction and quantitative reverse 
transcription–Polymerase Chain Reaction (qRT-PCR) analysis 
Previous investigations revealed that the Zymo Direct-zol RNA MiniPrep kit 
was the most effective for RNA isolation from seeded constructs and was 
therefore used for all further RNA isolation. Briefly, seeded dcECM constructs 
were washed with PBS, placed in 350 μL of Trizol (Invitrogen, Paisley, UK) 
and homogenised. Total RNA was isolated from each of the micromasses and 
dcECM using the Direct-zol RNA MiniPrep (Cambridge Biosciences, Cambs, 
UK) according to the manufacturers’ instructions.  Total RNA isolated was 
quantified using the Nanodrop 1000 spectrophotometer (ThermoFisher, 
Bedford, UK). Complementary DNA (cDNA) was synthesised by reverse 
transcription of 200ng of total RNA using the high capacity cDNA reverse 
transcription kit (Applied Biosciences, ThermoFisher, Bedford, UK). To detect 
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messenger RNA (mRNA) transcripts, primers (exon spanning, designed using 
Primer3 Plus, NCBI or obtained from published sources) were premixed with 
iTaq universal SYBR green supermix (Biorad, Herts, UK) and 10 μL aliquots 
were applied to Hard-Shell® 96-Well PCR Plates (Biorad, Herts, UK). Thermal 
cycling conditions were as follows: 10 min at 95°C, with 40 cycles of 15 
seconds at 95°C, 30 s at 60°C, and 20s at 72°C, on a Bio-Rad CFX1000 Real-
Time System (Biorad, Herts, UK). Target gene quantification was achieved 
using the 2-ΔΔCT method described by Livak et al. 437 relative to hPRT1 as the 
housekeeper gene. Primers were designed for this study using the Primer-
Blast tool (NCBI, USA). All primers were exon spanning with a product size of 
100-150 base pairs and primer sizes between 18-20 base pairs. Primer melting 
temperatures were between 60-63ºC with a GC content ranging from 50-55%. 
Primers used in this study are listed in Supp Table 1. 
 
4.2.7 Optimisation of chondrogenic media components. 
Standard chondrogenic media C+ consisting of low-glucose DMEM (Gibco, 
UK) supplemented with 100µM ascorbate-2-phosphate (Sigma-Aldrich, 
Dorset, UK), 100nM dexamethasone (Sigma-Aldrich, Dorset, UK), 40 mg/mL 
proline (Sigma-Aldrich, Dorset, UK), ITS+premix universal culture supplement 
(BD Biosciences, Bedford, MA) and  10 µM of Y27632 (Axon Medchem, 
Groningen, Netherlands ) and 10 ng/mL of TGF-β was compared to other 
published chondrogenic conditions that contained the same basal media from 
the C+ but an optimised growth factor combination. The study by L.Mendes 
and colleagues 411 illustrated the role of bone morphogenetic proteins as 
drivers of chondrogenic differentiation. This study incorporated the use of 
factorial design to ascertain various combinations of TGFβ1, FGF2, BMP2, 
BMP6 and GDF5, that promoted chondrogenesis and thence mineralisation.  
The results of this study indicate that the various combinations of growth 
factors have a different impact on chondrogenesis and hypertrophy. The 
overall conclusion of the study was that BMP2 and BMP6 enhanced 
chondrogenesis, while GDF5 promoted chondrocyte hypertrophy. Other 
studies investigating BMP2 and BMP6 have also confirmed their role in 
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chondrogenesis 438,439,440. The study by Mendes and colleagues concluded on 
two conditions that either promoted potent, stable chondrogenesis (C4) or 
chondrocyte hypertrophy (C8). The C4 condition contained the previously 
defined standard basal chondrogenic media formulation [C(-)] with the addition 
of addition to 0.1 ng/mL of TGF- (Peprotech, UK), 0.2 ng/mL of FGF-2 
(Thermofisher Scientific, UK), 100ng/mL of BMP-2 (Peprotech, UK), 100 
ng/mL of BMP-6 (Peprotech, UK) and 1 ng/mL of GDF5 (Peprotech, UK). The 
C8 contained standard basal chondrogenic media [C(-)] with the addition of 10 
ng/mL of TGF-β (Peprotech, UK), 0.2 ng/mL of FGF-2 (Thermofisher Scientific, 
UK), 100ng/mL of BMP-2 (Peprotech, UK), 1.0 ng/mL of BMP-6 (Peprotech, 
UK), and 100ng/mL GDF-5 (Peprotech, UK). Other than the media conditions 
seeding of the dcECM was the same as described in section 4.2.5. Both C4 
and C8 were investigated with hPDSC’s seeded onto the dcECM, using the 
standard seeding methodology described in section 4.2.5. 
 
4.2.7 Chorioallantoic membrane (CAM) assay 
Angiogenesis is a crucial process that occurs during endochondral fracture 
healing2. It has been suggested that costal cartilage undergoes gradual 
endochondral ossification postnatally. Bahrami and colleagues have 
suggested that costal cartilage contains trace amounts of the hypertrophy-
associated protein collagen X155. It was, therefore, hypothesised that residual 
VEGF content might be present within native costal cartilage, potentially 
promoting angiogenesis in vivo. Therefore, the capacity of native costal 
cartilage and the dcECM to drive angiogenesis was investigated using a CAM 
assay. 
All animal procedures were carried out in accordance with the guidelines and 
regulations laid down in the Animals Scientific Procedures Act 1986. Eggs for 
the study were obtained from Medeggs (Henry Stewart & Co, UK). (Figure 4.2) 
Eggs were incubated horizontally at 37 °C and 60% humidity for 4 days. After 
the 4-day incubation period, the eggs were monitored using candling to verify 
the position of the embryo, a square incision area of 0.6cm2 was marked on 
the shell accordingly and covered using Scotch tape (Scotch, UK) to reduce 
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egg shell fragmentation during cutting. Fine scissors were used to make the 
0.6cm2 incision in sterile conditions three edges were cut leaving one edge 
intact so that the window could be covered again. The egg fragment held by 
the tape was lifted to expose the CAM. Sterile native cartilage and dcECM 
cylinders were individually placed on the CAM of each egg (n=10 per group). 
Scotch tape was used to re-seal the window, and the eggs were re-incubated. 
Candling was used to examine the eggs daily, and non-viable embryos or 
infected eggs were removed. After 6 days, the windows on each egg were 
opened and visualised. CAM integration and interaction with vasculature was 
visualised using the Stemi 305 compact stereomicroscope (Zeiss, UK). 
Photographs were captured using the paired Axiocam 506 colour camera 
(Zeiss, UK). Forceps were used to retrieve both native and dcECM samples 
from each egg. Samples were lysed for RNA extraction and gene expression 
analysis. 
 
97 
 
 
Figure 19: Schematic representation of the experimental procedures carried out during the 
CAM assay assessment of the dcECM and native costal cartilage. (1) Fertilised clinical eggs 
are obtained and incubated at 37 ºC for 4 days. (2) Candling is utilised to locate the embryo 
and eggs without an embryo will be discarded. (3) A window ~0.6 mm2 is cut out to reveal the 
CAM below. (4) The dcECM and native costal cartilage samples are cut into cylinders (D= 6 
mm, H= 1 mm) and placed on top of the CAM. Samples were incubated for another 6 days. 
(4) Samples were retrieved from the CAM and subjected to histological and molecular 
analysis. Figure was created using the Servier medical art database 
(http://www.servier.com/Powerpoint-image-bank 
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4.2.9. In vivo biocompatibility 
A controlled inflammatory response is an essential underlying process in 
fracture healing, uncontrolled or pro-inflammatory responses associated with 
graft rejection could have a significant impact on the clinical translatability of 
the dcECM441. After successfully in vitro demonstration of the removal of 
immunogenic components the immunogenicity of the dcECM was further 
investigated in vivo (Figure 4.3). The in vivo biocompatibility study was carried 
out by Dr Wenhui Song (UCL, United Kingdom), Dr Gui Teoh (UCL, United 
Kingdom), and Shudong Zhao (UCL, United Kingdom) at the Biology Unit, 
Royal Free and University College London Medical School, London, UK 
 
Figure 4.3: In vivo biocompatibility experimental layout. Schematic representation of the in 
vivo biocompatibility study. (1) Native costal cartilage was subjected to Vac-OS 
decellularisation. (2&3) Both native costal cartilage and the dcECM were sterilisation. (4&5) 
Sterile dcECM and native costal cartilage samples were implanted subcutaneously; 2 of each 
group were implanted into each mouse. (6) Samples were retrieved, fixed and processed for 
histology. (7) Samples were assessed using IHC for the immune cell markers DC86 (M1-
macrophage marker), CD163 (M2-macrophage marker) and CD68 (Pan-macrophage marker). 
Figure was created using the Servier medical art database 
(http://www.servier.com/Powerpoint-image-bank. 
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6-week old BALB/C mice were purchased from Charles River, UK and were 
housed in polypropylene cages at 21°C (±2°C), subjected to 12-hour light and 
dark cycles, and were acclimatised for one week before use.  Mice were fed a 
standard RM1 maintenance diet ad libitum (Rat and Mouse No.1; Special Diet 
Services).  All procedures were conducted in accordance with the United 
Kingdom Animal Scientific Procedures Act, 1986 and were approved by the 
Ethics and Welfare Committee of the Comparative Biology Unit, Royal Free 
and University College London Medical School, London.   
Mice were anesthetised (3–5% isoflurane, O2 flow rate of 1.0 mL/min) and two 
8 mm dorsal incisions created per mouse.  The subcutaneous pockets on each 
mouse were filled with either two dcECM constructs or two native cartilage 
constructs (6 mm in diameter and 1 mm thick). The incisions were then sutured 
with Vicryl Rapide sutures (Ethicon, UK). After 2 and 8 weeks of implantation 
(Figure 19), mice were sacrificed by CO2 inhalation.  The dorsal skin was 
carefully resected and implants retrieved.  The dcECM and native cartilage 
tissue were fixed in 10% neutral buffered formalin (pH 7.4) (VWR, UK) for 24 
hours at room temperature (18-21°C). 
The 10% NBF fixed tissues ((n=4) dcECM; (n=4) native costal cartilage), 2 and 
8 weeks respectively) were dehydrated in graded alcohol, embedded in 
paraffin, and sectioned at 5 μm.  Immunohistochemical analysis of CD68 (Pan-
macrophage marker; Abcam, Cambridge, UK), CD86 (M1 macrophage 
marker; Abcam, Cambridge, UK), and CD163 (M2 macrophage marker; 
Abcam, Cambridge, UK) was performed following deparaffinization and 
rehydration of the tissue sections.  All sections were blocked in 2.5% horse 
serum (VectorLabs, Cambs, UK) and 3% H2O2 (Sigma-Aldrich, Dorset, UK). 
For CD68 and CD163 detection, antigen retrieval was performed by incubation 
with Tris-EDTA buffer (10 mM Tris base, 1 mM EDTA solution, 0.05% Tween 
20, pH 9.0) at 60°C overnight. Antigen retrieval for CD86 was performed by 
incubation with proteinase K (Proteinase K ready to use solution (Dako, UK) 
for 2 minutes at room temperature (18-21°C). Sections were then incubated 
with primary anti-CD68 (1:500 rabbit polyclonal anti-mouse; VectorLabs, 
Cambs, UK), anti-CD86 (1:500 mouse monoclonal anti-mouse; VectorLabs, 
Cambs, UK) and anti-CD163 (1:500 rabbit polyclonal anti-mouse; VectorLabs, 
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Cambs, UK) at 4°C overnight. Subsequently, CD86 and CD163 sections were 
incubated with HRP-conjugated anti-rabbit secondary antibody solution 
(VectorLabs, Cambs, UK), CD86 sections were incubated with HRP-
conjugated anti-mouse secondary antibody solution (VectorLabs, Cambs, UK) 
for 1 hour at room temperature (18-21°C). All targets were visualised by 
incubation with the substrate 3,3′-diaminobenzidine (VectorLabs, Cambs, UK) 
for 1 minute.  Tissue sections were counterstained with Haematoxylin solution 
(Sigma-Aldrich, Dorset, UK) and visualised using the Zeiss Apotome.2 
microscope under bright field settings (Zeiss, UK). 
 
4.2.10. Statistical analysis 
Data are expressed as the mean ± standard deviation (SD) or mean ± standard 
error mean (SEM). Statistical analysis was carried out as described in Chapter 
2.  All statistical analysis was performed using GraphPad Prism version 6.0f 
for windows (GraphPad Prism Software, La Jolla California USA, 
www.graphpad.com). 
 
4.3 Results 
 
4.3.1. The dcECM is capable of re-establishing the chondrogenic 
phenotype in dedifferentiated human articular cartilage-derived 
chondrocytes. 
To assess the capacity for cellular differentiation towards a chondrogenic 
phenotype, de-differentiated human chondrocytes, the predominant cell 
population in hyaline articular cartilage308, were seeded onto the dcECM 
(Figure 4.4).  
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Figure 4.4: Chondrocyte seeding experimental layout. Schematic representation 
highlighting the seeding and media conditions for seeding dedifferentiated Human articular 
cartilage-derived chondrocytes. 
 
Brightfield microscopy revealed that cells near the dcECM had a distinct 
cobblestone morphology (Figure 4.5; A&B), this also suggested that several 
cells did not localise on the dcECM surface. Nuclear and cytoskeletal staining 
using DAPI and Phalloidin illustrated cell attachment onto the dcECM (Figure 
4.5; C&D). Moreover, the attached cells established themselves in the vacant 
chondrocyte lacunae. The re-establishment of a chondrogenic phenotype of 
seeded cells was confirmed by a significant 4-fold (p<0.01) increase in 
COL2A1 mRNA expression associated with cartilage matrix maintenance 
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(Figure 4.6). There was, however, no significant difference in the expression 
of the chondrogenic commitment marker SOX9.  
 
Figure 4.5: Histological analysis of chondrocyte seeded dcECM(A) Brightfield microscopy 
image of a micromass seeded in a six-well plate. (B) Brightfield microscopy image of the 
seeded dcECM surrounded by dedifferentiated chondrocytes on tissue culture plastic. (C&D) 
Structured illumination microscopy images of dedifferentiated chondrocytes seeded on 
dcECM and stained with DAPI/phalloidin indicating cells residing within the lacunae. The figure 
has been reproduced from Val et al281 with permission from Mary Ann Liebert, Inc., New 
Rochelle, NY 
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Figure 4.6: Gene expression of dcECM seeded chondrocytes. Gene expression analysis 
of dedifferentiated chondrocytes both in micromass and seeded onto the surface of the 
dcECM( ns = non-significant, p<0.05, **).(Fold changes normalised to micromasses. Statistical 
analysis performed using an unpaired t-test with Welch's posthoc correction., error bars = 
SEM). 
 
4.3.2. Optimisation of scaffold seeding methodology for optimal 
RNA yield. 
Initial seeding experiments in 6-well plates revealed that some cells did not 
localise precisely on the scaffold as cells were visible on the tissue culture 
plastic. It was hypothesised that the lack of cell localisation on the dcECM 
surface had an impact on mRNA retrieval. This required optimisation of the 
seeding conditions by seeding cells onto the dcECM in a 96-well plate, with or 
without agar (Figure 4.1). Furthermore, two RNA extraction kits were also 
utilised, each containing a proprietary mix of chaotropic salts, affecting nucleic 
acid isolation and binding to the silica column. There was a significant 600 and 
700 ng increase in RNA yield when using the Zymo Kit (p<0.05) when 
comparing micromass and dcECM samples extracted using the Qiagen vs 
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Zymo kits respectively (Figure 4.7). There was also a trend towards a higher 
RNA yield with the Zymo kit when considering dcECM(Agar) samples. 
Additionally, while there was no significant difference in total RNA retrieval 
between dcECM and dcECM(Agar) for each extraction technique, the addition 
of agar increased variation in total RNA content when using the Zymo kit. 
 
Figure 4.7: Total RNA content for RNA seeding optimisation (A) Simplified schematic 
protocol for the purification of RNA using the Zymo DirectZol kit. (B) Simplified schematic 
protocol for the Qiagen RNA extraction kit. (C) Total RNA content comparing values obtained 
using Qiagen and Zymo RNA extraction kits. (Statistical analysis performed using a one-way 
ANOVA, corrected for multiple comparisons using Tukey's post hoc multiple comparisons test, 
error bars = SEM; *p<0.05, ** p<0.001). 
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4.3.3. The dcECM enhances chondrogenic differentiation in 
hPDSC’s in the presence of ROCKi.  
To further examine the chondrogenic potential of the scaffolds, hPDSCs were 
seeded onto the dcECM and as control micromasses cultures.  Chondrogenic 
conditions [C(+)] were compared to control conditions (CTRL). Additionally, 
TGFβ and ROCKi are commonly incorporated into chondrogenic media 
formulations due to their ability to drive and enhance chondrogenesis. ROCK 
is a downstream effector of the Rho kinase family of GTPases that are involved 
in regulating chondrogenic gene expression by regulating actin cytoskeleton 
rearrangement442,443. Therefore, ROCKi was eliminated from comparator 
culture conditions. (Figure 4.8).  
Brightfield microscopy images revealed distinct curling of the micromasses 
when ROCKi was eliminated from the culture(Figure 4.9). Gene expression, 
however, revealed molecular changes associated with chondrogenic 
differentiation. dcECM in combination with the C(+) condition enhanced 
chondrogenic gene expression(Figure 4.10 & 4.11) , highlighted by the 
significant upregulation of the SOX-trimer; SOX9; SOX5 and SOX6 with a 3-, 
5- and 3.6-fold (p<0.05) respectively, compared to micromasses in the same 
condition. Furthermore, under chondrogenic C(+) conditions an 8- and 4-fold 
(p<0.05, p<0.01) upregulation in cartilage matrix specific markers ACAN and 
COL2A1 were observed. This was also accompanied by an upregulation of 
markers associated with chondrocyte hypertrophy with a 2-, 2.9- and 5-fold 
(p<0.05, p<0.01, p<0.01) increase in RUNX2, COL10A1 and VEGFA 
expression respectively. When ROCKi was eliminated from the basic 
chondrogenic media (-R), there was a trend towards a decrease in SOX-trimer 
and a significant 9-fold decrease in COL2A1 (p<0.01) with micromasses in 
C(+) conditions. There was, however, a trend towards an increase in the 
hypertrophic markers RUNX2 and VEGFA but a decrease in COL10A1. The 
dcECM cultured in C(+) conditions without ROCKi, resulted in significant 1.5-, 
1- and 2-fold decrease in SOX9, 5 and 6 (p<0.01, p<0.05 , p<0.01) 
respectively, Alongside a 3-fold decrease in COL2A1 (p<0.01). In contrast, 
there was a 5-fold increase in VEGFA (p<0.001).  
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The elimination of TGFβ in the C(-) conditions had a significant impact on the 
expression of chondrogenic markers with SOX9, SOX5, ACAN and COL2A1 
not being expressed above the basal levels (CTRL) when compared to 
micromass cultures. 
 
Figure 4.8: Requirement of ROCKi for chondrogenesis. Schematic representation 
highlighting the seeding and various media conditions for the assessment of the dcECM using 
hPDSC’s. 
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Figure 4.9: Investigation of removing ROCK on micromass morphology Representative 
brightfield images of micromass cultures at a seeding density of 300,000/cm2 in CTRL[A] , C(-
)[B], C(+)[D] conditions. C(+) and C(-) conditions also had ROCKi eliminated from the culture 
(-R)[C&E]. (E) C+ conditions without ROCKi resulting in the curling of the micromass, while 
there were no distinct changes observed in the rest of the cultures. Images were obtained 7 
days post culture. Scale bar = 100µm. 
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Figure 4.10: Removal of ROCKi and its impact on chondrogenic gene expression. 
Chondrogenic gene expression (SOX9,5,6 and ACAN) of hPDSCs seeded in MM and dcECM 
under control conditions (CTRL), chondrogenic conditions (C+) and chondrogenic media 
without TGF-β (C-). C(+) and C(-) conditions were also had ROCKi eliminated from their 
formulations (-R). n=3 *p<0.05, **p<0.01, ***p<0.001)(Fold changes normalised to 
micromasses in CTRL conditions).  Statistical analysis was performed using one-way ANOVA 
corrected for multiple comparisons using Bonferroni’s posthoc analysis. 
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Figure 4.11: Chondrogenic and chondrocyte hypertrophy gene expression (COL2A1, 
COL10A1, RUNX2 & VEGFA) of hPDSCs seeded in MM and dcECM under control conditions 
(CTRL), chondrogenic conditions (C+) and chondrogenic media without TGF-β (C-). C(+) and 
C(-) conditions were also had ROCKi eliminated from their formulations (-R). n=3 *p<0.05, 
**p<0.01, ***p<0.001) (Fold changes normalised to micromasses in CTRL conditions).  
Statistical analysis was performed using one-way ANOVA corrected for multiple comparisons 
using Bonferroni’s posthoc analysis. 
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4.3.4. Hypoxia has limited effect on chondrogenesis in hPDSC 
seeded onto the dcECM in tested conditions. 
During fracture repair, oxygen tension can play a crucial role in stem cell 
chondrogenesis444. The role of hypoxia in contributing to the bioactivity of the 
dcECM was, therefore, investigated by culturing cells in 5% O2. Gene 
expression was measured 3 and 7 days post culture (Figure 4.11). 
 
Figure 4.12: Experimental layout to investigate the chondrogenic potential of hypoxia 
in hPDSC seeded dcECM. Schematic representation highlighting the seeding and various 
media conditions for the assessment of the dcECM using hPDSC’s in low-oxygen conditions. 
No differences in gene expression were observed in C(-) conditions both at 3 
and 7 days(Figure 4.13 & 4.14). Hypoxia had a positive impact on 
chondrogenesis and hypertrophy only in micromass conditions with a 2.5- and 
a 2-fold increase in the relative expression of chondrogenic markers SOX6 
(p<0.05) and hypertrophic marker COL10A1 (p<0.05), this trend present at day 
3 was repeated at day 7. An interesting observation, however, was that 
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hypoxia did not facilitate chondrogenesis in 3D cultures containing at dcECM. 
In normoxia, however, the dcECM demonstrated an enhanced 2-, 3.2-fold 
upregulation of the chondrogenic markers SOX9 (p<0.05), and COL2A1 
(p<0.05) at day 7 in chondrogenic conditions. 
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Figure 4.13: Hypoxia investigation gene expression data. Chondrogenic gene expression 
(SOX9,5,6 & ACAN) of hPDSCs seeded in MM and dcECM under control conditions (CTRL), 
chondrogenic conditions (C+) and chondrogenic media without TGF-β (C-) at day 3 and 7. 
Each group was also subjected to hypoxia (5% O2). One set of the stared conditions was 
subjected to hypoxia. Fold changes normalised to micromasses cultures in control (MM-CTRL) 
conditions at day 3 . Significance in relation with control micromasses is indicated by # (# 
p<0.05,## p<0.01, ### p<0.001) Significance between experimental groups is indicated by * 
(* p<0.05, ** p<0.01 and *** p<0.001) .  Statistical analysis was performed using one-way 
ANOVA corrected for multiple comparisons using Bonferroni’s posthoc analysis. 
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Figure 4.14: Chondrogenic gene expression (COL2A1, COL10A1, RUNX2 and VEGFA) of 
hPDSCs seeded in MM and dcECM under control conditions (CTRL), chondrogenic conditions 
(C+) and chondrogenic media without TGF-β (C-) at day 3 and 7. Each group was also 
subjected to hypoxia (5% O2). One set of the stared conditions was subjected to hypoxia. Fold 
changes normalised to micromasses cultures in control (MM-CTRL) conditions at day 3 . 
Significance in relation with control micromasses is indicated by # (# p<0.05,## p<0.01, ### 
p<0.001) Significance between experimental groups is indicated by * (* p<0.05, ** p<0.01 and 
*** p<0.001) .  Statistical analysis was performed using one-way ANOVA corrected for multiple 
comparisons using Bonferroni’s posthoc analysis. 
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4.3.5. Conditions containing BMP2 and GDF5 enhances the 
expression of chondrogenic and hypertrophic genes in hPDSC’s.  
Previous work carried out by Mendes and colleagues411 demonstrated that the 
inclusion of differential concentrations of TGFβ, FGF2, BMP2, BMP6 and 
GDF5 could enhance chondrogenic differentiation of hPDSC’s. Condition C4 
and C8, as previously defined, enhanced stable chondrogenesis and 
hypertrophy respectively. These conditions and their growth factor 
concentration profile were, therefore, selected for investigation with the dcECM 
(Figure 4.15).  
 
Figure 4.15: Growth factor optimisation experimental layout. Schematic representation 
highlighting the assessment of various growth factor combinations on hPDSC’s seeded onto 
the dcECM. Conditions C(4) and C(8) were adapted from Mendes and colleagues411. 
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Brightfield microscopy images revealed some curling of micromasses cultured 
in C(+) conditions and visible differences in morphology in micromasses that 
were cultured in C(8) conditions (Figure 4.16). To evaluate the chondrogenic 
capacity under the C(+) and C(8) conditions, chondrogenic markers were 
evaluated (Figure 4.17 & 4.18). C8 conditions potently upregulated 
chondrogenic markers with a 3.5, 6.5, 3 and 120 fold upregulation of SOX5, 
SOX6, ACAN and COL2A1 respectively, when compared to C(+) conditions. 
Moreover, similar results were observed when comparing hPDSC’s in C(8) 
micromasses cultures to C(8) conditions containing the dcECM. However, the 
dcECM in C(+) conditions demonstrated a trend towards higher COL10A1 
expression.  
 
Figure 4.16: Growth factor optimisation brightfield images. (A-D) Representative 
brightfield images of hPDSC micromass cultures at a seeding density of 300,000/cm2. 
hPDSC’s were cultured in CTRL[A], C(+)[B], C(4)[C] and C(8)[D] conditions at day 1,3 and 7 
(scale bar = 100 µm). 
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Figure 4.17: Growth factor optimisation gene expression data. qPCR based gene 
expression analysis for the chondrogenic marker genes  SOX9,  SOX5, ACAN and COLL2A1. 
Fold changes normalised to micromasses cultures in control (MM-CTRL) conditions 
significance in relation with control micromasses indicated by # (# p<0.05,## p<0.01, ### 
p<0.001). Significance between experimental groups is indicated by * (* p<0.05, ** p<0.01, 
***).(Statistical analysis performed using a one-way ANOVA, corrected for multiple 
comparisons using Tukey's post-hoc multiple comparisons test, error bars = SEM). 
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Figure 4.18: Growth factor optimisation gene expression data. qPCR based gene 
expression analysis for the chondrogenic marker genes SOX6, RUNX2, COL10A1 and 
RUNX2. Fold changes normalised to micromasses cultures in control (MM-CTRL) conditions 
significance in relation with control micromasses indicated by # (# p<0.05,## p<0.01, ### 
p<0.001). Significance between experimental groups is indicated by * (* p<0.05, ** p<0.01, 
***).(Statistical analysis performed using a one-way ANOVA, corrected for multiple 
comparisons using Tukey's post-hoc multiple comparisons test, error bars = SEM). 
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4.3.6. CAM assays demonstrate that the dcECM retains some 
inherent ability to promote angiogenesis.  
The inherent capacity of the native costal cartilage and the dcECM to promote 
angiogenesis were investigated using a CAM assay. Images obtained using a 
brightfield stereomicroscope demonstrated blood vessel attraction towards 
both the native costal cartilage and the dcECM when placed on the CAM 
(Figure 4.19; A-B1&2). Explanted native and dcECM constructs also 
demonstrated blood vessel infiltration into the constructs (Figure 4.19; A3&B3). 
Gene expression data for cd31 indicated that the native costal cartilage caused 
a 10-fold higher expression when compared to dcECM constructs (p<0.001) 
(Figure 4.20). 
 
 
 
Figure 4.19: dcECM CAM assay Images. (A-B, 1-2) Representative images of the native 
costal cartilage and the dcECM placed onto the CAM of a 4 day old chick embryo and imaged 
after 6 days of in ovo culture. (A3&B3) Native costal cartilage and dcECM samples explanted 
after 6 days of culture in ovo. Scale Bar = 1 mm 
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Figure 4.20: dcECM CAM assay gene expression. Gene expression analysis of chicken 
cd31. (*** p<0.001). Fold changes normalised to native costal cartilage. Statistical analysis 
performed using an unpaired t-test with Welch's posthoc correction., (error bars = SEM). 
 
4.3.7. Subcutaneously implanted dcECM elicits a predominantly 
M2 macrophage-mediated anti-inflammatory, regenerative 
response 
The dcECM was subcutaneously implanted into mice to assess the in vivo 
immune response in comparison to native costal cartilage tissue. Explanted 
samples were subjected to immunohistochemical (IHC) analysis for CD68 
(Pan-macrophage marker), CD86 (M1-macrophage marker) and CD163 (M2-
macrophage marker) (Figure 4.3). Qualitative analysis (Figure 4.21) of the 
stained sections revealed a similar CD68 positive immune cell presence within 
the fibrous tissue (FT) that bordered the implant, between both the native 
costal cartilage and the dcECM at 2 and 8 weeks. After 8 weeks, however, 
there was an observed decrease in CD86 staining with the dcECM compared 
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to the 2-week samples and native samples at this time point. Another distinct 
observation was the presence of CD163 positive cells in the FT surrounding 
the dcECM both at the 2 and 8-week time points, compared to the native 
cartilage samples. This indicated a predominantly M2 macrophage-mediated 
immune response towards the dcECM. 
 
Figure 4.21: In vivo biocompatibility IHC analysis. (A) Representative in vivo photographs 
of subcutaneously implanted native costal cartilage and the dcECM 8 weeks post-implantation 
(B) Representative brightfield images of subcutaneously implanted native and dcECM 
cartilaginous constructs (CT) and host cellular infiltrate (FT). IHC was performed to visualise 
CD68 (Pan-macrophage marker), CD86 (M1-macrophage marker) and CD163 (M2-
macrophage marker).  Scale bars = 50 μm. The figure has been reproduced from Val et al281 
with permission from Mary Ann Liebert, Inc., New Rochelle, NY 
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4.4 Discussion 
The successful clinical application of a tissue-engineered implant depends on 
its ability to attract and direct tissue-specific remodelling via its interaction with 
relevant stem cell populations445. The work carried out within this chapter, 
therefore, focuses on investigating the ability of the dcECM to interact 
favourably with skeletal cell populations and drive chondrogenic differentiation 
processes and are crucial for endochondral fracture healing. 
Chondrocytes are the predominant cell type in hyaline cartilage and a key 
modulator of cartilage homoeostasis 435, they are, however, known to rapidly 
lose their chondrocytic phenotype following culture in monolayer, in a process 
that has been termed dedifferentiation446,447. Interestingly, dcECM promoted 
the re-establishment of a chondrogenic phenotype from culture expanded 
(dedifferentiated) chondrocytes, indicated by a significant upregulation of 
COL2A1 expression (Figure 4.6).  These results could potentially be the result 
of the retention of sufficient sGAG content 94,270,448, an undisrupted ECM 
ultrastructure449 and, although not investigated in this thesis, the presence of 
remnant growth factors such as TGF- 450, BMP2 451, FGF-2 and FGF-18452. 
Investigations using de-differentiated chondrocytes also highlighted an 
inefficient localisation of cellular content on the surface of the dcECM, 
potentially, due to the dcECM surface not being perfectly flat, this could result 
in a lower and more inconsistent cell density on the surface of the dcECM. It 
was essential to obtain more consistent seeding as work by Bornes, and 
colleagues highlight the impact of varying cell densities on the chondrogenesis 
of MSC’s seeded onto 3D collagen scaffolds453. The seeding methodology 
was, therefore, modified by seeding into a 96-well that closely matched the 6 
mm diameter of the dcECM construct, thus improving localisation and 
maintaining a consistent seeding density.  
hPDSC’s were used to further investigate the bioactivity of the dcECM due to 
extensive published results and work within the group, highlighting the role of 
hPDSC’s in fracture repair and bone tissue engineering 209,384,454,455. Overall, 
gene expression data (Figure 4.10 & 4.11) highlighted that in chondrogenic 
conditions the dcECM significantly upregulated the expression of the SOX-
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timer (SOX9,5&6). Lui and Lefebvre, suggest that the cooperative action of the 
SOX-trimer forms a super-enhancer complex that drives potent 
chondrogenesis400, further highlighting the chondroinductive potency of the 
dcECM. Chung and colleagues do, however, note that the individual 
transcription factors within the SOX-trimer are upregulated during different 
stages of chondrogenesis456. Therefore, to further elucidate the underlying 
process of chondrogenic differentiation, several earlier time points may be 
required. An interesting observation was that the upregulation of chondrogenic 
markers was limited to seeded dcECM constructs, cultured in conditions 
containing TGF-β; these findings helped formulate two conclusions. Firstly, the 
dcECM may lack the endogenous growth factors necessary for chondrogenic 
differentiation of hPDSCs. Secondly, the dcECM may still be capable of 
enhancing the chondrogenic properties of exogenously added TGF-β due to 
the retention of the sGAGs content within the dcECM, capable of sequestering 
exogenously added TGF-β, and thus enhancing its chondrogenic potential. 
Previous work has extensively highlighted the role of sGAG’s in facilitating and 
enhancing chondrogenesis 94,270,448. 
Additionally, dcECM conditions containing TGF-β also demonstrated 
upregulation of hypertrophic markers such as COL10A1 and VEGFA. Zeng 
and colleagues suggest that the expression of the COL10A1 gene is critical for 
chondrocyte hypertrophic differentiation457. However, Mwale and colleagues 
suggest that COL10A1 may be an unreliable marker for hypertrophy due to its 
upregulation during early chondrogenesis399. Pelttari and colleagues suggest 
that the early induction of COL10A1 expression during chondrogenesis in vitro 
correlates with in vivo calcification and vascular invasion when MSC’s derived 
cartilage constructs were ectopically implanted into SCID mice458. VEGFA was 
also upregulated in dcECM conditions and plays and is involved in facilitating 
cartilage hypertrophy and the blood vessel infiltration that eventually leads to 
new bone formation during endochondral ossification459. Overall, these 
findings suggest the dcECM may have the potential to undergo endochondral 
ossification in vivo.  
Previously studies have demonstrated that culturing differentiated chondrocyte 
cell populations on tissue culture plastic often results in stress fibre formation 
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mediated via the ROCK pathway, subsequently, leading to their 
dedifferentiation460. This finding highlighted a potential mechanism for 
inhibition to enhance chondrogenesis461,462. Therefore, the inhibition of the 
ROCK pathway using a ROCK inhibitor (ROCKi) has become more prominent 
in chondrogenic media formulations411,463 as it limits stress fibre formation and 
enhances chondrogenesis464. It was hypothesised that the 3D surface of the 
cartilage ECM derived dcECM constructs would not induce stress fibre 
formation when seeded with hPDSC’s, therefore did not require the addition of 
ROCKi. Interestingly, the removal of ROCKi from the C(+) media formulations 
resulted in suppressed chondrogenic differentiation both in micromass and 3D 
cultures (Figure 4.10 & 4.11) Moreover, the removal of ROCKi, caused the 
micromass cultures to curl, potentially, due to the production of stress fibres. 
Moreover, there is still an upregulation of chondrogenic markers (ACAN & 
COL2A1) with chondrogenic conditions that contain the dcECM, but no ROCKi 
compared to MM’s in the same conditions. These findings are in agreement 
with Woods and colleagues who suggest that ROCKi may regulate SOX9 
expression independently of the seeding surface461. Moreover, Xu and 
colleagues suggested a synergistic mechanism for ROCKi with TGF-β, via 
their interaction with the SMAD signalling pathway465. Therefore, conditions for 
the chondrogenic and hypertrophic priming of hPDSC’s even when seeded 
onto a 3D cartilaginous scaffold may require the inclusion of ROCKi. 
Alternatively, Kim and colleagues suggest that inhibition of the RhoA and not 
the ROCK pathway enhances chondrogenesis in chick limb MSC’s466. Future 
optimisation of seeding conditions could, therefore, include both ROCKi and 
RhoA inhibitors, however, since RhoA, B and C are all implicated in stress fibre 
formation inhibiting ROCKi may be a more effective approach467. Overall, the 
potent ability of the dcECM to upregulate both chondrogenic and hypertrophic 
marker expression within just 7 days may demonstrate the importance of 
preventing the loss of crucial structural and biological cues in the dcECM. 
Hypoxia was also considered for investigation due to its pivotal role in 
facilitating early chondrogenesis during fracture repair401. hPDSC’s in 
micromass cultures demonstrated enhanced chondrogenesis in hypoxia, 
agreeing with similar findings in MSC’s as highlighted by Lee and 
123 
 
colleagues468. Interestingly, when hypoxia was coupled with the dcECM, 
chondrogenesis was suppressed at day 7, however, upon examination of the 
results obtained 3-days post culture, there was an upregulation of COL2A1 
suggesting that hypoxia could drive earlier chondrogenesis that could have 
been suppressed by day 7 (Figure 4.13 & 4.14).  There currently are no studies 
that precisely measure oxygen levels at the fracture site in humans, and more 
importantly oxygen levels at fracture sites with reduced viable vascular tissue. 
Therefore, the hypoxic conditions used in the study may not be representative 
of in vivo conditions.  Moreover, although both MSC’s and hPDSC’s reside in 
highly vascularised native environments, there may be subtle differences in 
oxygen concentrations384,469. The role of hypoxia should, therefore, be further 
investigated with a broader array of oxygen concentrations and other skeletal 
cell populations in tandem with hPDSC’s.  
Several factors in addition to TGF-β that can promote chondrogenesis and 
hypertrophy in mesenchymal cell populations470,471. A study by Mendes and 
colleagues411 is, however, the only study that investigates the effect of several 
of these factors on chondrogenesis specifically in hPDSC’s. The study was, 
however, limited to micromass cultures. Therefore, the experiments carried out 
in this chapter were aimed at further investigating chondrogenesis using two 
of the optimal conditions (C4 & C8) when combined with a the dcECM. In line 
with previous results within this chapter, the dcECM demonstrated a robust 
upregulation of both chondrogenic and hypertrophic markers in standard 
chondrogenic conditions (Figure 4.17 & 4.16). Moreover, the findings in this 
chapter are in agreement with Mendes and colleagues as they demonstrated 
a potent upregulation of the hypertrophic markers COL10A1 and VEGFA in 
the C8 but not C4, suggesting that C4 may drive the establishment of a more 
stable chondrocyte phenotype. More interestingly, although the dcECM 
enhanced chondrogenesis in C4 and C(+) conditions, compared to 
micromasses in the same comditions, rthe micromasses outperformed the 
dcECM in C8 conditions and the greatest upregulation overall. As Coleman 
and colleagues suggest, although factors such as GDF5, present in high levels 
can promote chondrocyte hypertrophy472, their interaction with components of 
the dcECM such as heparin sulfate may alter their functionality, as also 
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proposed in a study by Ayerst and colleagues473. Moreover, these results 
further highlight the importance of TGF-β in promoting chondrogenesis474–476, 
as C4 containing low TGF-β levels do not promote chondrogenic gene 
expression as potently as C8 that contained higher levels of TGF-β. Moreover, 
as suggested bt Shen and colleagues BMP2 enhances TGF-β3 mediated 
chondrogenesis, potentially demonstrated in the synergistic interaction of 
TGF-β and BMP2 in C8477. The underlying mechanism for this synergy could 
rely on the fact that both BMP2 and TGF-β bind to specific type II receptors 
and utilise the Smad pather for signal transduction (Figure 4.22). However, 
while TGF-β signalling is transduced through Smad2 and 3, BMP signalling 
relies on Smad 1, 5 and 8478.  Overall, the evidence presented strongly 
suggests that conditions optimised in micromass cultures cannot always be 
directly translated into conditions containing a 3D bioactive scaffold. It further 
highlights the need for tuning the ideal growth factor cocktail with the dcECM, 
a crucial factor when considering priming tissue engineered scaffolds for in 
vivo implantation. A key factor to consider for a future study would be the 
potential disparity between gene expression and protein expression due to 
layers of post-transcriptional regulation479,480. The use of protein expression 
may, therefore, be more definitive.  
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Figure 4.22: TGF-β superfamily signalling pathway.  Schematic representation of the 
SMAD signalling pathway utilised by the TGF-β superfamily. Schematic was adapted from 
Danisovic and colleagues470. 
 
Angiogenesis plays a key role during fracture repair, facilitating cellular 
migration during the early stages of repair and driving callus ossification during 
the latter stages481. We, therefore, investigated the dcECM’s capacity to 
facilitate angiogenesis using a  in ovo CAM assay. Overall, the dcECM 
constructs did not remained localised under the window, this was a major issue 
when for obtainig sufficient visualisation of the surrounding vasculature, 
required to draw any difinitive conclusions. Gene expression data obtained 
form the cellular content localised on the implanted native costal cartilage 
constructs, 6 days post in ovo culture, indicated an upregulation of CD31, a 
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marker associated with endothelial cell populations482. These findings 
potentially suggest some degree of angiogenic potency in native costal 
cartilage tissue or a lack of angiogenic inhibitors. However, the gene 
expression seems to highlight that this ability to attract angiogenic cells is lost 
post Vac-OS decellularisation. The CAM assay was not conclusive. However, 
future work can consider alternative approaches such as the use of ex ovo 
CAM assays483, providing a much larger and more even area for the 
localisation and visualisation of the constructs. Moreover, the 1 mm thick 
constructs could be breaking through the CAM and failing to localise on the 
surface; future work should use smaller and lighter dcECM fragments.  
In vitro testing provided valuable data on the bioactivity of the dcECM; 
however, these conditions fail to mimic the more dynamic and multicellular in 
vivo environment. Successful translation of a tissue engineered constructs is 
dependent on its ability to elicit a favourable immune response upon 
implantation, predictive of clinical response to the engineered constructs. The 
dcECM was, therefore, implanted into immunocompetent BALB/c mice for the 
assessment of biocompatibility. There was a distinct lack of granular tissue 
formation around both native costal cartilage constructs and the dcECM when 
observed macroscopically(Figure 4.20; A), It has been suggested that whole 
hyaline cartilage may have some degree of immune privilege due to its dense 
avascular structure484. Upon microscopic examination (Figure 4.20; B), 
however, more distinct differences were observed. The dcECM demonstrated 
a predominantly M2 macrophage response at 2 and 8 weeks, which was 
indicative of favourable long-term outcomes and tissue-specific remodelling 
485. This was in contrast with the native costal cartilage comparator that 
demonstrated a predominantly M1 macrophage response, linked to the 
initiation of inflammation425, further supporting the in vitro analysis in chapter 3 
that demonstrated the effective removal of immunogenic factors. Due to the 
dense nature of hyaline costal cartilage, cellular infiltration into the cartilage is 
limited, which could be a limiting factor in eliciting a more aggressive cellular 
response. Almeida and colleagues also observed that Macrophages with 
higher metabolic activity were pro-inflammatory486. Future work could take 
advantage of live cell metabolism imaging techniques such as FLIM487 for the 
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assessment of the immune cell metabolic profile. Moreover, there are a 
plethora of other markers associated with cell populations that are involved in 
foreign body mediated immune response; These include CD44 (helper T-
Lymphocytes) and CD8 (Cytotoxic T-Lymphocytes)488. The biocompatibility 
study was carried out in non-primate species and, therefore, cannot be used 
as a model to confirm the presence of Alpha-Gal a key limitation of this study. 
Non-primate species lack circulating Anti alpha-gal antibodies and are, 
therefore, non-reactive to the alpha-gal epitope, otherwise highly immunogenic 
in humans222. 
In conclusion, the dcECM demonstrated an inherent capacity to enhance 
chondrogenesis and chondrocyte hypertrophy, surpassing similar published 
studies employing decellularised cartilage derived scaffolds such as those 
employed by Gawlitta et al150 and Cunniffe and et al. 431. Moreover, the use of 
a bioactive scaffolding material can overcome the limited tissue volume 
available from the cell only approaches such as those applied by Cunniffe et 
als431. Additionally, the predominantly regenerative response elicited by the 
dcECM makes it an ideal candidate for clinical application. It has to be noted, 
however, that the size of the dcECM used in this study would be too small to 
be implanted into critical-sized clinical non-union defects. Further work is, 
therefore, required to explore alternative and optimised methods to transform 
the dcECM into a suitable format for clinical delivery, while not compromising 
the chondroinductive properties of the dcECM. As the preliminary in vivo work 
has yielded promising results, it warrants further development of more tailored 
tools for seeding, chondrogenic priming, and investigating cellular behaviour. 
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5. Preparation of an upscaled dcECM 
scaffold for clinical application 
 
5.1. Introduction 
Bone tissue engineering has yielded a diverse range of implants that aim to 
address skeletal pathologies such as fractures and large bone defects, arising 
from injury and metabolic bone diseases. During the development of these 
solutions, careful consideration of the clinical scenario and current treatment 
approachs is required. Currently, depending on the severity and location of the 
fracture, effective reparative options can range from mechanical support to 
vascularised bone grafts that are capable of rapidly remodelling and 
integrating with surrounding bone tissues489,490, tissues engineered 
alternatives have to, therefore, demonstrate similar or improved efficacy to the 
current approaches.  
 
5.1.1 Clinical developments in the management of bone disease 
pathologies. 
With between 3.6 to 6 million bone fractures occurring in the united states and 
around 850,000 occurring in the UK bone is the second most transplanted 
tissue, after blood, driving research into novel approaches to address the 
demand33,491. Over a decade ago Medtronic® and Stryker® developed a 
caged putty-based BMP delivery system derived from demineralised bone. 
The osteoinductive capacity of these collagenous constructs effectively drove 
endochondral bone regeneration and was harnessed for non-union fracture 
intervention and spinal fusion492,493. They also offered a key advantage when 
used clinically due to their adaptability. Investigations into the use of BMP’s for 
bone regeneration, however, raised some speculation with regards to the 
treatment of open tibial fractures494. Moreover, there have also been reports of 
adverse side effects when using supraphysiological levels of BMP-2495, 
resulting in complications such as heterotrophic ossification or osteolysis, and 
possibly their association with promoting the pathogenesis of some cancer 
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sub-types496–498. Therefore, the use of stem cell populations with an 
osteogenic potential was as an alternative approach to fracture 
management190. In an attempt to find an alternative approach, fresh bone 
marrow aspirate was combined with ceramic bone grafts, which has shown 
efficacy for spinal fusion procedures499,500. A study by Damron and colleagues 
has, however, demonstrated that for the treatment of large bone defects, the 
addition of bone marrow aspirates provides no advantage501. There is 
however, growing evidence for the use of skeletal stem cells for the treatment 
of non-union fractures, with a consensus that highlights the advantages of 
using a scaffolding material in conjunction with the relevant stem cell 
populations, as this allows for the localisation of therapeutic stem cells and a 
better ability to treat large bone defects502,503.  
The majority of clinically available bone grafts and tissue engineering 
approaches focus on mimicking the characteristics of the clinically accepted 
gold standard; Autologous bone grafts. However, chapter 1 highlights a shift 
towards developing grafts that mimic tissue intermediates involved in the 
fracture healing process, such as the cartilaginous callus. Engineering the 
cartilage niche, however, presents a unique set of challenges, especially with 
regards to creating cell-laden constructs. 
 
5.1.2 Engineering the cartilage niche.  
Native hyaline cartilage is an avascular, dense tissue, which limits cellular 
infiltration if seeded, which restricts the use of whole cartilage ECM-derived 
constructs without further processing. Huey and colleagues have extensively 
reviewed and discussed these challenges504. Currently, the gold standard 
methodology for creating cell-laden cartilage construct relies on the 
developmental process of stem cell condensation and chondrogenesis. 
Several stem cell populations have been studied for their ability to undergo 
chondrogenesis, and are extensively reviewed in chapter 1. The general 
principle for chondrogenic differentiation involves seeding relevant cells into 
high-density cultures in conjunction with the addition of exogenous 
chondroinductive growth factors505–509. As demonstrated by Detzel and 
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colleagues this process of condensation in vitro can be further enhanced using 
centrifugal force510. Obtaining cell-derived cartilage constructs requires a large 
vast number of cells and extensive culture times, thus limiting its scalability. 
Moreover, the mechanical properties of the cell-generated cartilage ECM is 
dependent on the cell type used, with chondrocytes producing more robust 
cartilage-ECM compared to bone marrow-derived(BM) MSC’s511–513. Overall, 
these findings provide further evidence for coupling stem cell populations with 
a cartilage-mimetic construct. 
Several factors must be considered when engineering a cartilage mimetic 
construct; these include ECM biochemical composition, structure, and ability 
to achieve efficient cellular distribution when seeded. Additionally, as these 
factors are paramount for the clinical translatability, novel fabrication and 
seeding approaches have been developed. Nasiri and colleagues have 
achieved this by generating chemically cross-linked chitosan-ECM constructs, 
which allow for the control of pore size and, therefore, cellular infiltration514. 
Moreover, methodologies such as freeze-drying have been applied by 
Amadari and colleagues for the generation of highly porous cartilage mimetic 
constructs, the principle of which relies on the extraction of water from a 
hydrated gel-like construct, leaving behind a porous material515. Yang and 
colleagues have further incorporated decellularised cartilage ECM-derived 
granules into a cross-linked gel suspension that was freeze-dried to give 
porous constructs516. When implanted into nude mice in combination with bone 
BM-MSC’s, cartilage ECM deposition was observed. The poor seeding 
efficiency and homogeneity of cartilage mimetic constructs have been 
addressed in a study by Chen and colleagues buy incorporation a hydrostatic 
pressure bioreactor system to better mimic the native microenvironment 
present during cartilage development in vivo 517.  
The previous chapters highlighted the development of the dcECM; a 
chondroinductive cartilage mimetic scaffold that retains its native biochemical 
composition post-decellularisation. This chapter builds upon these previous 
findings to further investigates a proof of concept methodology for processing 
the dcECM to create scalable chondrogenic constructs with the potential for 
clinical translation.  
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5.2. Methods 
5.2.1 Preparation of compressed dcECM derived constructs.  
Sterile dcECM was placed into a T-75 tissue culture flask with a 0.2 micron 
vented cap (Corning, UK), the vented cap allowed for gas exchange while 
maintaining the sterility of the samples. Samples were frozen at -80 ºC for 8 
hours prior to initiating the freeze-drying process The T-75 flask containing the 
dcECM were freeze-dried (Christ, UK) for 24 hours at -55 ºC.  Freeze-dried 
dcECM samples were subsequently removed from the T-75 flask and placed 
into sterile cyromill tubes (Spex sample prep, UK). The freeze-dried dcECM 
was then freeze-milled in a liquid nitrogen cooled mill (Spex sample prep, UK) 
at a rate of 15 cycles per second (cps) for 10 mins. The milling process was 
repeated 3 times per sample after which the milled contents were transferred 
into a 50 mL falcon tube (Corning, UK) and stored at room temperature (18-
21°C). To maintain sterility, the transfer of the dcECM was carried out in a 
sterile environment.  
For the fabrication of the compressed dcECM constructs either 5mg, 10mg or 
15mg of the freeze-dried dcECM was added into 1 mL C-DMEM containing 
10% FBS (Invitrogen, Paisley, UK) and antibiotic-antimycotic solution (100 
units/mL penicillin, 100 μg/mL streptomycin and 0.25 μg/mL amphotericin B; 
Invitrogen, Paisley, UK). 100 µL of the mixture was added into a well of a 96-
well plate. A 96-well absorber (Lonza, UK) was used to remove the media 
resulting in the compression of the freeze-dried dcECM granules into a circular 
construct (Figure 5.1). The compression process occurred from the removal of 
the water and soluble content from the mixture. The varying weight of the 
absorber also provided the additional force required for compression, this 
however varied throughtout the compression process due to the absorbtion of 
water from the mixture. The resultant compressed dcECM derived constructs 
(C-dcECM) were subsequently seeded and assessed for cellular infiltration. 
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Figure 5.1: Schematic representation of the fabrication of compressed dcECM-derived 
constructs. (1) freeze-dried dcECM granules are mixed with C-DMEM containing 10% FBS 
and antibiotic-antimycotic solution. (2) The mixture of dcECM granules and C-DMEM is 
compressed using an absorber, removing a portion of the water content and soluble 
components. (3) The absorber is removed leaving behind a compressed dcECM derived 
construct. 
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5.2.2. Human periosteal stem cells (hPDSCs).  
hPDSCs were isolated as previously described in Chapter 4.2 (obtained from 
Prof Frank Luyten, KU Leuven, Belgium).   
 
5.2.3. hPDSC expansion and micromass culture. 
hPDSC’s were expanded and seeded into micromass cultures as described in 
Chapter 4.2 
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5.2.4 Fabrication of porous dcECM-collagen type 1 hybrid 
constructs. 
 
Figure 5.2: Schematic representation of the creation of porous dcECM derived 
constructs. (1)  A gel mix is created by adding freeze-dried dcECM to neutralised rat tail 
collagen type I. The gel mix is placed into a freeze-drier for 24 hours, removing water content 
from the mix. (3) Post freeze-drying, a porous dcECM derived construct is left behind.  
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To fabricate porous dcECM derived constructs, rat tail collagen type I (First-
link, UK) was neutralised using a neutralising agent (Lonza, UK), amount of 
neutralising agents vary depending on the amount being neutralised, this is 
provided as part of the standard protocol included in the RAFT 3D cell culture 
kit (Lonza, UK). Freeze-dried and milled dcECM was added into the gel mixture 
at a concentration of 16 mg/mL. 150 µL of the gel mixture was added into 6 
mm cloning rings or 96 well plates and incubated at 37ºC to gelate (Figure 
5.2). The 96-well plates were placed in the freeze drier while, the cloning rings 
containing the gelated mix were transferred into T75 flask before being freeze-
dried, as previously described. The process of freeze drying was used to 
remove the water content from within the gelated constructs, thus creating air 
pockets within the construct, and subsequently creating a porous dcECM-
derived construct (P-dcECM) (Figure 5.2). 
 
5.2.5 Differential scanning calorimetry (DSC) analysis of the P -
dcECM 
DSC was used to measure collagen denaturation temperatures of the P-
dcECM as an indicator of the structural integrity of the matrix as previously 
described in Chapter 3.2.  
 
5.2.6 Multiphoton Imaging of P-dcECM samples 
Second harmonic generation and fluorescence-lifetime imaging microscopy 
(FLIM) were used to measure changes in the collagen biochemical 
environment as a measure of matrix integrity. Without any prior processing 
native costal cartilage (dimension ∼5 mm height × 10 mm in diameter) and P-
dcECM (dimensions ∼9 mm height x 3 mm in diameter) were placed in PBS in 
preparation for imaging. Laser scanning microscopy with multiphoton 
excitation was carried out as described in Chapter 3.2. 
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5.2.7 Seeding P-dcECM constructs. 
Porous dcECM derived constructs formed using cloning rings (P-dcECM) were 
selected for further in vitro analysis using hPDSC’s (Figure 5.3). Sterile P-
dcECM constructs were placed into 15 mL falcon tubes (Corning, UK). 
hPDSC’s were seeded onto the surface of each of the P-dcECM constructs at 
a density of 3x105 cells in 10 µL of C-DMEM supplemented with 10% FBS, 
(Invitrogen, Paisley, UK) and antibiotic-antimycotic solution (100 units/mL 
penicillin, 100 μg/mL streptomycin and 0.25 μg/mL amphotericin B; Invitrogen, 
Paisley, UK). The constructs were left for 2 hours at 37ºC and 5% CO2. In 
parallel cells were seeded into pellet cultures of equivalent density. Briefly, 
hPDSC’s were pipetted into 15 mL falcon tubes at a density of 3x105 in 5 mL 
of C-DMEM. Subsequently, the samples were centrifuged (Fisher scientific, 
UK) at 1500 RPM for 10 minutes to form pellets, that were also incubated for 
2 hours at 37ºC and 5% CO2. After two hours the media was switched to 
control (CTRL) and chondrogenic C(+) conditions, these conditions are 
previously defined in Chapter 4.4. Cells were cultured for 7 days.  
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Figure 5.3: Schematic representation of the methodology for seeding the P-dcECM. (1) 
The P-dcECM is placed into a 15 mL falcon tube. (2) 300,000 hPDSC’s are dispensed onto 
the surface of the P-dcECM in 10 µL cell suspension. (3) Seeded P-dcECM constructs are 
incubated for 30 mins to allow the cell suspension and cells to impregnate the whole construct. 
(4) culture DMEM is added into the tube containing the seeded construct. Figure generated 
using the Servier medical art database (http://www.servier.com/Powerpoint-image-bank 
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5.2.8. Total RNA extraction and quantitative reverse 
transcription–Polymerase Chain Reaction (qRT-PCR) analysis 
Gene expression analysis was used as an indicator of cellular differentiation. 
Briefly, all seeded constructs were washed with PBS, before being transferred 
into new 1.5 mL micro centrifuge tubes (Star Labs, UK), placed in 350 μL of 
Trizol (Invitrogen, Paisley, UK) and homogenised. Total RNA was isolated 
from each of the micromasses, pellets, compressed dcECM and P-dcECM 
using the Direct-zol RNA MiniPrep (Cambridge Biosciences, Cambs, UK) 
according to the manufacturers’ instructions. mRNA isolation and qRT-PCR 
was carried out as described in Chapter 4.2. Primers used in this study are 
listed in Supp Table 1. 
 
5.2.9. Statistical analysis 
Statistical analysis was carried out as described in Chapter 2.2.  All statistical 
analysis was performed using GraphPad Prism version 6.0f for windows 
(GraphPad Prism Software, La Jolla California USA, www.graphpad.com). 
 
5.3 Results 
5.3.1 Compressed dcECM derived constructs do not allow for 
cellular infiltration when seeded. 
Brightfield microscopy images of H&E stained sections reveal that constructs 
formed with a dcECM granule concentration of 15 mg/mL had sparse 
distribution of dcECM granules and were unable to form a scaffold, unlike 
constructs fabricated with 10 or 15 mg/mL of dcECM granules. (Figure 5.4; 
D&E). At all concentrations variation in dcECM granule size can be observed 
(Figure 5.4; A&B). 
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Figure 5.4: Histological examination of compressed dcECM-derived constructs (A-C) 
Representative brightfield microscopy images of compressed dcECM derived constructs 
containing 5,10 and 15 mg of freeze-dried dcECM, sections (scale bar = 50 µm). (A&B) 
Representative stereomicroscopy images of dcECM derived constructs containing 10 mg/mL 
of freeze-dried dcECM (scale bar = 3 mm). 
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Figure 5.5: Seeding schematic highlighting the seeding and media conditions used for the 
investigation of compressed dcECM derived constructs (C-dcECM) using hPDSC’s. 
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The compressed scaffold containing a dcECM granule concentration of 10 
mg/mL were seeded using hPDSC’s to assess cell attachment and infiltration 
(Figure 5.5). DAPI stained images of the scaffold surface indicates the 
presence of cells attached to the surface of the scaffold, both in CTRL and 
chondrogenic conditions (Figure 5.6; A&B). However, H&E stained cross-
sections reveal that a majority of the cellular population is localised on the 
surface of the scaffold, with little migration into the deeper regions (Figure 5.6; 
C&D). Closer examination also revealed a dense matrix that potentially limited 
cellular migration. 
 
Figure 5.6: Histological analysis of seeded compressed dcECM-derived constructs. 
(A&B) Structured illumination microscopy images of hPDSC’s seeded onto the on the surface 
of compressed dcECM derived constructs in CTRL and C (+) conditions and stained with 
DAPI. (C&D) Brightfeild images of the seeded dcECM derived constructs with hPDSC’s 
localised on the surface (black arrow) stained using H&E. (scale bar = 50µm) 
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5.3.2 The dcECM can be combined with collagen type I to give 
porous freeze-dried constructs. 
Histological examination of the compressed dcECM derived constructs 
indicated a lack of porosity, as a result, seeded hPDSC’s although attached, 
remained primarily localised on the seeding surface. Therefore, a methodology 
to obtain a more porous scaffold (P-dcECM) was developed.  
Macroscopic examination of the P-dcECM constructs revealed visiably porous 
cylindrical structure when fabricated with either cloning rings or 96-well plates 
(Figure 5.7; A-D). Upon qualitative histological inspection of the P-dcECM 
constructs using H&E stained sections, the cloning ring fabrication approach 
produced a more porous scaffold with pore size ranging from ~70-200µm. 
Additionally, both methods resulted in P-dcECM constructs with a 
homogenous distribution of the dcECM (Figure 5.7; E&F). Due to its porosity, 
the cloning ring based approach was selected for further analysis. 
One of the key findings highlighted in this thesis was the minimal damage 
inflicted to the native costal cartilage ECM post Vac-OS decellularisation, 
potentially resulting in a more chondroinductive scaffold. It was, therefore, 
crucial that the biochemical structure of the P-dcECM is assessed.  
DSC analysis of the P-dcECM revealed a significant decrease in collagen 
denaturation temperatures (p<0.01) compared to both the native costal 
cartilage samples and the dcECM (Figure 5.8; A). Similarly, there was also a 
significant difference in flourescence lifeitime images(Figure 5.8; B). Overall 
these results highlight changes in the matrix structure of the P-dcECM.  
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Figure 5.7: Histological analysis of the P-dcECM. (A-D) Stereomicroscopy images of 
porous dcECM derived scaffolds formed using 96-well plates and 6 mm cloning rings. (E&F) 
Brightfield microscopy images of dcECM derived porous scaffold sections stained using H&E. 
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Figure 5.8: Quantitative FLIM analysis of the P-dcECM. (A-C) False colour images of FLIM 
readouts of Control, dcECM and P-dcECM. Quantification of average denaturation 
temperatures comparing control cartilage vs dcECM vs P-dcECM samples. (D-E) ImageJ 
quantification of the ROI’s, measuring the average fluorescence lifetimes (n=4 *p<0.05, 
**p<0.01, ***p<0.001).  Representative quantification data is represented as mean ± SD.  
Statistical analysis performed using an unpaired t-test with Welch's post-hoc correction. 
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5.3.3 The P-dcECM supports cellular infiltration and 
chondrogenic differentiation. 
One of the key requirements for developing the P-dcECM was its potential to 
allow for cellular migration into scaffold, unlike the dcECM or the compressed 
dcECM derived scaffolds previously investigated. Moreover, it was essential 
the P-dcECM maintain the chondroinductive properties observed with the 
dcECM.  hPDSC’s were, therefore, seeded onto the P-dcECM and cultured for 
7 days before being assessed (Figure 5.9).  
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Figure 5.9: Schematic representation highlighting the seeding and media conditions used for 
the investigation of porous dcECM derived constructs (P-dcECM) using hPDSC’s 
 
Histological examination of H&E stained cross-sections of the seeded P-
dcECM reveals the migration of seeded hPDSC’s into the centre of the 
scaffold. This occurred in both control and chondrogenic conditions (Figure 
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5.10; A&B). Closer examination of the sections reveals that hPDSC’s have 
primarily localised around the centre of the P-dcECM and potentially attached 
to dcECM fragments present. Overall, the cells are non-uniformly distributed. 
 
 
Figure 5.10: Histological analysis of P-dcECM. (A-D) Representative H&E stained 
histological sections of the P-dcECM seeded with hPDSC and cultured for 7 days. (Cells are 
indicated by black arrows) Scale bar = 400 µm (A&B) and 100 µm (C&D) respectively. 
 
When examined for gene expression on day 7, it was evident that hPDSC’s 
seeded into the P-dcECM in chondrogenic conditions demonstrated a 
significant 20-, -9, 10-, 45 and 5- fold increase in the chondrogenic markers 
SOX9, SOX5, SOX6, ACAN and COL2A1, respectively when compared to 
control chondrogenic pellet conditions (Figure 5.11&5.12). Moreover, there is 
also a significant 5-fold upregulation in the hypertrophic marker COL10A1. 
148 
 
S O X 9
F
o
ld
 c
h
a
n
g
e
P
e
ll
e
t
P
-d
c
E
C
M
P
e
ll
e
t
P
-d
c
E
C
M
0
1 0
2 0
3 0
4 0
* * *
* * *
C +C T R L
S O X 5
F
o
ld
 c
h
a
n
g
e
P
e
ll
e
t
P
-d
c
E
C
M
P
e
ll
e
t
P
-d
c
E
C
M
0
1 0
2 0
3 0
* * *
* * *
C +C T R L
S O X 6
F
o
ld
 c
h
a
n
g
e
P
e
ll
e
t
P
-d
c
E
C
M
P
e
ll
e
t
P
-d
c
E
C
M
0
1 0
2 0
3 0
4 0
5 0
* * *
* * *
C +C T R L
A C A N
F
o
ld
 c
h
a
n
g
e
P
e
ll
e
t
P
-d
c
E
C
M
P
e
ll
e
t
P
-d
c
E
C
M
0
5
1 0
1 5
2 0
2 5 * *
* *
C +C T R L
 
Figure 5.11: Chondrogenic and chondrocyte hypertrophy gene expression (SOX9, SOX5, 
SOX6 & ACAN) of hPDSCs seeded in MM and dcECM under control conditions (CTRL) and 
chondrogenic conditions (C+). (n=3 *p<0.05, **p<0.01, ***p<0.001). (Fold changes normalised 
to pellet cultures in CTRL conditions). The culture period was 7 days. Statistical analysis was 
performed using one-way ANOVA corrected for multiple comparisons using Bonferroni’s 
posthoc analysis. 
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Figure 5.12: Chondrogenic and chondrocyte hypertrophy gene expression (COL2A1, 
COL10A1 & RUNX2) of hPDSCs seeded in MM and dcECM under control conditions (CTRL) 
and chondrogenic conditions (C+). The culture period was 7 days (n=3 *p<0.05, **p<0.01, 
***p<0.001). (Fold changes normalised to pellet cultures in CTRL conditions). Statistical 
analysis was performed using one-way ANOVA corrected for multiple comparisons using 
Bonferroni’s posthoc analysis. 
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5.4 Discussion 
One of the key aims of the thesis was the development of a chondrogenic 
construct capable of mimicking the cartilage callus phase of fracture repair. 
The previous chapters and published findings have demonstrated that the Vac-
OS decellularisation methodology was capable of producing a non-
immunogenic, potently chondroinductive construct281. However, the dcECM in 
its native form was not of sufficient size for clinical application. Moreover, due 
to the dense avascular nature of the native source costal cartilage tissue, the 
dcECM did not allow for homogenous seeding throughout the entire scaffold. 
Therefore, this chapter focused on developing a proof of concept methodology 
for the development of a an upscalable and cell-permeable construct. 
There have been several studies utilising cartilage ECM derived granules for 
the fabrication of constructs that aimed to mimic the cartilage niche514,518,519.  
Intial attempts highlighted in this chapter were, therefore, focused on 
compressing freeze-milled dcECM into a mouldable construct. Qualitative 
histological examination of the resultant constructs revealed a pore size 
between 30-70 µm  (Figure 5.4). It was evident that the C-dcECM was too 
dense for cellular infiltration limiting cellular localisation at the seeding surface 
(Figure 5.6). Work by Griffon and colleagues suggested that a pore size 
between 70-120µm is required for cell infiltration and cartilage matrix 
deposition when creating chitosan-based cartilage constructs 520. Nasiri and 
colleagues have further expanded on this approach by combining 
decellularised cartilage granules with chitosan to fabricate constructs that had 
sufficient porosity, allowing for the homogenous distribution of the 
decellularised cartilage derived granules514. Collectively, both these studies 
highlight the need for a supporting structure within which cartilage granules 
can be homogenously distributed, providing a porous scaffold that supports 
cellular infiltration. 
Based on this principle, the fabrication methodology was further modified by 
adding freeze-dried dcECM granules into a collagen type I gel. Collagen type 
I was chosen due to its excellent gelation properties and its ability to bind to 
collagen type 2, a major component of the dcECM521. Once fabricated the 
constructs were freeze-dried to remove water content from the construct 
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resulting in the P-dcECM a pore size of approximately 70-200µm (Figure 5.7). 
This pore size was ladger than most skeletal cell populations, allowing for 
infiltration. In addition to producing porous constructs, the freeze-drying 
process was also a useful approach for creating a scaffold permissive for long-
term storage and transport; key factors when creating an off the shelf solution. 
The effecacy of using freeze dried, ECM-derived grafts has been 
demonstrated by their widespread clinical use 522,523. The process of freeze-
drying isnt, however, without its limitations. A report by  Draenert and colleague 
suggested  that the process of freeze-drying form ice crystals thus damaging 
cartilage-derived tissues524. DSC and FLIM were previously used to 
investigate the ECM structural integrity of the dcECM281 and were, therefore, 
applied to study the degree of biochemical changes in the P-dcECM. Both the 
DSC and FLIM investigations reveal a significant shift in denaturation 
temperatures and lifetimes (Figure 5.8), suggesting there were substantial 
differences in collagen crosslinking and biochemical composition. These 
changes could have resulted from the removal of one of the most abundant 
components of native cartilage ECM; water, or through the addition of collagen 
type I. It was, therefore, essential to assess if these changes had an impact 
the capacity of the P-dcECM to enhance chondrogenesis as effectively as the 
dcECM alone. Therefore, the P-dcECM was seeded with hPSC’s. Qualitative 
histological examination of the seeded P-dcECM revealed efficient cellular 
infiltration, aided by the larger pore size compared to the C-dcECM. However, 
the cellular distribution appreared to be primarily at the center of the P-dcECM, 
this may be indicative of the overall structural heterogeneity of the scaffold, 
that may vary between the periphery and center of the scaffold. The 
histological method used to determine pore size does not give the 3D porosity 
across the scaffold, a technique such as µCT may provide a more 
comprehensive view of the scaffold allowing for determination of pore size and 
distribution, as utilised by previous studies525–527.  
Gene expression analysis (Figure 5.11 & 5.12) revealed that in standard 
chondrogenic conditions the P-dcECM potently upregulated the SOX-trimer 
(SOX9, SOX5 and SOX6) as well as cartilage matrix-specific markers COL2A1 
and ACAN. Additionally, there was also an upregulation in the hypertrophic 
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marker COL10A1. These findings suggest that the P-dcECM retained its 
chondorinductive properties despite significant changes to its biochemical 
structure that resulted from the fabrication methodology.  
The methodology for seeding the P-dcECM could be further improved to 
provide a better approach for priming. Work by Leijten and colleagues 
suggests harnessing a crucial process in cartilage development; cell 
agregation528. A patterned silicon wafer was used to produce hPDSC derived 
micro-aggregates of homogenous density. This approach could potentially be 
applied to seeding the P-dcECM, thus further enhancing chondrogenesis and 
cartilage matrix deposition via both cell-matrix and cell-cell interactions. 
Furthermore, this could be combined with a bioreactor system that aims to 
mimic native cartilage developmental environment while incorporating novel 
external chondroinductive stimuli such as ultrasound529 or mechanical 
stimulation530 or electrical stimulation531. Moreover, the concentration of 
dcECM granules within the P-dcECM could also be investigated as work by 
Rowland and colleagues suggest that the overall concentration of the 
decellullarised cartilage-ECM within a porous construct impacts 
chondrogenesis and cartilage matrix deposition518, as previously hilighted the 
approach by Nasiri and colleagues514 of using chitosan as a supporting gel for 
dcECM granules may alternatively be combined with the dcECM. Several 
studies have hilighted the potential of chitosan to support the chondrogenesis 
of mesenchymal stem cells532–534, making it a more effective choice than 
collagen type I. Moreover, future studies should include control conditions that 
contain only the supporting scaffold such as collagen type I, without the 
presence of the dcECM to determine the degree of impact the dcECM actually 
has on the chondrogenesis of skeletal cell populations.  
The work in this chapter has provided preliminary data that suggests a 
promising approach for the fabrication of porous chondroinductive scaffolds for 
clinical traslation towards fracture repair. However, further developments in 
seeding and chondrogenic priming are needed to improve the applicability of 
the P-dcECM in clinical scenarios.  
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6. Development of a chondrogenic cell 
culture coating for stem cell priming 
 
6.1. Introduction 
Standard methodologies for the expansion of adult cell population that involve 
the use of tissue culture plastic are an extremely different from the native in 
vivo cell microenvironment as they lack a majority of structural and functional 
moieties present in ECM89, these include cartilage specific factors such as 
aggrecan, collagen type 2 and Glycosaminoglycans313,535. Often, this disparity 
between physiological and in vitro conditions cause  phenotypic changes that 
can result in loss of native function536, altering cellular response to 
exogenously added growth factors or drugs537,538 and affecting their capacity 
for differentiation539,540. An example of this occurs when chondrocytes cultured 
on tissue culture plastic. Over as little as two passages they rapidly lose their 
phenotype, a process that is known as dedifferentiation446. This limited 
capacity for in vitro expansion restricts their usage to procedures dealing with 
small cartilage defects, applied in approaches such as autologous chondrocyte 
implantation (ACI)541–543. Several studies have, therefore, suggested the use 
of chondroprogenitors as an alternative for cartilage tissue engineering544–546. 
This approach, however, requires consideration of optimal conditions for their 
chondrogenic differentiation. 
 
6.1.1. ECM-derived cell culture coating. 
The ECM’s role in regulating cell survival, attachment, proliferation and 
differentiation are well established547–550. However, a majority of studies 
generally investigate coating single ECM associated proteins and defining their 
influence on cell behaviour551,552. Some strategies attempt to mimic the more 
complex native microenvironment using a combination of ECM-derived 
components such as fibronectin, collagen and laminin553,554 It has long been 
known that the adsorbtion of components such as fibronectin to the cell culcute 
surface facilitates cell attachment and survival, in most standard cell culture 
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mediums, FBS is used to derive a number of proteins that adsorb to the culture 
plastic surface555, these tissue culture treated surfaces when combined with 
FBS drastically improve cell survivibility compared to non-treated culture 
surfaces556. The use of cartilage-ECM derived components to induce 
chondrogenesis in vitro has been studied, which highlighted their advantages 
over synthetic biomaterials281,557,558. Recent work by Cheng and colleagues 
suggest that Recombinant human fibrillin-1 and fibronectin fragments we 
capable of driving chondrogenesis of human embryonic stem cells (hESCs)559. 
There is also further evidence to suggest enhanced chondrogenesis in cultures 
that employ collagen type 2560,561 and GAG’s507, both key component of hyaline 
cartilage ECM. Lei and colleagues further validate this finding by  
demonstrating enhanced chondrogenesis in cultures that include heparin 
sulfate562. The addition of individual ECM-associated components, however, 
does not mimic the complex tissue-specific combinations, or ratios present in 
the ECM. In response, studies have explored the use of cell-derived ECM 
coatings; these include fibroblast treated plates563–565. This approach has also 
been harnessed to produce commercially available gel coatings such as 
Matrigel566. The inclusion of these cell-derived cell culture coatings has been 
shown to enhance cell attachment, and survivability567, they do not, however, 
mimic tissue-specific ECM such as hyaline cartilage568–570. Moreover, 
extended culture periods are required for the generation of these coatings571, 
followed by the removal of the cellular component using trypsin before they are 
used as a substrate for seeding, making the process inefficient. Therefore, it 
could be advantageous to develop a gel coating that is tissue ECM derived, 
an approach that was employed by by DeQuach and colleagues572. 
Furthermore, Shawn and colleagues demonstrated the efficacy of enhancing 
chondrogenesis using zonal cartilage derived ECM gels that contained key 
components such as collagen type II and hyaluronan573. Despite this 
overwhelming evidence there are no known studies that are aimed at 
developing a chondroinductive cartilage ECM derived tissue culture coating. 
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6.1.2. Nano-topography and control of cellular differentiation. 
A study by Wu and colleagues investigated the modulation of nano-
topographical design using thermal nano-imprinting on polycaprolactone 
surface to generate various nano-patterns. These were assessed for their 
effect on cell phenotype and differentiation574. The investigation revealed that 
changes in the surface nanotopography directly affected cellular cytoskeleton 
arrangement, resulting in morphological changes. Moreover, they also found 
that specific patterns resulted in enhanced chondrogenesis and cartilage-
specific ECM deposition when compared to a non-patterned surface. This is 
supported by previous studies that establish the link between a more rounded 
spherical shape and chondrocytic phenotype.461,575,576.  
The previous chapters have investigated the efficacy of using the dcECM to 
enhance chondrogenesis in hPDSC’s and created porous scaffolds that could 
be upscaled for clinical use. There is, however, much room for optimising 
culture conditions to support the chondrogenic priming of hPDSC’s and 
expansion of chondrocytes. The chondroinductive potency of the dcECM was, 
therefore, harnessed to create ECM-derived coatings with the potential of 
enhancing chondrogenesis or maintain a chondrocytic phenotype. 
 
6.2. Methods 
6.2.1 Creation of dcECM derived digests.  
Sterile dcECM was digested for the creation of coatings (Figure 6.1). The 
methodology was adapted from Sawkins and colleagues577. Briefly, the 
digestion solution was prepared by first adding 50 µL of a 10M HCL solution 
to deionised water and mixed gently. 50mg of Pepsin (Singma-Aldrich, UK) 
was then added to the solution giving a final pepsin concentration of 1 mg/mL 
in 0.01M HCL. Sterile freeze-milled dcECM granules were added into the 
digestion solution at a concentration of 10 mg/mL and mixed thoroughly to 
ensure no clumps were present. The digestion mix was left to digest for 96 
hours at 21 ºC. Digests were stored at 4ºC and subsequently  sterilised prior 
to being used to  coat tissue culture plastic. 
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Figure 6.1: The creation of dcECM derived digests. (1) The digestion solution was created 
by mixing HCL and pepsin into deionised water giving a final pepsin concentration of 1 mg/mL 
in 0.01M HCL. (2) sterile freeze-dried dcECM granules are added into the digestion solution 
at a concentration of 10 mg/mL. (3) Solution is left to digest at 21ºC for 96 hours. Figure 
generated using the Servier medical art database (http://www.servier.com/Powerpoint-image-
bank 
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6.2.2 Sterilisation and coating of dcECM derived digests.  
 The dcECM derived digest was sterilised using either UV light or heat-
mediated autoclave sterilisation (Figure 6.2). 
 
Figure 6.2: Sterilisation and coating of dcECM derived digests. (1) The dcECM digest was 
sterilised using one of the two methods, UV sterilisation and autoclaving. For autoclave 
sterilisation dcECM digest was transferred into autoclave before running it on a standard 
autoclave cycle, Alternatively, the sample was placed into a 96-well plate and left under UV 
light for 12 hours. (2) Autoclaved digest was pipetted into a 96-well plate and left to dry for 72 
hours. (3) UV sterilised digests were left to dry for a further 60 hours. Figure generated using 
the Servier medical art database (http://www.servier.com/Powerpoint-image-bank 
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For UV sterilisation, 30 µL of the dcECM digest was pipetted onto each well of 
a 96-well plate. Samples were left under UV light in a tissue culture flow hood 
(Thermofisher, UK) for 12 hours at room temperature(18-21°C); the digest 
coating was further dried without UV exposure for 60 hours. Autoclave 
sterilisation was carried out by pipetting 4 mL of the dcECM digest into glass 
autoclave tubes (Corning, UK). Samples were, subsequently, autoclaved 
(Invitrogen, UK) using the standard media sterilisation cycle. 30 µL of the 
solution was pipetted onto 96-well plates and left to dry in a sterile dry incubator 
(Thermofisher, UK) for 72 hours after which cells were seeded onto the 
surface. As a control, dcECM-derived digest was coated as previously 
described, without any sterilisation steps, referred to as non-sterile (NS) 
coatings. 
 
6.2.3. Human periosteal stem cells (hPDSCs).  
hPDSCs were isolated as previously described in Chapter 4.2 (obtained from 
Prof Frank Luyten, KU Leuven, Belgium).   
 
6.2.4. hPDSC seeding and micromass culture. 
hPDSC’s were seeded onto the surface of the dcECM derived digest coated 
wells to assess cell attachment and differentiation. All wells were seeded with 
hPDSCs (passage 6) at a cell density of 1x106 per cm2 in 100 µL of growth 
media (10%FBS) into 96-well plates. Control micromasses of the same density 
(n=3) were seeded onto the surface of the 96 well plate as a control. Cells were 
left to attach for 3 hours before the media was changed to CTRL and C(+) 
conditions as previously described in Chapter 4.2. 
 
6.2.5. Total RNA extraction and quantitative reverse 
transcription–Polymerase Chain Reaction (qRT-PCR) analysis of 
dc-ECM digest coated samples. 
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Gene expression analysis was used as an indicator of cellular differentiation. 
Briefly, both Coated and non-coated wells were washed with 300 µL of PBS. 
Samples were lysed and processed for qRT-PCR using the method described 
in Chapter 4.2. 
 
6.2.6. Statistical analysis 
Statistical analysis was carried out as described in Chapter 2.2.  All statistical 
analysis was performed using GraphPad Prism version 6.0f for windows 
(GraphPad Prism Software, La Jolla California USA, www.graphpad.com). 
 
6.3 Results 
 
6.3.1 dcECM can be used to form a sterile chondroinductive 
coating for tissue culture plastic.  
dcECM derived coatings were created, sterilised and tested for their ability to 
enhance chondrogenesis. Brightfield images taken at Day 7 highlighted 
distinct morphological changes in hPDSC’s that were seeded onto the 
autoclaved dcECM derived (Auto) coating, reminiscent of a cobblestone 
pattern. Moreover, the differences observed in the Auto coated well were 
limited to chondrogenic conditions; no other seeded group demonstrated any 
distinct morphological changes (Figure 6.3). Qualitative analysis of the live-
dead staining (Figure 6.4) revealed a visibly higher number of dead cells in the 
chondrogenic condition containing the auto dcECM-derived coating, not 
observed in any other condition. 
The gene expression at day 7 highlighted that only the Auto coating resulted 
in a significant 2- and 1.7 fold upregulation in SOX9 and ACAN respectively, 
when compared to non-coated micromasses in chondrogenic conditions 
(Figure 6.5& 6.6). Interestingly, the non-sterile coating did not upregulate any 
chondrogenic genes. Moreover, to determine if the coatings were driving cells 
down an osteogenic lineage, ALP expression was quantified as it has been 
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identified as an early marker of osteogenesis578. However, there was no 
significant upregulation in ALP with any of the coated or non-coated 
chondrogenic conditions. The Auto coating was chosen as the optimal coating 
methods, due to its ability to potently enhance chondrogenesis and was 
subject to further optimisation and analysis. 
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Figure 6.3: Brightfield microscopy images of hPDSC’s seeded on dcECM- derived 
coatings. The coating was either non-sterile (B), UV sterilised (C) or Autoclaved (D). hPDSC’s 
were also seeded in micromass on non-coated tissue culture plastic (A). All samples were 
seeded in either CTRL (1) or C+(2) conditions. There was a distinct cobblestone pattern 
observed in hPDSC’s seeded onto the autoclaved dcECM coating (D2). (Scale bar = 50µm) 
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Figure 6.4: Fluorescence images of cells stained using calcein AM (Live) and ethidium 
homodimer (Dead). hPDSC’s were seeded on dcECM- derived coatings that was non-sterile 
(B), UV sterilised (C) and Autoclaved (D). hPDSC’s were also seeded in micromass on non-
coated tissue culture plastic (A). All samples were seeded in either CTRL (1) or C+(2) 
conditions. Cells seeded in Autoclave conditions (D2) demonstrated visibly higher staining for 
dead cells as compared to the other conditions. (Scale bar = 100µm) 
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Figure 6.5: Gene expression analysis of hPDSC seeded P-dcECM. Chondrogenic gene 
expression (SOX9, SOX5, SOX6 & ACAN) of hPDSCs seeded in MM and dcECM under 
control conditions (CTRL) and chondrogenic conditions (C+). Micromasses were also seeded 
on the non-coated surface (NC), Non-sterile coating (NS), Ultraviolet sterilised coating (UV) 
and Autoclaved coating (Auto). (n=3 *p<0.05, **p<0.01, ***p<0.001). (Fold changes 
normalised to micromasses in CTRL conditions). Statistical analysis was performed using one-
way ANOVA corrected for multiple comparisons using Bonferroni’s posthoc analysis. 
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Figure 6.6: Gene expression analysis of hPDSC seeded P-dcECM. Chondrogenic and 
chondrocyte hypertrophy gene expression (COL2A1, COL10A1, PRG4 & ALP) of hPDSCs 
seeded in MM and dcECM under control conditions (CTRL) and chondrogenic conditions (C+). 
Micromasses were also seeded on the non-coated surface (NC), Non-sterile  coating (NS), 
Ultraviolet sterilised coating (UV) and Autoclaved coating (Auto). (n=3 *p<0.05, **p<0.01, 
***p<0.001). (Fold changes normalised to micromasses in CTRL conditions). Statistical 
analysis was performed using one-way ANOVA corrected for multiple comparisons using 
Bonferroni’s posthoc analysis. 
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6.3.2. Autoclaved dcECM-derived coating requires thorough 
drying to maintain chondrogenic potential.  
The Auto coating was optimised through analysis of insufficient drying and of 
various seeding densities, defined by its effect on cell morphology and 
chondrogenic gene expression. Therefore, the Auto coating was dried for 
either 48 or 72 hours at 37ºC  in a dry incubator and seeded with a cellular 
density of either 1.6x106, 7x105 or 5x105 cells per cm2 or 100, 70 or 50 
thousand cells per 96-werespectively.  
Brightfield microscopy images highlighted that after 48 hours of drying there 
was no significant changes in morphology when comparing hPDSC’s in Auto 
C(+) conditions to its non-coated comparator in C(+) conditions. Moreover at 
48 hours, variation in seeding densities also did not have an impact on cellular 
morphology. However, hPDSC’s combined with CTRL conditions 
demonstrated a distinct rounded morphology, only when seeded at a density 
of 100,000 cells per 96-well (Figure 6.7). A similar observation was made when 
the Auto coating was dried for 72 hours, with hPDSC’s demonstrating a distinct 
rounded morphology in CTRL conditions, when at a seeded at a density of 
100000 cells. Moreover, drying the Auto coating for 72 hours also resulted in 
the distinct cobblestone pattern when combined with C(+) conditions. Both 
seeding densities of 100 and 70 thousand demonstrated the distinct 
cobblestone pattern, which was not present in the 50 thousand seeding density 
(Figure 6.8).  
Gene expression analysis revealed a higher COL2A1 expression in samples 
dried over 72 hours when cultured in C(+) conditions, with a 4000-fold 
(p>0.001) increase when compared to samples dried for just 48 hours. 
Moreover, samples from the 48-hour group demonstrated a trend towards 
having lower SOX9 expression levels. However, this was not observed in the 
72-hour group (Figure 42). Interestingly, the 48-hour group in C(+) conditions 
did not demonstrate a trend towards higher COL10A1 levels. There were also 
no significant differences in RUNX2 or FABP4 expression. This intimates that 
a 72 hour drying period is more effective in promoting a chondrogenic 
phenotype, especially at a cell density of 100 thousand (Figure 6.9, 6.10 & 
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6.11). These conditions were, therefore, selected for further in vitro testing of 
the ato coating.  
 
Figure 6.7: Seeding density and digest coating optimisation brightfield images. 
hPDSC’s seeded on the autoclaved dcECM-derived coating and compared to non-coated 
tissue culture plastic. The dcECM-digest coating was air dried at 37 ºC for 48 hours (h) before 
seeding. Images were obtained 7 days post-culture. All samples were seeded in either control 
(CTRL) (A1-B3) or Chondrogenic C(+) conditions (C1-D3). hPDSC’s were seeded at a density 
of 1.6x106(100) 7x105(70) or 5x105(50) cells per cm2 respectively, into a 96-well plate. Scale 
bar = 50µm. 
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Figure 6.8: Seeding density and digest coating optimisation brightfield images. 
hPDSC’s seeded on autoclaved dcECM-derived coating and compared to non-coated tissue 
culture plastic. The dcECM-digest coating was air dried at 37 ºC for 72 hours (h) before 
seeding. Images were obtained 7 days post-culture. All samples were seeded in either control 
(CTRL) (A1-B3) or Chondrogenic C(+) conditions (C1-D3). hPDSC’s were seeded at a density 
of 1.6x106(100) 7x105(70) or 5x105(50) cells per cm2, into a 96-well plate. Scale bar = 50µm. 
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Figure 6.9: Seeding density and digest coating optimisation gene expression analysis. 
Chondrogenic gene expression (COL2A1 & ACAN) of hPDSCs seeded as micromasses on 
autoclaved dcECM-derived (Auto) coating and compared to non-coated tissue culture plastic 
(NC). The coating was air dried at 37 ºC for either 48 or 72 hours [h] before seeding. All 
samples were seeded in either control (CTRL) or Chondrogenic C(+) conditions. hPDSC’s 
were seeded at a density of 1.6x106(100) 7x105(70) or 5x105(50) cells per cm2, into a 96-well 
plate. Gene expression was obtained 7 days post-culture (n=3 *p<0.05, **p<0.01, ***p<0.001). 
(Fold changes normalised to micromasses in CTRL conditions). Statistical analysis was 
performed using one-way ANOVA corrected for multiple comparisons using Bonferroni’s 
posthoc analysis. 
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Figure 6.10: Seeding density and digest coating optimisation gene expression analysis. 
Chondrogenic gene expression (COL10A1 & SOX9) of hPDSCs seeded as micromasses on 
autoclaved dcECM-derived (Auto) coating and compared to non-coated tissue culture plastic 
(NC). The dcECM-digest coating was air dried at 37 ºC for either 48 or 72 hours [h] before 
seeding. All samples were seeded in either control (CTRL) or Chondrogenic C(+) conditions. 
hPDSC’s were seeded at a density of 1.6x106(100) and 7x105(70) cells per cm2 respectively, 
into a 96-well plate. Gene expression was obtained 7 days post-culture (n=3 *p<0.05, 
**p<0.01, ***p<0.001). (Fold changes normalised to micromasses in CTRL conditions). 
Statistical analysis was performed using one-way ANOVA corrected for multiple comparisons 
using Bonferroni’s posthoc analysis. 
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Figure 6.11: Seeding density and digest coating optimisation gene expression analysis. 
Chondrogenic gene expression (RUNX2 & FABP4) of hPDSCs seeded as micromasses on 
autoclaved dcECM-derived (Auto) coating and compared to non-coated tissue culture plastic 
(NC). The dcECM-digest coating was air dried at 37 ºC for either 48 or 72 hours [Hrs] before 
seeding. All samples were seeded in either control (CTRL) or Chondrogenic C(+) conditions. 
hPDSC’s were seeded at a density of 1.6x106(100) 7x105(70) or 5x105(50) cells per cm2 
respectively, into a 96-well plate. Gene expression was obtained 7 days post-culture (n=3 
*p<0.05, **p<0.01, ***p<0.001). (Fold changes normalised to micromasses in CTRL 
conditions). Statistical analysis was performed using one-way ANOVA corrected for multiple 
comparisons using Bonferroni’s posthoc analysis. 
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To establish a detailed picture of the early changes in gene expression that 
underlie the enhanced chondrogenesis demonstrated by the Auto coated 
tissue culture plastic, hPDSC’s were seeded onto Auto coated and non-
coated plates in either CTRL or C(+) conditions. Samples were monitored for 
changes in morphology and gene expression over a period of 1,3,5,7 and 21 
days.  
Brightfield microscopy imaging at day 7, revealed the establishment of a 
distinct cobblestone phenotype with hPDSC’s seeded onto Auto coated 
samples in C(+) (Figure 6.12), this was accompanied by a significant 2-fold 
upregulation of the early chondrogenic marker SOX9 when compared to non-
coated conditions. At day 3 (Figure 6.14), the cobblestone morphology was 
maintained and accompanied by a significant 2.6-fold (p<0.05) & 3.3-fold 
(p<0.05) upregulation in SOX9 and ACAN expression, while demonstrating a 
trend towards an increase in SOX9 expression. At day 5 brightfield images 
revealed that the cobblestone pattern observed with the auto conditions was  
not as distinct as Day 1 & 3. However, there was a significant 75-fold 
increase (p<0.01) in COL2A1 when compared to the Auto coated conditions 
at Day 3 and a 100-fold (p<0.01) upregulation compared to the non-coated 
condition at Day 5. There was also a significant 5-fold increase in PRG4 from 
day 3 and an overall 2.7 fold (p<0.05) upregulation when compared to the 
non-coated controls at day 5. In contrast, however, there was an overall 2.3-
fold (p<0.05) decrease in SOX9 compared to the previous Day 3 timepoint, 
although this was accompanied  with a trend towards SOX9 expression being 
maintained at a higher level than with the non-coated condition. By day 7 
brightfield images revealed a loss of the cobblestone pattern with gaps 
forming in the micromass culture (Figure 6.12). Moreover, At day 7, both the 
Auto coated and non-coated conditions revealed a trend towards the 
increased expression of the hypertrophic marker COL10A1. Enhanced 
chondrogenesis in the Auto coated groups was further highlighted by the 
increased Alcian blue staining at day 7, indicative of increased sGAG 
deposition (Figure 6.13). Furthermore, quantification of Alcian blue did indeed 
reveal a significant upregulation in sGAG deposition in C(+), Auto coated 
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samples compared to all other conditions. Moreover, in the Auto coated 
CTRL condition there is a trend towards higher Alcian blue deposition. By 
day 21 gaps in the monolayer were filled. However, there was no restoration 
in the cobblestone pattern previously observed with the Auto coated 
samples. 
 
Figure 6.12: Brightfield microscopy images of the Auto coating time course analysis.  
Brightfield microscopy images of hPDSC’s seeded on autoclaved dcECM-derived coating and 
compared to non-coated tissue culture plastic. Images were obtained at Day 1, 3, 5, 7 and 21. 
Cells were cultured in both CTRL (A&C) and Chondrogenic C(+) conditions (B&D). Scale bar 
= 50 µm. 
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Figure 6.13: Alcian blue analysis of seeded Auto coated surfaces. Brightfield microscopy 
images of Alcian blue stained samples containing hPDSC’s seeded as micromasses onto 
either tissue culture plastic (NC) or autoclaved dcECM (Auto). Samples were cultured for a 
period of 7 days in either control (CTRL) (A&B) or Chondrogenic C(+) conditions (C&D). (E) 
Alcian blue quantification data 7 days post culture. (n=3 *p<0.05, **p<0.01, ***p<0.001) 
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Figure 6.14: Gene expression time course analysis of seeded Auto coated surfaces. 
Chondrogenic gene expression of hPDSCs seeded as micromasses on autoclaved dcECM-
derived (Auto) coating and compared to non-coated tissue culture plastic (NC). Samples were 
cultured for a period of 1,3,5,7 and 21 days in Chondrogenic C(+) conditions (C&D). (n=3 
*p<0.05, **p<0.01, ***p<0.001). (Fold changes normalised to micromasses in CTRL 
conditions). Statistical analysis was performed using one-way ANOVA corrected for multiple 
comparisons using Bonferroni’s posthoc analysis. 
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6.4 Discussion 
With an ever-increasing demand for more robust stem cell therapies, the ECM 
and its components have been exploited to generate novel methodologies to 
enhance cell isolation, survival, proliferation and differentiation579,580. This 
chapter highlights the development of a method for creating dcECM-derived 
coatings that are capable of enhancing chondrogenesis. 
dcECM-derived digests were generated by pepsin digestion of freeze-dried 
dcECM. The method was adapted from similar approaches to generate ECM-
derived hydrogels577,581,582. Moreover, these studies suggest that the resultant 
ECM digest is still capable of inducing chondrogenesis. However,process was 
not carried out under strictly sterile conditions, thus limiting extended culture. 
Therefore, the dcECM-derived coating was subject to further sterilisation using 
either UV or heat mediated autoclave sterilisation. UV sterilisation is capable 
of inactivating vegetative bacteria and viruses, while also resulting in the 
crosslinking of collagen components583. A study by Rowland and colleagues584 
suggested that cartilage-derived scaolds that were crosslinked by UV 
exposure drive more robust chondrogenesis and sGAG deposition when 
seeded with MSC’s. However, UV is ineffective at inactivating bacterial spores, 
mycobacteria and prions and was, therefore, deemed ineffective as a 
sterilisation methodology, especially considering future clinical applications585. 
There are no known studies that investigate the use of an autoclave for heat-
mediated sterilisation of the ECM-derived products, potentially, due to the high 
temperatures that could result in heat-induced conformational changes in the 
protein components of the ECM586,587. Despite the destructive effect of heat on 
the ECM, autoclave sterilisation has a proven track record of being able to 
eliminate all micobiological contaminaton including spores588. Other 
sterilisation techniques such as gamma irridiation and ethylene oxide are also 
effective alternatives that have been previously employed and compared. 
Future work should consider these alternative approaches.  
Post-sterilisation, the dcECM digest was used to coat tissue culture plastic on 
96-well plates by drying 30 µL of the dcECM-digest in each well. Drying was 
employed instead of creating a gel layer, as the drying process would 
concentrate the ECM components onto the culture surface. A similar approach 
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is employed by DeQuach and colleagues who used pepsin digested 
decellularised cardiac tissue derived coatings and reported efficient ECM 
deposition onto tissue culture plastic when allowed to dry572. This process 
could be further improved by drying the plates at cooler temperatures under 
agitation, potentially, slowing down further degradation of the coated ECM 
components and, moreover, the agitation may generate an even layer.  The 
bioactivity of the coated surfaces was subsequently assessed using hPDSCs.  
Brightfield images of the cells seeded onto the autoclaved dcECM-digest 
coated surface remarkably revealed a cobblestone morphology, as early as 
Day 1 post culture C+ conditions (Figure 6.12). The rounded cobblestone 
morphology is a a distinct characteristic of chondrocytes seeded onto tissue 
culture plastic before dedifferentiation589. Moreover, the rounded morphology 
has also been linked with the upregulation of chondrogenic genes and, 
subsequently, cartilage-specific matrix deposition461,575,576. These findings 
were confirmed by assessing the associated gene expression data (Figure 
6.14). hPDSCs seeded onto Autoclaved samples in C(+) conditions 
demonstrated significantly higher SOX9 expression when compared to the 
non-coated control conditions. The upregulation of SOX9, could be a direct 
result of the synergistic action of ROCKi461 present in the C(+) conditions and 
the creation of a chondroinductive topography as a result of the Auto coating 
process. Previous studies have demonstrated that ROCKi can inhibit the 
flattening of cultured chondrocytes on tissue culture plastic, thus promoting 
SOX9 expression461,590.Similarly, studies have also hilighted the importance of 
nanotopography on cellular morphology and chhondrogenesis461,574–576.  
Furthermore, the significant upregulation of SOX9 in C(+) autoclave conditions 
was accompanied by a significant upregulation in ACAN, an early marker of 
chondrogenesis. In addition to enhanced chondrogenesis, there was 
observable increase in the number of dead cells present in the C(+) autoclave 
samples. It is unclear why this occurred only in the C(+) conditions and were 
not present in auto CTRL conditions or with the other non-coated 
samples(Figure 6.4). Tsang and colleagues suggest that cells undergoing 
hypertrophy may eventually result in cell death591, potentially explaining the 
observed cell death. Moreover, there is an upregulation in COL10A1 compared 
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to control micromass conditions also suggesting chondrocyte 
hypertrophy(Figure 6.5). Further investigation is required for the assessment 
of deposited collagen X, as gene expression onlt provides a snapshot and may 
not be a direct indicator of cumulative protein expression.   
Cell-cell interactions mediate chondrogenesis592. Therefore,  cellular density 
has a significant impact on chondrogenic differentiation, especially, with 
regards to mesenchymal stem cell populations593. Moreover, the effect of 
improper drying of coated plastic before seeding remained untested. 
Therefore, the impact of seeding density and incomplete drying were 
assessed. Interestingly, the distinct rounded morphology was only present in 
wells that were sufficiently dried over a for 72 hours (Figure 6.7). This finding 
suggested that improper drying of the autoclaved digest could prevent 
sufficient adherence of the matrix proteins to the cell culture surface, facilitating 
its subsequent removal from the surface when seeded. Cellular density also 
had an impact on the morphology. The cobblestone pattern observed with auto 
coated plates in C(+) was the most distinct at a seeding density of 100,000 
cells, less distinct at a seeding density of 70,000 cells and not present at 
50,000 cells. As previously discussed, the link between seeding density and 
chondrogenesis has been well established and, therefore, this finding is 
unremarkable. These results are further supported by the gene expression that 
reveals a significantly higher expression in the chondrogenic marker COL2A1 
in chondrogenic conditions that contained cells seeded at a density of 100,000 
compared to 70,000. To further ensure that the rounded morphology was 
indicative of chondrogenesis and not adipogenesis, the adipogenic marker 
FABP4 was assessed. All autoclave coated conditions expressed FABP4 at a 
level that was not significantly different to control non-coated conditions.  
Initially, gene expression of the differentiating hPDSC’s was assessed at Day 
7. However, it was essential to investigate earlier and later time points to 
monitor changes in gene expression that may have otherwise been missed 
(Figure 6.14). Therefore, gene expression from the Auto coated group was 
compared to non-coated controls both cultured in chondrogenic C(+) 
conditions. The Auto conditions demonstrate a trend towards the early 
upregulation of SOX9 at Day 1, with a significant upregulation at Day 5. A 
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significantly higher upregulation of COL2A1 followed this early upregulation of 
SOX9 at day 5. These findings are in line with literature that suggests the role 
of SOX9 in promoting the expression of cartilage matrix associated genes391, 
further demonstrated by a significantly higher upregulation of the chondrogenic 
marker PRG4594. PRG4 expression may hiilight the increased expression of 
lubricin, a key component for the lubrication of the articular joint595. In a study 
by Musumeci and colleagues596 higher lubricin expression was noted in 
chondrocytes that were cultured from healthy human articular when compared 
to articular chondrocytes extracted from patients with OA, with overall decline 
as the cells were cultured in vitro. In addition Musumeci and colleagues,596 
also demonstrate that OA chondrocytes encapsulated in Poly (ethylene glycol) 
based hydrogels restored lubricin protein expression, however there was a 
significant reduction after 25 days in culture, the Auto coated plates 
downregulate PRG4 expression after 7 days, however, the protein levels of 
lubricin were not measured. Due to the ability of the Auto coating to drive the 
upregultion of PRG4 the coating may be used as an ideal way to expand 
chondrocytes for use in ACI. In addition to the gene expression data the 
potency of the Auto coating was also shown by staining for alcian blue (Figure 
46). 7 Days post-seeding, hPDSC’s seeded onto the auto coated surface show 
a significantly higher deposition of sulfated GAG’s when compared to non-
coated samples in both CTRL and C(+) conditions. Moreover, significantly 
higher SOX9 and COL2A1 expression are maintained through to 21 days. 
However, an increase in the marker COL10A1 may suggest the gradual 
differentiation towards a pre-hypertrophic phenotype597. Recently Shi and 
colleagues published work that indicates the use of a C-type natriuretic peptide 
(CNP), a peptide expressed in the of long bones could be combined into the 
culture conditions of MSC-derived chondrocytes to maintain stable 
chondrocyte phenotype and prevent hypertrophy598. Future work may benefit 
from investigating other factors that could be used in combination with the auto 
coating to preserve a stable chondrogenic phenotype, potentially.  
As demonstrated in chapter 4, hypoxia may further enhance chondrogenesis 
in micromass 2D micromass cultures, also validated by other studies599,600601. 
Overall, these data highlight the capacity of the auto dc-ECM derived coating 
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to drive early chondrogenesis but suggests a limited ability to maintain a stable 
chondrogenic state after long-term culture, likely due to the eventual loss of 
the attached chondroinductive ECM components after repeated media 
changes. The autoclave sterilisation used for the generation of the Auto digest 
coating, may potentially result in the generation of gelatin from the collagenous 
component of the digested dc-ECM, as high heat is used for the industrial 
generation of gelatin602. A study by brown and colleagues demonstrated that 
a combination of gelatin and heparin in methacryloyl hydrogels improves 
chondrogenesis603. Similarly, Honarpardaz and colleagues produced 
gelatin/glycosaminoglycan electrospun nanofibers that enhanced 
chondrogenesis in MSC’s604. Therefore, the potential presence of both Gelatin 
and sGAG’s in the digest may synergistically drive chondrogenesis. However, 
further work is required to compare the dc-ECM derived digest to other gelatin 
sGAG coatings to determine if it is nesessary to derive the digests from the 
dcECM.  
Within the scope of this chapter, the auto dcECM-derived coating was only 
tested in the 96-well format. Moreover, as there was no analysis to determine 
the composition of the dcECM, the mechanisms by which it interacts with 
hPDSCs remains unexplored. Additionally, although not investigated in this 
chapter, future work could employ alternative methodologies for sterilisation 
may prove less damaging to the digested ECM components, while still proving 
effective for sterilisation. Plasma sterilisation offers a promising alternative that 
is capable of inactivating viable bacteria and their spores605. However, the 
mechanisms for the inactivation of bacteria and its effect on the extracellular 
matrix is poorly understood606. Alternatively, given the correct resources, the 
process of digestions could be carried out under sterile conditions. 
Furthermore, the auto dcECM-derived coating may result in the formation of 
distinct nano-topographical features present on the coated surface, these 
features may, subsequently, drive a morphological change in the attached 
cells, inducing chondrogenesis, as demonstrated by Wu and colleagues574. 
Coating different tissue culture surfaces and sizes may result in a shift in 
nanotopography. Future work should, therefore, look into the assessment of 
surface topography using approached such as scanning electron microscopy 
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or atomic force microscopy607. Mendes and colleagues608, have demonstrated 
that hPDSC’s can be driven towards a chondrogenic phenotype with visibly 
higher GAG deposition as early as 7 days. The combination of an optimised 
growth factor cocktail and Auto coated plates can be combined for fututre 
studies as a potential approach to further enhance the chondrogenesis 
process. Moreover, factors such as the pH of the digest were not measured, 
this, in combination with residual pepsin this may influence cell behaviour. 
Therefore, future work should investigate both factors. 
In conclusion the use of auto dcECM-coated plastic is a promising approach 
for the rapid differentiation of hPDSCs, potentially shortening the time required 
for their chondrogenic priming. Moreover, the speed of differentiation of vastly 
faster than traditional methods for the diferentiation of mesenchymal stem cells 
that can take around 2-3 weeks609. Substantial further optimisation and 
assessment are, however, needed to determine whether the auto coating 
results in similar findings when combined with various chondroprogenitor cells 
populations or when combined with various culture surfaces. 
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7. Final discussion and future work. 
 
Herein we describe the development of an optimised decellularisation 
methodology, resulting in the production of the dcECM; a non-immunogenic 
scaffold capable of enhancing chondrogenesis of hPDSC’s; a key cellular 
population involved in fracture healing. Moreover, the dcECM was further 
processed to give porous scaffolds that retain their chondroinductive potential 
while being upscalable to meet clinical needs. Moreover, a tissue culture 
plastic coating was also obtained by processing the dcECM, offering an 
alternative approach for the expansion and enhanced chondrogenic priming of 
hPDSC’s. In doing so, this thesis aimed to contribute to the growing body of 
work that aims at addressing some of the challenges faced when addressing 
bone regeneration, especially, considering the treatment of non-union 
fractures. 
The foundation of current clinical management strategies for non-union 
fractures is fixation. Therefore, inadequate fixation is a primary underlying 
cause of delayed or non-union fractures610. However, In addition to improper 
fixation, non-union fractures are also linked with significant bone and soft 
tissue loss, therefore, requiring further surgical intervention to achieve fracture 
healing36–40. Overall, the treatment of non-unions relies on facilitating 
favourable biological conditions that allow for bone regeneration. Therefore, 
the current gold standard treatment for non-unions is autologous bone grafting 
(ABG). Autologous bone grafts have the three properties that have long been 
considered to be ideal for bone regeneration; osteoconductivity, 
osteoinductivity and osteogenecity41. Despite these characteristics, good 
histocompatibility and promising clinical outcomes51,46,52, complication rates 
have been reported to be as high as 50% primarily associated with donor site 
mobility, compounded by the limited availability graft tissue54–56,58,59. To 
address these shortcomings, research has focused on mimicking the desirable 
properties of ABG’s without the associated limitations; these include the 
development and use of demineralised bone matrix (DBM), obtained from 
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cadaveric bone tissue. However, processing of these tissues can significantly 
impact their osteogenic and osteoinductive properties to a varying extent, 
producing inconsistent clinical outcomes63. Synthetic biomaterials attempt to 
overcome the limitations but are unable to mimic the complex native structure 
and biochemical composition of bone and therefore its osteogenic, 
osteoinductive and osteoconductive properties69. One of the key advantages 
that should be considered with DMB is, however, the availability of large 
quantities of non-autologous bone tissue. Advances in bone tissue engineering 
have, therefore, focused on incorporating both cellular and pharmacological 
factors into bone regeneration strategies, either in combination with a grafting 
material or individually201,611. 
Parathyroid hormone (PTH) is produced in response to reduced calcium 
levels, with the primary function of serum calcium and phosphate homeostasis, 
achieved via the indirect control of bone resorption612. Investigations in both 
pre-clinical and clinical models have demonstrated that intermittent dosing with 
PTH can result in increased bone mass613–615. Therefore, a modified peptide 
derived from PTH (teriparatide) has received FDA approval for the treatment 
of osteoporosis in patients with a high risk of fractures. Moreover, there is also 
evidence to suggest that teriparatide may enhance fracture healing primarily 
by accelerating endochondral remodelling of the cartilaginous callus616,617. A 
study by Kim and colleagues suggests that this is facilitated via the 
differentiation of bone lining cells into osteoblasts618. One of the limitations of 
using PTH alone, however, may be the inability to large segmental bone 
defects, requiring a grafting material. The P-dcECM was engineered to mimic 
the cartilage callus phase of fracture repair, therefore, any interventions that 
promote callus remodelling may be beneficial to enhance the remodelling of 
the P-dcECM implant, enhancing endochondral bone formation. It would, 
therefore, be worthwhile investigating the intermittent dosage of PTH 
alongside the P-dcECM in non-union fracture models. 
Interestingly, a recent study by Kiminori and colleagues presents data to 
suggest that cartilage callus formation was enhanced in mice fracture models 
when PTH was administered continuously, however, an overall delay in the 
fracture healing process was also reported619, since the P-dcECM aims to 
183 
 
mimic the callus phase when implanted delaying the remodelling process may 
be detrimental to the overall healing times, however, priming the P-dcECM with 
PTH may be a viable alternative. Moreover, there is currently little evidence to 
suggest that standard bone-derived ECM would less effective than the P-
dcECM at being remodelled into mature bone, therefore, it would have to be 
included in future investigations as a comparator. Alternatively, fibroblast 
growth factor-2 (FGF-2) has been shown to enhance cartilaginous callus 
formation and overall size when tested in small animal models620,621. However, 
there was no improvement in the remodelling of the cartilage callus into 
osseous tissue and did not enhance the overall healing process; suggesting 
the need for a supporting matrix, growth factor or cell population that can 
facilitate osseous remodelling of the fracture callus into mature bone. FGF-2 
may be, therefore, be effective during the initial priming of the P-dcECM as 
there is also evidence to suggest that FGF-2 acts synergistically with TGF-B1 
signalling to enhance, chondrogenesis in periosteum-derived cells622, the cell 
type chosen in this thesis. Furthermore, FGF signalling is enhanced through 
its binding with heparan sulfate an s-GAG623, abundant in the dcECM.  
Pharmacological approaches to bone regeneration rely on modulating local 
cellular populations to enhance bone formation and repair. However, 
underlying factors such as soft tissue loss, ageing, or diseases can limit the 
number or functionality of resident cell populations that are essential for bone 
regeneration and fracture healing1,28. Therefore, introducing functional cellular 
populations into a bone defect is also considered a viable option for the 
treatment of fractures or bone defects201. A recent example of using the cellular 
approach includes ALLOB®, a population of allogeneic osteoblastic cells derived 
from healthy donor patients. The latest Phase I/IIA study investigates the efficacy 
of the approach for the treatment of delayed union. Due to the osteoblastic cell 
population used in the ALLOB approach, the resulting bone formation would 
primarily be driven via the intramembranous ossification pathway. This approach 
may, therefore, be ineffective at participating in early long bone fracture healing, 
especially, in larger bone defects, where bone healing occurs via the 
endochondral ossification pathway. Moreover, osteoblasts are not the primary cell 
source of choice due to their limited self-renewal capacity and heterogeneous cell 
populations624. The P-dcECM aims to mimic the early cartilaginous callus phase 
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of fracture repair, thus potentially being more effective when treating large bone 
defects or pathologies such as atrophic non-union fractures, where there is a 
distinct lack of callus formation. However, the innovative approach used to 
develop a cell bank of donor cells is worth considering when selecting cell 
population to be used in combination with the P-dcECM. MSC based therapies 
have also shown promising results and are, therefore, currently the stem cell of 
choice. However, articles reviewing cell therapies have suggested that there is 
still work required to obtain a mainstream cell therapy for the treatment of non-
union fractures, and limitations in treating large bone defects still limit an MSC 
only approach503 
As highlighted, pharmacological and cell-only approaches do not address the 
need for a grafting material capable of bridging or filling large bone defects, with 
some questions also being raised about the localisation or the pharmacological 
and cellular components of each stratergy201. These limitations have resulted in 
the development of combinational therapies combining pharmacological or 
cellular approaches with a carrier or grafting material625. Quatro and colleagues626 
were the first to report the use of autologous bone marrow-derived MSC’s (BM-
MSC’s) in a pilot study that combined them with Hydroxyapatite blocks to fill bone 
large bone defects ranging from 4-7 cm. The 3 patients involved were successfully 
treated for large bone defects in their ulna, humerus and tibia, confirmed in a 
follow-up screen 6-7 years later627. However, there is yet to be any widely applied 
clinical approach utilising MSC based combinational therapies. 
Similar combinational approaches have also been applied for the delivery of 
pharmacological components. GeneraResearch Ltd has developed Osteogrow, a 
whole blood coagulum based delivery system for rhBMP-6, aimed at the treatment 
of non-union fractures628. A clinical trial for (EudraCT Number: 2014-005101-21) 
is currently being undertaken to assess its safety and efficacy when delivered at 
a fracture site. This is crucial as previously, the use of BMP’s, especially BMP-2 
has been associated with concerns of adverse effects495, primarily, due to the non-
localised and non-physiological levels of BMP’s being used. The Osteogrow 
system aims to localise rhBMP-6 within the coagulum, with the hope of localising 
it at the fracture site. Unlike the P-dcECM, this approach is more mimetic of the 
early inflammatory phase of fracture repair. Moreover, the mechanical properties 
of the whole blood coagulum have yet to be assessed but could potentially have 
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insufficient deriable mechanical properties such as compressive strength, 
compared to a cartilage-based grafting material such as the P-dcECM. 
A vast majority of the pharmacological, cellular and scaffold-based therapies still 
aim to mimic the individual components of the bone microenvironment or 
signalling to promote bone formation via the intramembranous pathway. However, 
the fracture healing process, especially, in long bones is driven by endochondral 
ossification (EO), a process that results in tissue intermediates such as the 
cartilage callus, before forming bone. Dennis and colleagues reviewed emerging 
strategies in tissue engineering that harness the intermediate phases of fracture 
repair, suggesting that mimicking early fracture intermediates such as the 
cartilage callus may be more effective as they are primed to follow the biological 
cues present during early fracture repair8. The development of the dcECM and P-
dcECM described in this thesis is reflective of the paradigm shift towards a more 
developmental engineering approach to tissue engineering85,86,629. 
 
Limitations and considerations for translation 
Both promise and doubt have always accompanied the concept of 
xenotransplantation. Early attempts yielded mixed results often leading to 
death from an acute host response630, until the later discovery of key 
immunological barriers to xenotransplantation such as the alpha-gal epitope 
and donor DNA222,631. Initial attempts to overcome these barriers via the use 
of potent anti-rejection drugs often led to short-lived success and questionable 
ethics. An article by Annas and colleagues632 highlights a pivotal case where 
a baboon heart was transplanted into a heavily immunosuppressed infant, 
resulting in catastrophic failure and death. Although this was a step back for 
the concept of xenotransplantation, it later re-emerging when bolstered by the 
process of decellularisation, with the novel claim of eliminating immunogenic 
components in non-autologous graft materials rather than suppressing the 
host immune response to them. A key achievement of this thesis was 
harnessing previous knowledge on decellularisation and optimising a 
decellularisation methodology that effectively eliminated Alpha-gal from the 
xenogeneic cartilage tissue, a key factor in xenogeneic transplant rejection and 
persistent long-term graft failure if not considered in decellularised 
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tissues222,287,288. Interestingly, this was achieved while maintaining 80% of the 
native sGAG content, unreported in other studies that investigate 
decellularisation methodologies for hyaline cartilage. Despite these promising 
results, there are, however, limiting factors that need to be considered for the 
successful translation of the concepts discussed in this thesis. 
In-depth characterisation of the dcECM and P-dcECM will be a crucial aspect 
for translation. Although sGAG content was measured, further analysis to 
elucidate the exact composition of individual sGAG components and 
associated growth factors may help determine possible mechanisms of action. 
Moreover, the levels of residual growth factors present within the 
decellularised tissues is crucial to determine appropriate cell and growth factor 
priming strategies before implantation. Indeed, factors such as VEG-F, if 
present in the decellularised tissues, may be advantageous due to the 
promotion of local vascularisation, a process that is crucial for endochondral 
fracture healing1,633.   
Findings in the thesis report the complete elimination of alpha-gal and 
reduction of residual DNA content to levels that are below the in vivo 
immunological threshold. In vivo implantation in mice further confirmed the 
non-inflammatory nature of the dcECM, primarily elucidating a reparative 
immune response. However, the dcECM was implanted as whole constructs 
approximately 6 mm in diameter and 1 mm in thickness. Post-explantation, it 
was observed that there was minimal degradation to the dcECM and native 
cartilage constructs, this may highlight that cartilage may be naturally 
immunoprivileged, primarily due to its dense avascular nature, limiting cellular 
infiltration. The P-dcECM contains smaller fragments of the P-dcECM, 
provided a relatively larger surface area for interaction with immune cell 
populations, potentially highlighting a different immune response to whole 
intact dcECM constructs. Moreover, the processing of the p-dcECM may lead 
to the generation of more collagen fragments, which may in turn alter its 
bioactivity at an orthotopic site compared to the dcECM alone. Therefore, 
future biocompatibility studies with the P-dcECM implantation at an orthotopic 
site are essential to fully elucidate biocompatibility and the functionality of the 
constructs, both of which could be limiting factors to translation. 
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The cell population of choice to be used in combination with the P-dcECM 
should also be carefully considered. Factors such as ease of isolation, 
expansion and their functionality are all key factors that will be used to 
determine the ultimate choice for translation. It is also important to note that 
grafting materials that contain a cellular component are generally subject to 
more stringent FDA guidelines to limit variability in the processing of cell 
populations634. In Europe, stem cell-based products are classified as advanced 
therapeutic medicinal products (ATMP), In general, the more complicated the 
product or strategy, the tighter the regulations required for approval635. It may, 
therefore be favourable to consider priming the P-dcECM with a chemotactic 
factor such as SDF-1, proven to facilitate mesenchymal cell chemotaxis to the 
fracture site and improve fracture healing outcomes in pre-clinical models636–
638. Additionally, the dc-ECM derived coating developed during this study could 
be employed during the stem cell chondrogenic priming process, establishing 
a workflow that will yield not only a usable endochondral grafting material but 
the rapid generation of a chondrogenically primed cell population that can be 
used to enhance in vivo bioactivity, improving the P-dcECM’s potential for 
translation.  
 
7.1 Future work. 
Upscaling the decellularisation process 
Much of the Vac-OS decellularisation process is carried out within the vacuum 
desiccator. Consequently, it would be relatively easy to upscale and automate 
the process for large-scale production as the constructs remain within the 
same container. The delivery of each reagent could be automated and 
controlled by a liquid handling unit linked to a computer (Figure 7.1). The 
described method is similar to the approach used by Price and colleagues639.  
There are several approaches to evaluate decellularised tissues, and although 
methodologies can vary depending on the source of native tissue type, the 
general principle remains the same. Decellularised tissues must fulfil two key 
criteria; the elimination or reduction of immunogenic components while 
causing minimal disruption to the collagen integrity. However, as highlighted 
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by Philips and colleagues in a recent review, there is no standardised method 
for the evaluation of decellularised tissues640. The FDA’s minimal manipulation 
criteria require evidence to demonstrate that processing strategies such as 
decellularisation and sterilisation inflict minimal disruption to donor tissue641. A 
standardised and automated decellularisation process will further help to 
reduce variation in Vac-OS decellularised tissues due to minimal human error. 
Additionally, the FLIM methodology discussed in chapter 3 was effective at 
monitoring biochemical changes in the costal cartilage ECM, this approach 
could be further developed and tested as a potential methodology for the rapid 
assessment of the resultant Vac-OS decellularised tissues and used for batch 
monitoring and process control. Moreover, collaborative work could be 
undertaken to incorporate biological assays such as ELISA’s into microfluidic 
lab-on-chip systems that can be automated to provide a rapid point of need 
analysis, while simultaneously analysing a large number of biological targets 
such as DNA and alpha-gal642,643, further speeding up batch analysis and 
process control.  
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Figure 7.2: Simplified schematic illustrating an automated system for the Vac-OS 
methodology. Figure generated using the Servier medical art database 
(http://www.servier.com/Powerpoint-image-bank 
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In vivo characterisation of the dcECM 
Translation of the concepts described in this thesis requires future work to 
focus on investigating the bone forming capacity of the dcECM or porous 
dcECM-derived constructs when challenged in an orthotopic non-union 
fracture model. Moreover, In vivo assessment will also provide crucial 
information regarding the mechanical kinetic, and presence of toxic 
degradation products that may result in chronic inflammation.  
Large animals were traditionally the ideal choice for fracture models644,645. 
However, there was a gradual shift towards using smaller animal models such 
as rodents, primarily due to costs associated with their housing and 
maintenance of large animals646. A critical criteria for investigating the P-
dcECM would be its ability to facilitate bone regeneration and union when 
presented with a critical-sized defect (CSD) as the primary aim is the treatment 
of atrophic non-union fractures. The clinical presentation of non-union 
fractures is also driven by several additional factors such as age, diabetes, 
infection, osteoporosis and periosteal damage4,647. Therefore, the animal 
model chosen to investigate the P-dcECM should include one or a combination 
of these factors. Several non-union fracture models have emerged in both Rats 
and mice; these have been summarised in supplementary table 2. The options 
must be carefully considered depending on the clinical requirements being 
addressed. Moreover, the addition of hPDSC’s was also hypothesised to 
compensate for impaired stem cell availability due to damage caused by 
surrounding tissues such as the periosteum. Therefore, the ideal fracture 
model to investigate the efficacy of using the P-dcECM primed with hPDSC’s 
should contain a critical-sized gap that consistently results in non-union 
fractures without intervention, with further damage to the surrounding 
periosteum. Other factors such as age and diabetes can eventually be 
investigated to gauge the regenerative potential of the P-dcECM in various 
clinical conditions.  
In conclusion, there is an extensive range of strategies that target bone 
regeneration and fracture repair. However, traditional approached to bone 
tissue engineering did not consider the complex biological processes that 
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underpin fracture repair, driving a paradigm shift towards the development of 
bone repair strategies that are biomimetic of the fracture repair process by 
harnessing repair intermediates such as the cartilage callus, rather than end-
stage tissues such as bone. The work carried out in this thesis aims to harness 
this shift in strategy by developing an efficient decellularisation methodology, 
resulting in the first reported production of a porcine cartilage-derived 
decellularised tissue281. The resultant dcECM was capable of re-establishing 
the chondrocytic phenotype in dedifferentiated human articular chondrocytes 
while enhancing chondrogenic differentiation in human periosteal stem cells. 
Importantly, the dcECM could be further processed to give upscalable 
chondroinductive porous scaffolds that supported cellular infiltration, providing 
a viable approach to the development of cartilage callus mimetic constructs. 
Overall, bone regeneration remains a key topic for research, with the work in 
this thesis provided a potential alternative for translation. 
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Appendix 
 
Gene 
ID/Ref 
NCBI accession 
number/ 
Species 
 
Sequence 5'-3' 
COL2A1528 NM_001844.4 Forward GGCTTCCATTTCAGCTATGG 
Human Reverse AGCTGCTTCGTCCAGATAGG 
SOX9528 NM_000346.3 Forward TGGAGACTTCTGAACGAGAGC 
Human Reverse CGTTCTTCACCGACTTCCTC 
SOX5 NM_001261414.2 Forward TGCTTACTGACCCTGATTTACC 
Human Reverse CACTCTCCTCTTCTTCCACTTTC 
SOX6 NM_001145811.1 Forward AACAACGGCAGCAAATGGAC 
Human Reverse CATGTGACCCTGAACCTGGA 
VEGF-A648 NM_001025366.2 Forward AGTCCAACATCACCATGCAG 
Human Reverse TTCCCTTTCCTCGAACTGATTT 
RUNX2649 NM_001015051.3 Forward CGCATTCCTCATCCCAGTAT 
Human Reverse GCCTGGGGTCTGTAATCTGA 
COL10A1528 NM_000493.3 Forward ACGATACCAAATGCCCACAG 
Human Reverse GTGGACCAGGAGTACCTTGC 
ACAN NM_001135.3 Forward TGTGGGACTGAAGTTCTTGG 
Human Reverse AGCGAGTTGTCATGGTCTG 
HPRT1650 NM_000194.2 Forward TGAGGATTTGGAAAGGGTGT 
Human Reverse GAGCACACAGAGGGCTACAA 
hprt1 NM_204848.1 Forward GATGAACAAGGTTACGACCTGGA 
Chicken Reverse TATAGCCACCCTTGAGTACACAGAG 
cd31 XM_004946203.2 Forward GGCAGAACATAGCTCAGCACAA 
Chicken Reverse GCACAGGGAGTTCAGCACAA 
hprt1 NM_013556.2 Forward GTTGGGCTTACCTCACTGCT 
Mouse Reverse TCATCGCTAATCACGACGCT 
cd163 NM_001170395.1 Forward CCAGTGCCTCCCAAAAATGAC 
Mouse Reverse AGTCGCTGAATCTGTCGTCG 
cd31 NM_001032378.2 Forward CACCAAGAGAACGGAAGGCT 
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Mouse Reverse TGGGGACAGGCTCATAAATACG 
cxcl9 NM_008599.4 Forward TCGGACTTCACTCCAACACAG 
Mouse Reverse AGGGTTCCTCGAACTCCACA 
il-6 NM_001314054.1 Forward GGAGCCCACCAAGAACGATA 
Mouse Reverse GTCACCAGCATCAGTCCCAA 
cd86 NM_001291058.1 Forward GCAAAGGGGATTGGATTGAGG 
Mouse Reverse TCCTCTGTTCCTTGGGCTAT 
il-2r NM_008367.3 Forward CTGGCAACACAGATGGAGGA 
Mouse Reverse CGTTAGGTGAATGCTTGGCG 
tnf-a NM_001278601.1 Forward CCCTCACACTCACAAACCAC 
Mouse Reverse ACAAGGTACAACCCATCGGC 
inf-g651 NM_008337.4 Forward GAACTGGCAAAAGGATGGTGAC 
Mouse Reverse TTGCTGATGGCCTGATTGTC 
Supp Table 1: qPCR primer sequences. Primers were exon spanning, designed using 
Primer3 Plus, NCBI or obtained from published sources. 
 
Author Bone Fixation Fracture 
model 
Observati
on time 
Non-union 
Rate 
RAT 
Lisignoli 
et al. 
2002652 
radius no fixation 5 mm osteotomy 28 weeks 100% 
Hsu et al. 
2007653 
femur polyethylene 
plate with screws 
& cerclage 
6 mm osteotomy 
& periosteum 
elevated 
8 weeks 100 % 
Zhang et 
al. 
2010654 
femur radioluscent plate 7 mm osteotomy 12 weeks 100 % 
Kokubu 
et al. 
2003655 
femur metallic pin 
intramedullar 
closed fracture & 
periosteum 
cauterised 
8 weeks 100% 
Dickson 
et al. 
2008656 
femur external fixator 0 mm osteotomy 
& periosteum 
cauterised & 
endosteum 
reamed 
14 weeks 87.5 % 
260 
 
Schoen 
et al. 
2008657 
femur intramedullar pin 
and diaphysal 
screws 
5 mm osteotomy 12 weeks 100 % 
Kaspar et 
al. 
2008658 
femur external fixator ~0.5 mm 
osteotomy & 
bone marrow 
removal & 
periosteum 
cauterised 
8 weeks 100% 
Chen et 
al. 
2005659 
femur polyethylene 
plate with 
threaded K-wire 
6 mm osteotomy 
& infection 
Staph. aureus 
12 weeks 100 % 
Azad et 
al. 
2009660 
femur polyethylene 
plate with screws 
and cerclage 
3 mm osteotomy 
& collagen 
sponge & 
diabetic rat 
9 weeks 100% 
MICE 
Choi et 
al. 
2004661 
tibia external fixator osteotomy + 
distraction 
4 weeks 60 % atrophic 
Garcia et 
al. 
2009662 
femur Locking Mouse 
Nail interlocked 
2.0 mm 
osteotomy 
10 weeks 100 % atrophic 
Supp Table 2: Non-union rodent fracture models. Adapted from Garcia et al, 2013663 
 
 
 
 
 
 
 
 
 
 
